日本臨牀　73/増刊3　膵癌・胆道癌

出版社： 日本臨牀社
発行日： 2015-03-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 膵癌・胆道癌　基礎と臨床の最新研究動向
電子書籍版： 2015-03-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 日本臨牀　73/増刊3　膵癌・胆道癌

    ―目次―

    特集　膵癌・胆道癌　基礎と臨床の最新研究動向

    膵　癌
    I．総　論
    　1　基礎編
    　2　臨床編

    II．各　論
    　1　上皮性腫瘍
    　2　非上皮性腫瘍

    III．特　論
    　1　膵癌診療ガイドライン2013の概要
    　2　IPMN/MCN国際診療ガイドライン2012年の概要
    　3　新しい化学療法と臨床試験
    　4　家族性膵癌と登録制度
    　5　生活習慣と膵癌
    　6　膵癌の早期発見と病診連携
    　7 Borderline resectable膵癌
    　8 膵臓癌に対するペプチドワクチンの現状と展望
    　9　膵腫瘍に対するロボット支援手術
    　10　膵癌の重粒子線療法

    胆道癌
    I．総　論
    　1　基礎編　
    　2　臨床編

    II．各　論
    　1　腺　癌
    　2　特殊な組織型(臨床病理学的特徴)

    III．特　論
    　1　胆道癌診療ガイドライン第2版の概要
    　2　新しい胆道癌の化学療法と臨床試験
    　3　IPNB,BilINの病理・病態
    　4　生活習慣と胆道癌
    　5　胆道ドレナージ法の進歩(悪性胆道閉塞)
    　6　胆道癌に対するペプチドワクチンの現状と展望
    　7　印刷労働者と胆管癌

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.7 掲載の参考文献
1) 江川新一ほか : 膵癌登録報告2007ダイジェスト. 膵臓 23 : 105-123, 2008.
Medical*Online
2) Miyakawa S, et al : Biliary tract cancer treatment : 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16 : 1-7, 2009.
PubMed
3) 祖父江友孝, 雑賀公美子 : 日本のがん統計の現状. 癌・統計白書 2012-データに基づくがん対策のために (祖父江友孝監), p1-14, 篠原出版, 2012.
 
4) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン2013年版, 金原出版, 2013.
 
5) Tanaka M, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
6) Conroy T, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 : 1817-1825, 2011.
PubMed
7) Uesaka K, et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 31 (Suppl) : Abstract 145, 2013.
 
8) Von Hoff D, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 : 1691-1703, 2013.
PubMed
9) Bosman FT : WHO Classification of Tumours of Digestive System, 4th ed, p13-14, International Agency for Research on Cancer, Lyon, 2010.
 
10) Valle J, et al : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 : 1273-1281, 2010.
PubMed
11) Okusaka T, et al : Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicenter study in Japan. Br J Cancer 103 : 469-474, 2010.
 

膵癌

P.14 掲載の参考文献
1) Hruban RH, et al : An illustrated on the classification of pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasms (IPMNs). Am J Surg Pathol 28 : 977-987, 2004.
PubMed
2) Sipos B, et al : Pancreatic intraepithelial neoplasia-revisited and updated. Pancreatology 9 : 45-54, 2009.
PubMed
3) Shi C, et al : KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN : implications for the human pancreatic cancer cell of origin. Mol Cancer Res 7 : 230-236, 2009.
PubMed
4) Aichler M, et al : Origin of pancreatic ductal adenocarcinoma from atypical flat lesions : a comparative study in transgenic mice and human tissues. J Pathol 226 : 723-734, 2012.
PubMed
5) Yachida S, et al : Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 : 1114-1117, 2010.
PubMed
6) Jones S, et al : Core signaling Pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (5897) : 1801-1806, 2008.
PubMed
7) Sato N, et al : CpG island methylation profile of pancreatic intraepithelial neoplasia. Modern Pathol 21 : 238-244, 2008.
 
8) Srivastava SK et al : MicroRNAs in pancreatic malignancy : progress and promises. Cancer Lett 347 : 167-174, 2014.
PubMed
9) Yu J, et al : MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res 18 : 981-992, 2012.
PubMed
10) Fukushima N, et al : Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Modern Pathol 21 : 1044-1053, 2008.
 
11) Rhim AD, et al : Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25 : 735-747, 2014.
PubMed
12) Ozdemir BC, et al : Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 : 719-734, 2014.
PubMed
P.20 掲載の参考文献
1) Matsuda A, et al : Japan Cancer Surveillance Research Group : Cancer incidence and incidence rates in Japan in 2008 : a study of 25 population-based cancer registries for the Monitoring of Cancer lncidence in Japan (MCU) project. Jpn J Clin Oncol 44 : 388-396, 2014.
 
2) 独立行政法人国立がん研究センターがん対策情報センター : 全国がん罹患モニタリング集計 2003-2005年生存率報告. 独立行政法人国立がん研究センターがん研究開発費「地域がん登録精度向上と活用に関する研究」平成22年度報告書, 2013.
 
3) 佐藤賢一 : 膵癌 : 発生・進展の分子機構 日消誌 110 : 2042-2050, 2013.
Medical*Online
4) Huber MA, et al : Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17 : 548-558, 2005.
PubMed
5) Ellenrieder V, et al : Transforming growth factor betal treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61 : 4222-4228, 2001.
 
6) Yang AD, et al : Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 66 : 46-51, 2006.
PubMed
7) Hamada S, et al : Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line. J Cell Physiol 213 : 768-774, 2007.
PubMed
8) Satoh K et al : Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells. Am J Pathol 172 : 926-939, 2008.
PubMed
9) von Burstin J, et al : E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 137 : 361-371, 2009.
PubMed
10) Gregory PA et al : The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10 : 593-601, 2008.
PubMed
11) Li Y, et al : Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelialto-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69 : 6704-6712, 2009.
 
12) Hamada S, et al : MiR-126 acts as a tumor suppressor in pancreatic cancer cells Via the regulation of ADM9. Mol Cancer Res 10 : 3-10, 2012.
 
13) Hamada S, et al : MiR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol 228 : 1255-1263, 2013.
PubMed
14) Harazono Y. et al : miR-655 is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS One 8 : e62757, 2013.
PubMed
15) Rhim AD, et al : EMT and dissemination precede pancreatic tumor formation. Cell 148 : 349-361, 2012.
PubMed
16) Collins MA, et al : Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 122 : 639-653, 2012.
PubMed
17) Collins MA, et al : Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS ONE 7 : 349707, 2012.
 
18) Morton JP, et al : Mutant p53 drives metastasis and overcomes growih arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 107 : 246-251, 2010.
PubMed
19) Weissmueller S. et al : Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell 157 : 382-394, 2014.
 
20) Yachida S, et al : Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 : 1114-1117, 2010.
PubMed
21) Kanno A, et al : Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer 122 : 2707-2718, 2008.
PubMed
22) Satoh K, et al : Infrequent stromal expression of gelatinase A and intact basement membrane in intraductal neoplasms of the pancreas. Gastroenterology 107 : 1488-1495, 1994.
PubMed
23) Hang RF, et al : Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68 : 918-926, 2008.
 
24) Kikuta K, et al : Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun 403 : 380-384, 2010.
PubMed
25) Ozdemir BC, et al : Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 : 719-734, 2014.
PubMed
26) Rhim AD, et al : Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25 : 735-747, 2014.
PubMed
P.25 掲載の参考文献
1) Jones S, et al : Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 : 1801-1806, 2008.
PubMed
2) Biankin AV, et al : Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491 : 399-405, 2012.
PubMed
3) Vogelstein B, et al : Cancer genome landscapes. Science 339 : 1546-1558, 2013.
PubMed
4) Furukawa T, et al : Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol 18 : 1034-1042, 2005.
PubMed
5) Zang ZJ, et al : Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44 : 570-574, 2012.
PubMed
6) Wu J, et al : Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3 : 92ra66, 2011.
PubMed
7) Furukawa T, et al : Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep1 : 161, 2011.
 
8) Landis CA, et al : GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340 : 692-696, 1989.
PubMed
9) Wu J, et al : Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 108 : 21188-21193, 2011.
PubMed
10) Komatsu H, et al : A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles With upregulation of mucin genes. PLoS One 9 : e87875, 2014.
PubMed
11) Amato E, et al : Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 233 : 217-227, 2014.
PubMed
12) Sakamoto H, et al : Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol, 2014. [Epub ahead of print]
 
13) Koo BK, et al : Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488 : 665-669, 2012.
PubMed
14) Jiang X, et al : Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA 110 : 12649-12654, 2013.
PubMed
P.29 掲載の参考文献
1) 石井源一郎, 落合淳志 : がん組織を構成する線維芽細胞の起源. 顕微鏡 43 : 104-108, 2008.
 
2) Erkan M, et al : The role of stroma in pancreatic cancer : diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 9 : 454-467, 2012.
PubMed
3) Masamune A, Shimosegawa T : Pancreatic stellate cells-multi-functional cells in the pancreas. Pancreatology 13 : 102-105, 2013.
PubMed
4) Apte MV, et al : Desmoplastic reaction in pancreatic cancer : role of pancreatic stellate cells. Pancreas 29 : 179-187, 2004.
PubMed
5) Xu Z, et al : Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol 177 : 2585-2596, 2010.
PubMed
6) Erkan M, et al : Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 11 : 497-508, 2009.
PubMed
7) Hingorani SR, et al : Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 : 469-483, 2005.
PubMed
8) Mantoni TS, et al : Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling. Cancer Res 71 : 3453-3458, 2011.
 
9) Mace TA, et al : Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 73 : 3007-3018, 2013.
 
10) Ene-Obong A, et al : Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 145 : 1121-1132, 2013.
PubMed
11) Olive KP, et al : Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 : 1457-1461, 2009.
 
12) Neesse A, et al : CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci USA 110 : 12325-12330, 2013.
PubMed
13) Provenzano PP, et al : Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinorna. Cancer Cell 21 : 418-429, 2012.
PubMed
14) Nakai Y, et al : A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer : GECA2. Invest New Drugs 31 : 1294-1299, 2013.
PubMed
15) Ozdemir BC, et al : Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 : 719-734, 2014.
PubMed
P.35 掲載の参考文献
1) Ryan DP, et al : Pancreatic adenocarcinoma. N Engl J Med 371 : 1039-1049, 2014.
PubMed
2) Hingorani SR et al : Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 : 437-450, 2003.
PubMed
3) Hingorani SR et al : Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 : 469-483, 2005.
PubMed
4) Aguirre AJ, et al : Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17 : 3112-3126, 2003.
PubMed
5) Bardeesy N, et al : Both p16 (Ink4a) and the p19 (Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 103 : 5947-5952, 2006.
PubMed
6) Ijichi H, et al : Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20 : 3147-3160, 2006.
PubMed
7) Bardeesy N, et al : Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20 : 3130-3146, 2006.
PubMed
8) Izeradjen K, et al : Kras (G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11 : 229-243, 2007,
 
9) Olive KP, et al : Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 : 1457-1461, 2009.
 
10) Singh M, et al : Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 28 : 585-593, 2010.
PubMed
11) Provenzano PP, et al : Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21 : 418-429, 2012.
PubMed
12) Ozdemir BC, et al : Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 : 719-734, 2014.
PubMed
13) Ying H, et al : Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149 : 656-670, 2012.
PubMed
14) Navas C, et al : EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22 : 318-330, 2012.
 
15) Ardito CM, et al : EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22 : 304-317, 2012.
PubMed
16) Habbe N, et al : Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci USA 105 : 18913-18918, 2008.
PubMed
17) De La O JP, et al : Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci USA 105 : 18907-18912, 2008.
PubMed
18) Guerra C, et al : Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11 : 291-302, 2007.
 
19) Gidekel Friedlander SY, et al : Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16 : 379-389, 2009.
PubMed
20) Kopp JL, et al : Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22 : 737-750, 2012.
PubMed
P.40 掲載の参考文献
1) Forman D, et al (ed) : Cancer Incidence in Five Continents, Vol.X (electronic version), IARC, Lyon. [http://ci5.iarc.fr]
 
2) Curado M, et al (ed) : Cancer Incidence in Five Continents, Vol.IX, p160 IARC Scientific Publication, Lyon, 2008.
 
3) Katanoda K, et al : An updated report of the trends in cancer incidence and mortality in Japan. Jpn J Clin Oncol 43 (5) : 492-507, 2013.
PubMed
4) Matsuda A, et al : Cancer incidence and incidence rates in Japan in, 2007 : a study of 21 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project Jpn J Clin Oncol 43 (3) : 328-336, 2013.
PubMed
5) Matsuo K, et al : Cigarette smoking and pancreas cancer risk : an evaluation based on a systematic review of epidemiologic evidence in the Japanese population. Jpn J Clin Oncol 41 (11) : 1292-1302, 2011.
PubMed
6) Dong J, et al : Coffee drinking and pancreatic cancer risk : a meta-analysis of cohort studies. World J Gastroenterol 17 (9) : 1204-1210, 2011.
 
7) Turati F, et al : A meta-analysis of coffee consumption and pancreatic cancer. Ann Oncol 23 (2) : 311-318, 2012.
PubMed
8) Kanda J, et al : Impact of alcohol consumption with polymorphisms in alcohol-metabolizing enzymes on pancreatic cancer risk in Japanese. Cancer Sci 100 (2) : 296-302, 2009.
PubMed
9) Suzuki T, et al : Alcohol drinking and one-carbon metabolism-related gene polymorphisms on pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev l 7 (10) : 2742-2747, 2008.
 
P.44 掲載の参考文献
1) 日本膵臓学会 (編) : 膵癌取扱い規約, 金原出版, 1980.
 
2) 日本膵臓学会 (編) : 膵癌取扱い規約, 第6版, 金原出版, 2009.
 
3) 日本膵臓学会 (編) : 膵癌取扱い規約, 第6版補訂版, 金原出版, 2013.
 
4) Gibson JB, et al : Histological Typing of Tumours of the Liver, Biliary Tract and Pancreas, International histological classification of tumours No.20, 1st ed, WHO Publications Centre, USA, 1978.
 
5) Kloppel G, et al : Histological typing of tumours of the exocrine pancreas 2nd ed, Springer, 1996.
 
6) Hamilton SR, Aaltonen LA : Pathology & Genetics, Tumours of the Digestive System, IARC, Lyon, 2000.
 
7) Bosman FT, et al : WHO Classification of Tumours of the Digestive System, 4th ed, IARC, Lyon, 2010.
 
P.49 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改定委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2013年版, 金原出版, 2013.
 
2) 宮崎敬子ほか : 糖鎖と臨床検査癌関連性糖鎖抗原-CA19-9を中心に. 臨床検査 52 : 573-583, 2008.
 
3) 山田高嗣ほか : 追跡調査からみた高CEA血症の癌診断における有用性. 日本外科系連合会誌 29 : 214-221, 2004.
 
4) 竹迫賀子ほか : 臨床検査, 診断に用いる腫瘍マーカー 膵癌・胆道癌. 癌と化学療法 31 : 1443-1446, 2004.
 
5) 恩田昌邦ほか : 大腸癌におけるNCC-ST-439抗原の血清学的および免疫組織化学的検討. 日消外会誌 31 : 2071-2079, 1998.
 
6) 今村正之 (総監修), 田中雅夫, 平田公一 (編) : 膵・消化管神経内分泌腫瘍 (NET) 診断・治療実践マニュアル, 総合医学社, 2011.
 
7) 土井隆一郎ほか : 膵内分泌腫瘍の診断と内科的治療-4. 非機能性内分泌腫瘍-. 膵臓 23 : 697-702, 2008.
 
8) Sugimoto M, et al : Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-spechic profiles. Metabolomics 6 : 76-95, 2010.
 
9) Zhang L, et al : Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 138 : 949-957, 2010.
PubMed
10) Schultz NA, et al : MicroRNA biomarkers in whole blood detection of pancreatic cancer. JAMA 311 : 392-404, 2014.
PubMed
P.54 掲載の参考文献
1) 日本膵臓学会, 膵癌診療ガイドライン改訂委員会 (編) : I診断法. 科学的根拠に基づく膵癌診療ガイドライン, 2013年版, p25-54, 金原出版, 2013.
 
2) Tanaka S, et al : Slight dilatation of the main pancreatic duct and presence of pancreatic cysts as predictive signs of pancreatic cancer : a prospective study, Radiology 254 : 965-972, 2010.
PubMed
3) Kitano M, et al : Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography. Gut 53 : 854-859, 2004.
PubMed
4) Oshikawa O, et al : Dynamic sonography of pancreatic tumors : comparison with dynamic CT. AJR Am J Roentgenol 178 : 1133-1137, 2002.
PubMed
5) Nagase M, et al : Evaluation of contrast enhancement patterns in pancreatic tumors by coded harmonic sonographic imaging with a microbubble contrast agent. J Ultrasound Med 22 : 789-795, 2003.
PubMed
6) Sofuni A, et al : Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol 40 : 518-525, 2005.
PubMed
7) Okamoto Y, et al : Contrast-enhanced ultrasonography depicts small tumor vessels for the evaluation of pancreatic tumors. Eur J Radiol 61 : 163-169, 2007.
PubMed
8) D'Onofrio M, et al : Pancreatic multicenter ultrasound study (PAMUS). Eur J Radiol 81 : 630-638, 2012.
PubMed
9) Kersting S, et al : Quantitative perfUsion analysis of transabdominal contrast-enhanced ultrasonography of pancreatic masses and carcinomas. Gastroenterology 137 : 1903-1911, 2009.
PubMed
10) Takeshima K, et al : Comparison of IV contrast-enhanced sonography and histopathology of pancreatic cancer. AJR Am J Roentgenol 185 : 1193-1200, 2005.
PubMed
11) Numata K, et al : Contrast-enhanced sonography of pancreatic carcinoma : correlations with pathological findings. J Gastroenterol 40 : 631-640, 2005.
PubMed
12) Masaki T, et al : Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma. Cancer 103 : 1026-1035, 2005.
PubMed
13) Sofuni A, et al : Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy. World J Gastroenterol 14 : 7183-7191, 2008.
PubMed
14) Tawada K, et al : Changes in tumor vascularity depicted by contrast-enhanced ultrasonography as a predictor of chelnotherapeutic effect in patients with unresectable pancreatic cancer. Pancreas 38 : 30-35, 2009.
PubMed
15) Itoh T, et al : Usefulness of contrast-enhanced transabdominal ultrasonography in the diagnosis of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol 100 : 144-152, 2005.
PubMed
P.66 掲載の参考文献
1) 日本膵臓学会癌登録委員会 : 日本膵臓学会癌登録20年間の総括. 膵臓 18 : 101-169, 2003.
 
2) 蒲田敏文ほか : 膵画像診断の最新動向 : 膵疾患診断におけるCT (MDCT) の役割. 肝胆膵画像14 : 113-121, 2012.
 
3) 蒲田敏文ほか : Borderline Resectable膵癌をめぐって : 膵癌におけるDynamic CT撮像方法と脈管浸潤. 胆と膵 32 : 585-592, 2011.
 
4) 彌永由美ほか : 腹部MDCTにおける最近の造影の考え方 : 造影剤注入時間一定法 (Multislice CT 2006 BOOK). 映像情報medical 38 : 106-111, 2006.
 
5) Brennan DD, et al : Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiographics 27 : 1653-1666, 2007.
PubMed
6) Uchida M, et al : Comparison of dynamic MRI at 3.0 T and MDCT of pancreatobiliary disease : evaluation with source, MPR, CPR, and MIP images for image quality and hepatic arterial and portal venous vessel conspicuity. J Magn Reson Imaging 29 : 846-852, 2009.
 
7) Ibukuro K, et al : Peripancreatic veins on thin-section (3mm) helical CT. AJR Am J Roentgenol 167 : 1003-1008, 1996.
PubMed
8) Yamada Y, et al : CT assessment of the peripancreatic veins : clinical significance. AJR Am J Roentgenol 174 : 677-684, 2000.
PubMed
9) Fukukura Y, et al : Pancreatic adenocarcinoma : analysis of the effect of various concentrations of contrast material. Radiat Med 26 : 355-361, 2008.
PubMed
10) 日本医学放射線学会/日本医学放射線科専門医会・医会 (編) : 画像診断ガイドライン2013年版 (第1版), 金原出版, 2013.
 
11) Kim HJ, et al : Focal fatty replacement of the pancreas : usefulness of chemical shift MRI. AJR Am J Roentgenol 188 : 429-432, 2007.
PubMed
12) Mochizuki K, et al : MDCT findings of extrapancreatic nerve plexus invasion by pancreas head carcinoma : correlation with en bloc pathological specimens and diagnostic accuracy. Eur Radiol 20 : 1757-1767, 2010.
PubMed
13) Gabata T, et al : Small pancreatic adenocarcinomas : efficacy MR imaging with fat suppression and gadolinium enhancement. Radiology 193 : 683-688, 1994.
PubMed
14) Fukukura Y, et al : Pancreatic adenocarcinoma : variability of diffusion-weighted MR imaging findings. Radiology 263 : 732-740, 2012.
PubMed
15) Gabata T, et al : Groove pancreatic carcinomas : radiological and pathological findings. Eur Radiol 13 (7) : 1679-1684, 2003.
PubMed
16) 蒲田敏文ほか : Groove領域の膵癌の画像所見-groove pancreatitisとの鑑別-. 消化器科 35 (3) : 310-315, 2002.
 
17) 蒲田敏文 : 5章 : 膵癌の発生部位による臨床的・画像的特徴. 画像と病理の対比から学ぶ膵癌診療アトラス (太田哲夫, 松井修監修), p72-85, 学研メディカル秀潤社, 2012.
 
P.73 掲載の参考文献
1) 尾花貴志ほか : ERCP像の読影. 消化器内視鏡 20 : 1821-1829, 2008.
Medical*Online
2) Kobayashi G, et al : Lymphoplasmacytic sclerosing pancreatitis forming a localized mass : a variant form of autoimmune pancreatitis. J Gastroenterol 42 : 690-693, 2007.
 
3) Chang WI, et al : The clinical and radiological characteristics of focal mass-forming autoimmune pancreatitis : comparison with chronic pancreatitis and pancreatic cancer. Pancreas 38 : 401-408, 2009.
PubMed
4) Wakabayashi T, et al : Clinical and imaging features of autoimmune pancreatitis with focal pancreatic swelling or mass formation : comparison with so-called tumor-forming pancreatitis and pancreatic carcinoma. Am J Gastroenterol 98 : 2679-2687, 2003.
 
5) 伊藤達雄ほか : 主膵管内に浸潤し膨張発育形式を示した膵内分泌腫瘍の一例. 膵臓 24 : 527-531, 2009.
 
6) 大池信之ほか : 腺房細胞腫瘍. 膵臓症候群, 第2版, p307-310, 日本臨牀社, 2011.
 
7) Ishii S, et al : Undifferentiated carcinoma of the pancreas involving intraductal pedunculated polypoid growth. Intern Med 51 : 3373-3377, 2012.
PubMed
8) Hewitt MJ, et al : EUS-guided FNA for diagnosis of solid pancreatic neoplasms : a meta-analysis. Gastrointest Endosc 75 : 319-331, 2012.
PubMed
9) Takasawa O, et al : Clinicopathological study on the intraductal spread of small pancreatic cancer, J Gastroenterol 42 : 957-961, 2007.
 
10) Iiboshi T, et al : Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer : establishing a new method for the early detection of pancreatic carcinoma in situ. Pancreas 41 : 523-529, 2012.
PubMed
11) van der Waaij LA, et al : Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions : a pooled analysis. Gastrointest Endosc 62 : 383-389, 2005.
PubMed
12) Hirooka Y, et al : Case of intraductal papillary mucinous tumor in which endosonography-guided fine-needle aspiration biopsy caused dissemination. J Gastroenterol Hepatol 18 : 1323-1324, 2003.
PubMed
13) Suzuki R, et al : Diagnostic yield of endoscopic retrograde cholangiopancreatography-based cytology for distinguishing malignant and benign intraductal papillary mucinous neoplasm : systematic review and meta-analysis. Dig Endosc 26 : 586-593, 2014.
PubMed
14) Sai JK, et al : Pancreatic duct lavage cytology with the cell block method for discriminating benign and malignant branch-duct type intraductal papillary mucinous neoplasms. Gastrointest Endosc 77 : 726-735, 2013.
PubMed
15) Hara T, et al : Preoperative histological subtype classification of intraductal papillary mucinous neoplasms (IPMN) by pancreatic juice cytology with MUC stain. Ann Surg 257 : 1103-1111, 2013.
 
P.77 掲載の参考文献
1) Rosch T, et al : Endoscopic ultrasonography in pancreatic tumor diagnosis, Gas trointest Endosc 37 : 347-352, 1991.
 
2) Gress FG. et al : Role of EUS in the preoperative staging of pancreatic callcer : A large single center experience. Gas trointest Endosc 50 : 786-791, 1999.
 
3) Hirooka Y. et al : Diagnosis of pancreatic disorders using contrast-enhanced endoscopic ultrasonography and endoscopic elastography. Clin Gastroenterol Hepatol 7 : S63-67. 2009.
PubMed
4) Niwa K. et al : Comparison of image quality between electronic and mechanical radial scanning echoendoscopes in pancreatic diseases. J Gastroenterl Hepatol 19 : 454-459, 2004.
 
5) Ishikawa H, et al : A comparison of image quality between tissue harmonic imaging and fundamental imaging with an elecironic radial scanning echoendoscope in the diagnos is of pancreatic diseases. Gastrointest Endosc 57 : 931-936, 2003.
PubMed
6) Hirooka Y, et al : Contrast-enhanced endoscopic ultrasonography in digestive diseases. J Gastroenterol 47 (10) : 1063-1072. 2012.
PubMed
7) Ohno E, ct al : Intraductal papillary mucinous neoplasms of the pancreas : differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules, Ann Surg 249 : 628-634, 2009.
 
8) Kitano M, et al : Dynamic imaging of pancreatic diseases by contrast enhanced coded plase inversion harmonic ultlasonography. GUT 53 : 854-859, 2004.
 
9) Matsubara H, et al : Dynamic quantitative evaluation of contrast-enhanced endoscopic ulrasonography in the diagnosis of pancreatic disease. Pancreas 40 (7) : 1073-1079, 2011.
 
10) Hirooka Y, et al : Utility of EUS : Elastography in the Diagnosis of Pancreatic Diseases. Gastrointestinal Endoscopy 61 (5) : AB282, 2005.
 
11) Giovannini M, et al : Endoscopic ultrasound elastography : the first steptowards virtual biopsy? Preliminary results in 49 patients. Endoscopy 38 : 344-348, 2006.
 
12) Iglesias-Garcia J, et al : Quantitative endoscopic ultrasound elastography : an accurate method for the differentiation of solid pancreatic masses. Gastroenterology 139 (4) : 1172-1180, 2010.
PubMed
13) Itoh Y, et al : Quantitative analysis of diagnosing pancreatic fibrosis using EUS-elastography (comparison with surgical specimens). J Gastroenterol 49 (7) : 1183-1192, 2014.
PubMed
14) Hartwig W, et al : Preoperative tissue diagnosis for tumours of the pancreas. Br J Surg 96 : 5-20, 2009.
PubMed
15) Hara K et al : Prospective clinical study of EUS-guided choledochoduodenostomy for malignant lower biliary tract obstruction. Am J Gastroenterol 106 : 1239-1245, 2011.
PubMed
P.82 掲載の参考文献
1) Takeshita K, et al : Imaging of early pancreatic cancer on multidetector row helical computed tomography. Br J Radiol 83 (994) : 823-830, 2010.
PubMed
2) Zubarik R, et al : Screening for pancreatic cancer in a high-risk population with serum CA 19-19 and targeted EUS : a feasibility study. Gastrointest Endosc 74 (1) : 87-95, 2011.
 
3) Seo S, et al : Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma. J Hepatobiliary Pancreat Surg 15 (6) : 634-639, 2008.
 
4) Okano K, et al : 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol 17 (2) : 231-235, 2011.
PubMed
5) Rijkers AP, et al : Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer : a meta-analysis. Eur J Surg Oncol 40 (7) : 794-804, 2014.
PubMed
6) Dibble EH, et al : PET/CT of cancer patients : part 1, pancreatic neoplasms. AJR Am J Roentgenol 199 (5) : 952-967, 2012.
PubMed
7) Tang S, et al : Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma : a meta-analysis. Eur J Radiol 78 (1) : 142-150, 2011.
PubMed
8) 山本立真ほか : FDG-PET陰性膵癌の特徴. 胆と膵 33 (5) : 407-412, 2012.
Medical*Online
9) Izuishi K et al : Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer, J Gastrointest Surg 14 (7) : 1151-1158, 2010.
PubMed
10) Kauhanen SP, et al : A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 250 (6) : 957-963, 2009.
PubMed
11) Nishiyama Y, et al : Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun 26 (10) : 895-901, 2005.
PubMed
12) Ruf J, et al : Detection of recurrent pancreatic cancer : comparison of FDG-PM with er/MRI. Pancreatology 5 (2-3) : 266-272, 2005.
 
13) Wakabayashi H, et al : Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 14 (1) : 64-69, 2008.
 
14) Maemura K, et al : Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg 13 (5) : 435-441, 2006
PubMed
P.86 掲載の参考文献
1) 水野伸匡 : CQ1-4膵癌の診断を確定するための次のステップはどうするか? 科学的根拠に基づく膵癌診療ガイドライン2013年版 (日本膵臓学会膵癌診療ガイドライン改訂委員会編), p38-42, 金原出版, 2013.
 
2) 中泉明彦ほか : ERCPによる細胞診・組織診. 消化器内視鏡ハンドブック (日本消化器内視鏡学会卒後教育委員会責任編集), p449-451, 日本メディカルセンター, 2012.
 
3) 松本和也ほか : 膵液細胞診. 肝胆膵 66 : 285-291, 2013.
Medical*Online
4) 中泉明彦 : 膵癌早期診断における細胞診の意義. 京都府立医科大学雑誌 121 : 417-425, 2012.
 
5) 花田敬士 : CQ1-7長期予後が期待できる早期の膵癌を診断するにはどうするか? 科学的根拠に基づく膵癌診療ガイドライン2013年版 (日本膵臓学会膵癌診療ガイドライン改訂委員会編), p48-53, 金原出版, 2013.
 
6) Imamura T, et al : Effectiveness of cytodiagnosis with pancreatic duct lavage fluid for pancreatic ductal carcinoma : new sampling technique. Digestive Endoscopy 18 : 303-307, 2006.
 
7) 木村公一ほか : ENPDチューブ留置での連続膵液採取による細胞診の小膵癌診断への有用性の検討. 日消誌 108 : 928-936, 2011.
Medical*Online
8) 中泉明彦, 竹中明美 : 膵液細胞診・擦過細胞診の判定基準と有用性. 病理と臨床 27 : 1157-1165, 2009.
Medical*Online
9) Eguchi H, et al : Role of intraoperative cytology combined with histology in detecting continuous and skiptype intraductal cancer existence for intraductal papillary mucinous carcinoma of the pancreas. Cancer 107 : 2567-2575, 2006.
 
10) 中泉明彦ほか : 膵癌ハイリスク群におけるリスク増強因子としての喫煙の意義. 平成25年度喫煙科学研究財団研究年報, p324-328, 2014.
 
11) Kanda M, et al : Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 62 : 1024-1033, 2013.
PubMed
12) Nakaizumi A, et al : Usefulness of simple endoscopic aspiration cytology of pancreatic juice for diagnosis of early pancreatic neoplasms : a prospective study. Dig Dis Sci 42 : 1796-1803, 1997.
PubMed
13) 中泉明彦ほか : 膵液細胞診で診断された1cm以下の膵癌. 胆と膵 30 : 325-334, 2009.
Medical*Online
14) Yamada T, et al : Cytologic detection of small pancreatico-duodenal and biliary cancers in the developmental stage. Acta Cytol 28 : 435-442, 1984.
PubMed
15) Kanda M, et al : Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142 : 730-733, 2012.
PubMed
P.91 掲載の参考文献
1) Chen G, et al : Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer : a meta-analysis. Pancreatology 12 : 298-304, 2013.
 
2) Fritscher-Ravens A, et al : Endoscopic ultrasound-guided fine needle aspiration training : evaluation of a new porcine lymphadenopathy model for in vivo hands-on teaching and training, and review of the literature. Endoscopy 45 : 114-120, 2013.
PubMed
3) Varadarajulu S, et al : Best practices in endoscopic ultrasound-guided fine-needle aspiration. Clin Gastroenterol Hepatol 19 : 697-703, 2012.
 
4) Kudo T, et al : Influence of the safety and diagnostic accuracy of preoperative endoscopic ultrasound-guided fine-needle aspiration for resectable pancreatic cancer on clinical performance. World J Gastroenterol 20 : 3620-3627, 2014.
PubMed
5) Konda VJ, et al : A pilot study of in vivo identification of pancreatic cystic neoplasms with needle-based confocal laser endomicroscopy under endosonographic guidance. Endoscopy 45 : 1006-1013, 2013.
PubMed
6) Hamada T, et al : Severe bleeding and perforation are rare complications of endoscopic ultrasound-guided fine needle aspiration for pancreatic masses : an analysis of 3,090 patients from 212 hospitals. Gut Liver 8 : 215-218, 2014.
PubMed
7) Affolter KE, et al : Needle size has only a limited effect on outcomes in EUS-guided fine needle aspiration : a systematic review and meta-analysis. Dig Dis Sci 58 : 1026-1034, 2013.
 
8) Strand DS, et al : EUS-guided 22-gauge fine-needle aspiration versus core biopsy needle in the evaluation of solid pancreatic neoplasms. Diagn Cytopathol 42 : 751-758, 2014.
PubMed
9) Suzuki R, et al : An automated spring-loaded needle for endoscopic ultrasound-guided abdominal paracentesis in cancer patients. World J Gastrointest Endosc 6 : 55-59, 2014.
PubMed
10) Lee JK, et al : A prospective, comparative trial to optimize sampling techniques in EUS-guided FNA of solid pancreatic masses. Gastrointest Endosc 77 : 745-751, 2013.
PubMed
11) Kudo T, et al : High and low negative pressure suction techniques in EUS-guided fine-needle tissue acquisition by using 25-gauge needles : a multicenter, prospective, randomized, controlled trial. Gastrointest Endosc 80 : 1030-1037, 2014.
 
12) Nakai Y, et al : Slow pull versus suction in endoscopic ultrasound-guided fine-needle aspiration of pancreatic solid masses. Dig Dis Sci 59 : 1578-1585, 2014.
PubMed
13) Bang JY, et al : Randomized trial comparing fanning with standard technique for endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic mass lesions. Endoscopy 45 : 445-450, 2013.
PubMed
14) 菅野敦ほか : 自己免疫性膵炎の診断におけるEUS-FNAのコツ. Gastroenterological Endosc 55 : 3795-3807, 2013.
 
15) Mehmood S, et al : Onsite cytopathology evaluation and ancillary studies beneficial in EUS-FNA of pancreatic, mediastinal, intra-abdominal, and submucosal lesions. Diagn Cytopathol, 2014. [Epub ahead of print]
 
P.98 掲載の参考文献
1) 日本膵臓学会 (編) : 膵癌取扱い規約, 第6版, p23-24, 金原出版, 2002.
 
2) 田中雅夫ほか : 膵癌登録報告2007. 膵臓 22 : e1-427, 2007.
 
3) 伊佐地秀司 : 膵臓癌. 専門医のための消化器病学, 第2版 (小俣政男ほか監, 下瀬川徹ほか編), p628-636, 医学書院, 2013.
 
4) 厚生労働省ホームページ : 平成25年人口動態統計月報年計 (概数) の概況. [http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai13/index.htm]
 
5) 若尾文彦ほか : がんの統計 '12, p12-35, 公益財団法人がん研究振興財団, 2012.
 
6) American Cancer Society : Cancer Facts and Figures. [http://www.cancer.org/Research/CancerFactsFigures/index]
 
7) Rahib L, et al : Projecting cancer incidence and deaths to 2030 : the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74 : 2913-2921, 2014.
PubMed
8) Egawa S, et al : Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 41 : 985-992, 2012.
PubMed
P.102 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン, 2013年版, 金原出版, 2013.
 
2) DiMango EP, et al : AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma, Gastroenterology 177 : 1464-1484, 1999.
 
3) Tada M, et al : Pancreatic cancer in patients with pancreatic cystic lesions : A prospective study in 197 patients. Clin Gastroenterol Hepatol 4 : 1265-1270, 2006.
PubMed
4) Kawakubo K, et al : Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. Gut 60 : 1249-1253, 2011
PubMed
P.105 掲載の参考文献
1) 日本膵臓学会 : 膵癌登録報告2007. 膵臓 22 : e1-e427, 2007.
 
2) 日本膵臓学会 (編) : 膵癌取扱い規約, 第6版補訂版, 金原出版, 2013.
 
3) 柳澤昭夫, 加藤洋 : 通常型膵癌における主膵管癌浸潤-とくに膵管鏡検査のために-. 消化器内視鏡3 (7) : 841-844, 1991.
 
P.108 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2013年版, 金原出版, 2013.
 
2) Palsson B, et al : Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer. Eur J Surg Oncol 23 : 151-156, 1997.
PubMed
3) 日本膵臓学会膵癌登録委員会 : 膵癌登録報告2007. 膵臓 22 : e1-e94, 2007.
 
4) 江川新一ほか : 膵癌登録からみた膵癌のリスクファクター. 肝胆膵 48 : 547-554, 2004.
 
5) Bakkevold KE, et al : Carcinoma of the pancreas and papilla of Vater : presenting symptoms, signs, and diagnosis related to stage and tumour site. A prospective multicentre trial in 472 patients. Norwegian Pancreatic Cancer Trial. Scand J Gastroenterol 27 : 317-325, 1992.
 
6) 山川正規ほか : 膵癌症例における膵癌危険因子の検討. 膵臓 18 : 479-488, 2003.
Medical*Online
7) Lin Y, et al : Obesity, physical activity and the risk of pancreatic in a large Japanese cohort. Int J Cancer 120 : 2665-2671, 2007.
 
8) Larsson SC, et al : Body mass index and pancreatic cancer risk : A meta-analysis of prospective studies. Int J Cancer 120 : 1993-1998, 2007.
 
9) Li D, et al : Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 301 : 2553-2562, 2009.
PubMed
P.113 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン, 2013年版, 金原出版, 2013.
 
2) Tanaka S, et al : Slight dilatation of the main pancreatic duct and presence of pancreatic cysts as predictive signs of pancreatic cancer : a prospective study. Radiology 254 : 965-972, 2010.
PubMed
3) 中泉明彦, 田中幸子 : 膵がん検診の有用性と限界. 膵臓 24 : 594-602, 2009.
Medical*Online
4) 日本超音波医学会膵癌診断基準検討小委員会 : 膵癌超音波診断基準. 超音波医学 40 : 511-518, 2013.
 
5) 日本膵臓学会 (編) : 膵癌取扱い規約, 第6版, 補訂版, 金原出版, 2013.
 
P.117 掲載の参考文献
1) 厚生労働省ホームページ : 人口動態統計2012. [http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/suikei12/]
 
2) 江川新一ほか : 膵癌登録報告2007 ダイジェスト. 膵臓 23 : 105-123, 2008.
Medical*Online
3) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2013年版, 金原出版, 2013.
 
4) Yasuda I, et al : Role of EUS in the early detection of small pancreatic cancer. Dig Endosc 23 : 22-25, 2011.
PubMed
5) 江川新一 : 膵癌登録された1cm以下の小膵癌の解析. 胆と膵 30 : 311-316, 2009.
Medical*Online
6) 坂本洋城ほか : 1cm以下小膵癌の診断のためのアプローチ-各画像診断の比較-. 胆と膵 30 : 335-341, 2009.
Medical*Online
7) Inoue K, et al : Severe localized stenosis and marked dilatation of the main pancreatic duct are indicators of pancreatic cancer instead of chronic pancreatitis on endoscopic retrograde balloon pancreatography. Gastrointest Endosc 58 : 510-515, 2003.
PubMed
8) 中原理紀 : 膵癌の再発診断. 胆と膵 33 : 413-416, 2012.
Medical*Online
9) Hartwig W, et al : Preoperative tissue diagnosis for tumours of the pancreas. Br J Surg 96 : 5-20, 2009.
PubMed
10) Wakatsuki T, et al : Comparative study of diagnostic value of cytologic sampling by endoscopic ultrasonography-guided fine-needle aspiration and the endoscopic retrograde pancreatography for the management of pancreatic mass without biliary stricture. J Gastroenterol Hepatol 20 : 1707-1711, 2005.
PubMed
11) Uchida N, et al : Utility of pancreatic duct brushing for diagnossi of pancreatic carcinoma. J Gastoroenterol 42 : 657-662, 2007.
 
12) 今村綱男ほか : 通常型膵管癌に対する膵管洗浄細胞診の有用性～胆膵領域の新たな検体採取方法. Gastroenterological Endoscopy 51 : 84-90, 2009.
 
13) 木村公一ほか : ENPDチューブ留置での連続膵液採取による細胞診の小膵癌診断への有用性の検討. 日消誌 108 : 928-936, 2011.
Medical*Online
14) Haba S, et al : Diagnostic ability and factors affecting accuracy of endoscopic ultrasound-guided fine needle aspiration for pancreatic solid lesions : Japanese large single center experience. J Gastroenterol 48 : 973-981, 2013.
PubMed
15) Ogura T, et al : Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses. Gastrointest Endosc 75 : 769-774, 2012.
PubMed
P.123 掲載の参考文献
1) 日本膵臓学会 (編) : 膵癌取扱い規約, 第6版, 金原出版, 2009.
 
2) Ishii S, et al : Undifferentiated carcinoma of the pancreas involving intraductal pedunculated polypoid growth. Intern Med 51 : 3373-3377, 2012.
PubMed
3) 大池信之ほか : 腺房細胞腫瘍. 膵臓症候群, 第2版, p307-310, 日本臨牀社, 2011.
 
4) Nakahara K, et al : Solid-pseudopapillary tumor of the pancreas showing a remarkable reduction in size over the 10-year follow-upperiod. Intern Med 47 : 1335-1339, 2008.
 
5) Kobayashi G, et al : Lymphoplasmacytic sclerosing pancreatitis forming a localized mass : a variant form of autoimmune pancreatitis. J Gastroenterol 42 : 690-693, 2007.
 
6) Koshita S, et al : Localized autoimmune pancreatitis, 9mm in size, without strictures of the main pancreatic duct. Gastrointest Endosc 75 : 920-922, 2012.
 
7) Chang WI, et al : The clinical and radiological characteristics of focal mass-forming autoimmune pancreatitis : comparison with chronic pancreatitis and pancreatic cancer. Pancreas 38 : 401-408, 2009.
PubMed
8) Wakabayashi T, et al : Clinical and imaging features of autoimmune pancreatitis With focal pancreatic swelling or mass formation : comparison with so-called tumor-forming pancreatitis and pancreatic carcinoma. Am J Gastroenterol 98 : 2679-2687, 2003.
 
9) Shimosegawa T, et al : International consensus diagnostic criteria for autoimmune pancreatitis : guidelines of the International Association of Pancreatology. Pancreas 40 : 352-358, 2011.
PubMed
10) Iwashita T, et al : Use of samples from endoscopic ultrasound-guided 19-gauge fine-needle aspiration in diagnosis of autoimmune pancreatitis. Clin Gastroenterol Hepatol 10 : 316-322, 2012.
 
11) Kanno A, et al : Diagnosis of autoimmune pancreatitis by EUS-FNA by using a 22-gauge needle based on the International Consensus Diagnostic Criteria. Gastrointest Endosc 76 : 594-602, 2012.
PubMed
12) 小林剛ほか : ERCPとEUSによる腫瘤形成性膵炎の診断. 胆と膵 20 : 285-292, 1999.
Medical*Online
13) Becker V, Mischke U : Groove pancreatitis. Int J Pancreatol 10 : 173-182, 1991,
PubMed
14) Itoh S, et al : CT findings in groove pancreatitis : correlation with histopathological findings. J Comput Assist Tomogr 18 : 911-915, 1994.
PubMed
15) Gabata T, et al : Groove pancreatic carcinomas : radiological and pathological findings. Eur Radiol 13 : 1679-1684, 2003.
PubMed
P.128 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2009年版, 金原出版, 2009.
 
2) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2013年版, 金原出版, 2013.
 
3) 日本緩和医療学会ホームページ : ガイドライン, [http://www.jspm.ne.jp/guidelines/]
 
4) 日本膵臓学会 (編) : 膵癌取扱い規約, 第6版補訂版, 金原出版, 2013.
 
5) Nimura Y, et al : Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 19 (3) : 230-241, 2012.
 
6) Kimura W, et al : A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system : the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg 259 (4) : 773-780, 2014.
PubMed
7) 元井冬彦ほか : 切除企図・切除可能膵癌に対する術前化学療法の有効性. 癌と化学療法 40 (12) : 1632-1636, 2013.
Medical*Online
8) Kinoshita T, et al : Effects of adjuvant intra-operative raditation therapy after curative resection in pancreatic cancer patients : Results of a randomized study by 11 institutions in Japan. J Clin Oncol 27 (15s) Suppl : Abstract 4622, 2009.
 
9) 木下平ほか : 肝胆膵領域におけるRCTの結果と今後の展望 膵癌治癒切除後の補助療法としての術中放射線治療 (IORT) の意義を問うRCT. 日外会誌 111 (臨増2) : 161, 2010.
 
10) Uesaka K et al : Randomized phase III trial of adjuvant chemotherapy with gemicitabine versus S-1 for patients With resetced pancreatic cancer (JASPAC-01 study). J Clin Oncol 31 Suppl : Abstract 145, 2013.
 
11) 日本膵臓学会ホームページ : 膵癌診療ガイドライン2013年版の一部改訂について. [http://www.suizou.org/2014/news-11.html]
 
P.133 掲載の参考文献
1) 梛野正人, 二村雄次 : 膵癌治療-最近の動向4. 拡大手術は生存率向上に寄与するか? 日外会誌 107 : 173-176, 2006.
 
2) Strasberg SM, et al : Radical antegrade modular pancreatosplenectomy. Surgery 133 : 521-527, 2003.
PubMed
3) Nakao A, Takagi H : Isolated pancreatectomy for pancreatic head carcinoma using catheter bypass of the portal vein. Hepatogastroenterology 40 : 426-429, 1993.
PubMed
4) 伊佐地秀司ほか : 下部胆管癌・乳頭部癌に対する幽門輪温存膵頭十二指腸切除-前方到達法による膵頭側切除術-. 手術 61 : 821-827, 2007.
 
5) Mizuno S, et al : Anterior approach to the superior mesenteric artery by using nerve plexus hanging maneuver for borderline resectable pancreatic head carcinoma. J Gastrointest Surg 18 : 1209-1215, 2014.
 
6) Azumi Y, Isaji S : Stented pancreaticojejunostomy (with video). J Hepatobiliary Pancreat Sci 19 : 116-124, 2012.
 
7) Murata Y, et al : Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. Pancreas 41 : 130-136, 2012.
 
P.137 掲載の参考文献
1) 日本内視鏡外科学会学術委員会 : 内視鏡外科手術に関するアンケート調査-第11回集計結果報告. 日本内視鏡外科学会雑誌 17 : 571-694, 2012.
 
2) 里井壮平ほか : 膵癌に対する腹腔鏡下細胞診と生検の意義. 胆と膵 31 : 869-873, 2010.
 
3) Gagner M, et al : Early experience with laparoscopic resections of islet cell tumors. Surgery 120 : 1051-1054, 1996.
PubMed
4) Gagner M, Pomp A : Laparoscopic pylorus-preserving panreatoduodenectomy. Surg Endosc 8 : 408-410, 1994.
PubMed
5) 森川孝則ほか : 腹腔鏡下脾動静脈温存膵体尾部切除術の手術手技. 手術 68 : 1101-1106, 2014.
 
6) Melotti G, et al : Laparoscopic distal pancreatectomy : result on a consecutive series of 58 patients. Ann Surg 246 : 77-82, 2007.
PubMed
7) Kooby DA, et al : Left-sided pancreatectomy : a multicenter comparison of laparoscopic and open approaches. Ann Surg 248 : 438-446, 2008.
PubMed
8) Kooby DA, et al : A multicenter analysis of distal pancreatectomy for adenocarcinoma : is laparoscopic resection appropriate? J Am Coll Surg 210 : 779-787, 2010.
PubMed
9) Baker MS, et al : A prospective single institution comparison of peri-operative outcomes for laparoscopic and open distal pancreatectomy. Surgery 146 : 635-645, 2009.
PubMed
10) Venkat R, et al : Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique : A systematic review and meta-analysis. Ann Surg 255 : 1048-1059, 2012.
 
11) Gumbs AA, et al : Laparoscopic pancreatoduodenectomy : a review of 285 published cases. Ann Surg Oncol 18 : 1335-1341, 2011.
PubMed
12) Correa-Gallego C, et al : Minimally-invasive vs open pancreaticoduodenectomy : Systematic review and meta-analysis. J Am Coll Surg 218 : 129-139, 2014.
PubMed
13) Horiguchi A, et al : Robot-assisted laparoscopic pancreatic surgery. J Hepatobiliary Pancreat Sci 18 : 488-492, 2011.
PubMed
14) Al-Rashedy M, et al : Laparoscopic gastric bypass for gastric outlet obstruction is associated with smoother, faster recovery and shorter hospital stay compared with open surgery. J Hepatobiliary Pancreat Surg 12 : 474-478, 2005.
PubMed
15) Huser N, et al : Systematic review and meta-analysis of prophylactic gastroenterostomy for unreseclable advanced pancreatic cancer. Br J Surg 96 : 711-719, 2009.
PubMed
P.142 掲載の参考文献
1) Yokoyama Y, Nagino M : Role of extended surgery for pancreatic cancer : critical review of the four major RCTs comparing standard and extended surgery. J Hepatobiliary Pancreat Sci 18 : 785-791, 2011.
PubMed
2) Esposito I, et al : Most pancreatic cancer resections are RI resections. Ann Surg Oncol 15 : 1651-1660, 2008.
 
3) Kayahara M, et al : Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion. Surgery 117 : 616-623, 1995.
PubMed
4) Nagakawa T, et al : Clinicopathological evaluation of long-term survivors treated for cancer of the head of pancreas. Hepatogastroenterology 45 : 1865-1869, 1998.
PubMed
5) Kitagawa H, et al : Carcinoma of the ventral and dorsal pancreas exhibit different patterns of lymphatic spread. Front Biosci 13 : 2728-2735, 2008.
PubMed
6) Makino I, et al : Nerve plexus invasion in pancreatic cancer, spreading patterns on histopathologic and embryological analyses. Pancreas 37 : 358-365, 2008.
PubMed
7) Noto M, et al : Panceas head carcinoma : frequency of invasion to soft tissue adherent to the superior mesenteric artery. Am J Surg Pathol 29 : 1056-1061, 2005.
 
8) 北川裕久ほか (編) : 画像と病理の対比から学ぶ膵癌診療アトラス (太田哲生, 松井修監), p88-171, 秀潤社, 2012.
 
9) 北川裕久ほか : SMA合併切除を伴う膵頭十二指腸切除術. 日外会誌 112 : 164-169, 2011.
 
10) Tajima H, et al : Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Exp Ther Med 3 : 787-792, 2012.
 
11) 北川裕久ほか : 膵頭部癌術後の消化吸収障害に対する高力価・腸溶性膵消化酵素剤投与の有用性についての検討. 膵臓 28 : 178-183, 2013.
Medical*Online
12) 田島秀浩ほか : 膵体尾部癌の手術成績からみた体尾部境界再考の必要性. 膵臓 27 : 742-745, 2012.
Medical*Online
13) Hirano S, et al : Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer : long-term results. Ann Surg 246 : 46-51, 2007
PubMed
P.147 掲載の参考文献
1) ReMine WH, et al : Total pancreatectomy. Ann Surg 172 : 595-604, 1970.
PubMed
2) Hicks RE, Brooks JR : Total pancreatectomy for ductal carcinoma. Surg Gynecol Obstet 133 : 16-20, 1971.
PubMed
3) Moossa AR, et al : The place of total and extended total pancreatectomy in pancreatic cancer. World J Surg 8 : 895-899, 1984.
PubMed
4) Dresler CM, et al : Metabolic consequences of (regional) total pancreatectomy. Ann Surg 214 : 131-140, 1991.
PubMed
5) van Heerden JA, et al : Radical pancreatoduodenectomy-a procedure to be abandoned? Mayo Clin Proc 56 : 601-606, 1981.
PubMed
6) Muller MW, et al : Is there still a role for total pancreatectomy? Ann Surg 246 : 966-974, 2007.
 
7) Reddy S, et al : Total pancreatectomy for pancreatic adenocarcinoma evaluation of morbidity and long-term survival. Ann Surg 250 : 282-287, 2009.
PubMed
8) Evans DB, et al : Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 : 3496-3502, 2008.
 
9) Takahashi H, et al : Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg 258 : 1040-1050, 2013.
PubMed
10) National Comprehensive Cancer Network (NCCN) : Practice Guidelines for pancreatic cancer. [http://www.nccn.org/clinical/.asp]
 
P.151 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2013年版, 金原出版, 2014.
 
2) Burris HA 3rd, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized tria1. J Clin Oncol 15 : 2403-2413, 1997.
 
3) Okada S, et al : Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 31 : 7-12, 2001.
PubMed
4) Okusaka T, et al : A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61 : 615-621, 2008.
PubMed
5) Ueno H, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 31 (13) : 1640-1648, 2013.
PubMed
6) Moore MJ, et al : Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 : 1960-1966, 2007.
 
7) Okusaka T, et al : Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102 (2) : 425-431, 2011.
PubMed
8) Conroy T, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19) : 1817-1825, 2011.
 
9) Von Hoff DD, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (18) : 1691-1703, 2013.
PubMed
10) Ryan DP, et al : TH-302 plus gemcitabine (G+T) versus gemcitabine (G) in patients with previously untreated advanced pancreatic cancer (PAC), 2013 Gastrointestinal Cancers Symposium. J Clin Oncol 30 (Suppl 34) : Abstract 325, 2012.
 
11) Meyer T, et al : A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. Eur J Cancer 46 (3) : 526-533, 2010.
 
P.157 掲載の参考文献
1) 日本膵臓学会膵癌登録委員会 (編) : 膵癌登録報告2007. 膵臓 1 : e29-32, 2007.
 
2) 独立行政法人国立がん研究センター がん対策情報センター : がん情報サービス. [http://ganjoho.jp/professional/statistics/index.html]
 
3) Neoptolemos JP, et al : Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer : a randomised controlled trial. Lancet 358 : 1576-1585, 2001.
PubMed
4) Oettle H, et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA 310 : 1473-1481, 2013.
PubMed
5) Ueno H, et al : A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Groupof Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101 : 908-915, 2009.
 
6) Uesaka K, et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 30 (Suppl 34) : Abstract 145, 2012.
 
7) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2013年版, p2-94, 金原出版t 2013.
 
8) Ando N, et al : A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19 : 68-74, 2012.
 
9) Evans DB, et al : Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 : 3496-3502, 2008.
 
10) Heinrich S, et al : Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 : 2526-2531, 2008.
 
11) Motoi F, et al : Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma : results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 20 : 3794-3801, 2013.
PubMed
12) Assifi MM, et al : Neoadjuvant therapy in pancreatic adenocarcinoma : a meta-analysis of phase II trials. Surgery 150 : 466-473, 2011.
PubMed
13) Motoi F, et al : Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer : Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 21 : 148-158, 2014.
PubMed
14) NCCNガイドライン日本語版 (膵腺癌). [http://www.tri-kobe.org/nccn/guideline/pancreas/japanese/pancreatic.pdf]
 
15) Conroy T, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 : 1817-1825, 2011.
PubMed
16) Von Hoff DD, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 : 1691-1703, 2013.
PubMed
17) Motoi F, et al : Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines. Ann Surg Oncol 18 : 371-379, 2011.
PubMed
18) 元井冬彦ほか : 膵臓 癌切除後腫瘍マーカー非正常化は重要な予後因子である. 日消外会誌 45 : 697-707, 2012.
 
19) 元井冬彦ほか : 膵癌に対する術前化学療法. 日消誌 108 : 1654-1660, 2011.
Medical*Online
20) 元井冬彦ほか : 切除企図膵癌に対する術前治療戦略の意義. 膵臓 28 : 25-33, 2013.
Medical*Online
21) 元井冬彦ほか : 切除企図・切除可能膵癌に対する術前化学療法の有効性. 癌と化学療法 40 : 1632-1636, 2013.
Medical*Online
22) UMIN臨床試験登録システム (UMIN-CTR) : UMIN-ID ; UMIN000009446. [http://www.umin.ac.jp/ctr/index-j.htm]
 
P.161 掲載の参考文献
1) Evans DB, et al : Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 : 3496-3502, 2008.
 
2) White RR, et al : Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 12 : 214-221, 2005.
PubMed
3) Talamonti MS, et al : A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13 : 150-158, 2006.
PubMed
4) Varadhachary GR, et al : Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 : 3487-3495, 2008.
 
5) Le Scodan R, et al : Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma : feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol 20 : 1387-1396, 2009.
PubMed
6) Takahashi H, et al : Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg 255 : 95-102, 2012.
PubMed
7) Gillen S, et al : Preoperative/neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS Med 7 : e1000267, 2010.
PubMed
8) Murphy JD, et al : Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68 : 801-808, 2007.
PubMed
P.166 掲載の参考文献
1) Van den Broeck A, et al : Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 35 : 600-604, 2009.
PubMed
2) Habermehl D, et al : Chemoradiation in patients with isolated recurrent pancreatic cancer-therapeutical efficacy and probability of re-resection. Radiat Oncol 8 : 27, 2013.
PubMed
3) Nakamura A, et al : Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis. Strahlenther Onkol 190 : 485-490, 2014.
PubMed
4) Maemura K, et al : Comparison of hyper-fractionated accelerated and standard fractionated radiotherapy with concomitant low-dose gemcitabine for unresectable pancreatic cancer. Anticancer Res 28 : 2369-2372, 2008.
PubMed
5) Shinchi H, et al : Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. Br J Cancer 96 : 1353-1357, 2007.
PubMed
6) Timmerman RD, et al : Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25 : 947-952, 2007.
 
7) Scorsetti M, et al : Stereotactic body radiation therapy for liver metastases. J Gastrointest Oncol 5 : 190-197, 2014.
PubMed
8) Yuan ZY, et al : Stereotactic body radiation therapy using the CyberKnife ((R)) system for patients with liver metastases. Onco Targets Ther 12 : 915-923, 2014.
 
9) Scorsetti M, et al : Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiat Oncol 12 : 113, 2011.
 
10) Habermehl D, et al : Palliative radiation therapy in patients with metastasized pancreatic cancer-description of a rare patient group. Eur J Med Res 19 : 24, 2014.
 
11) Thompson RF, et al : A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas. Med Phys 41 : 081711, 2014.
PubMed
12) Terashima K, et al : A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol 103 : 25-31, 2013.
 
13) Quispe-Tintaya W, et al : Nontoxic radioactive Listeria (at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci USA 110 : 8668-8673, 2013.
PubMed
P.171 掲載の参考文献
1) 山下泰伸ほか : 閉塞性黄疸の病態-胆道ドレナージの必要性. 胆と膵 34 : 773-777, 2013.
Medical*Online
2) 原和生ほか : ERCP困難例におけるEUSガイド下胆管ドレナージ. 肝・胆・膵 66 : 117-125, 2013.
Medical*Online
3) 吉田雅博ほか : 膵癌手術法の歴史的推移. 外科治療 90 : 272-281, 2004.
Medical*Online
4) 高田忠敬 : PTCD-そのはじめから発展-. 胆道 7 : 555-559, 1993.
Medical*Online
5) Iacono C, et al : Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection : highlights and drawbacks. Ann Surg 257 : 191-204, 2013.
PubMed
6) Singhirunnusorn J, et al : Value of preoperative biliary drainage in a consecutive series of resectable periampullary lesions. From randomized studies to real medical practice. Langenbecks Arch Surg 398 : 295-302, 2013.
 
7) van der Gaag NA et al : Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 362 : 129-137, 2010.
PubMed
8) Bittoni A, et al : Neoadjuvant therapy in pancreatic cancer : an emerging strategy. Gastroenterol Res Pract 2014 : 183852, 2014.
PubMed
9) Kubota K, et al : Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer. Dig Endosc 26 : 77-86, 2014.
PubMed
10) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2013年版, 金原出版, 2013.
 
11) Moss AC, et al : Malignant distal biliary obstruction : systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev 33 : 213-221, 2007.
PubMed
12) Isayama H, et al : A prospective randomized study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 53 : 729-734, 2004.
PubMed
13) Kitano M, et al : Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared With uncovered stents for distal biliary obstruction caused by pancreatic carcinoma : arandomized multicenter trial. Am J Gastroenterol 108 : 1713-1722, 2013.
 
14) Graber I, et al : The efficacy and safety of duodenal stenting : a prospective multicenter study. Endoscopy 39 : 784-787, 2007.
PubMed
15) Kim JY, et al : Comparison of treatment outcomes of endoscopic stenting for colonic and extracolonic malignant obstruction. Surg Endosc 27 : 272-277, 2013.
PubMed
P.175 掲載の参考文献
1) Andtbacka RH, et al : Surgical and endoscopic palliation for pancreatic cancer. Minerva Chir 59 : 123-136, 2004.
PubMed
2) 日本膵臓学会 (編) : 科学的根拠に基づく膵癌診療ガイドライン, 金原出版, 2013.
 
3) Watanapa P, Williamson RC : Surgical palliation for pancreatic cancer : developments during the past two decades. Br J Surg 79 : 8-20, 1992.
PubMed
4) Weaver DW, et al : Gastrojejunostomy : Is it helpful for patients with pancreatic cancer? Surgery 102 : 608-613, 1987.
PubMed
5) Doberneck RC, Berndit GA : Delayed gastric emptying after palliative gastrojejunostomy for carcinoma of the pancreas. Arch Surg 122 : 827-829, 1987.
 
6) 松田正道ほか : 十二指腸閉塞を伴う膵癌に対する消化管バイパス術の有効性と適応について. 膵臓 28 : 62-66, 2013.
Medical*Online
7) Maruno MA, et al : Advances in gastrointestinal intervention : the treatment of gastroduodenal and colorectal obstructions with metallic stents. Radiology 215 : 659-669, 2000.
 
8) Maetani I, et al : Comparison of duodenal stent placement with surgical gastrojejunostomy for palliation in patients with duodenal obstructions caused by pancreaticobiliary malignancies. Endoscopy 36 : 73-78, 2004.
PubMed
9) Meha S, et al : Prospective randomized trial of laparoscopic gastrojejunostomy versus stenting for malignant gastric outflow obstruction. Surg Endosc 20 : 239-242, 2006.
 
10) 栗原俊夫ほか : 膵・胆道癌緩和医療におけるIVR・IVEの役割. 胆と膵 31 : 89-94, 2001.
 
11) Lillemoe KD, et al : Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 230 : 322-328, 1999.
 
12) Van Heek NT, et al : The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer : a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg 238 : 894-902, 2003.
 
13) Cho YK, et al : Significance of palliative gastrojejunostomy for unresectable pancreatic head carcinoma. Hepatogastroenterology 55 : 254-258, 2008.
PubMed
P.180 掲載の参考文献
1) Egawa S, et al : Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 41 : 985-992, 2012.
PubMed
2) Wray CJ, et al : Surgery for pancreatic cancer : recent controversies and current practice. Gastroenterology 128 : 1626-1641, 2005.
PubMed
3) Neoptolemos Jp, et al : Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection : a randomized controlled trial. JAMA 304 : 1073-1081, 2010.
PubMed
4) Varadhachary GR, et al : Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol 8 : 377-384, 2005.
PubMed
5) Tempero MA, et al : Pancreatic adenocarcinoma. J Natl Compr Canc Netw 8 : 972-1017, 2010.
PubMed
6) Talamonti MS, et al : A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13 : 150-158, 2006.
PubMed
7) Crane CH, et al : Challenges in the study of adjuvant chemoradiation after pancreaticoduodenectomy. Ann Surg Oncol 17 : 950-952, 2010.
 
8) Okada K, et al : Surgical strategy for patients with pancreatic body/tail carcinoma : Who should undergo distal pancreatectomy with en-bloc celiac axis resection? Surgery 153 : 365-372, 2013.
PubMed
9) Hirono S, et al : Indication for the use of an interposed graft during portal vein and/or superior mesenteric vein reconstruction in pancreatic resection based on perioperative outcomes. Langenbecks Arch Surg 399 : 461-471, 2014.
PubMed
10) Satoi S, et al : Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments : results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20 : 590-600, 2013.
PubMed
P.184 掲載の参考文献
1) 江川新一ほか : 膵癌登録報告2007ダイジェスト. 膵臓 23 : 105-123, 2008.
Medical*Online
2) Neuhaus P, et al : Deutsche Krebsgesellschaft (CAO/AIO) CONKO-001 : Final results of the randominized, positive, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreas cancer (PC). J Clin Oncol 26 : Abstract LBA4504, 2008.
 
3) Uesaka K et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreas cancer (JASPAC-01 study). J Clin Oncol 31 (Suppl) : Abstract 145, 2013.
 
4) 船越顕博 (編) : インフォームドコンセントのための図説シリーズ, 膵がん, 改訂3版, 医薬ジャーナル社, 2013.
 
5) Lee SR, et al : Prognostic factors associated with long-term survival and recurrence in pancreatic adenocarcinoma. Hepatogastroenterology 60 : 358-362, 2013.
PubMed
6) Lewis R, et al : A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford) 15 : 49-60, 2013.
 
7) Sinn M, et al : Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. J Surg Oncol 108 : 398-402, 2013.
PubMed
8) Butturini G, et al : Influence of resection margins and treatment on survival in patients with pancreatic cancer : meta-analysis of randomized controlled trials. Arch Surg 143 (1) : 75-83, 2008.
PubMed
9) 元井冬彦ほか : 膵臓癌切除後腫瘍マーカー非正常化は重要な予後因子である. 日消外会誌 45 (7) : 697-707, 2012.
 
10) Ferrone CR, et al : Pancreatic ductal adenocarcinoma : long-term survival does not equal cure. Surgery 152 (3 Suppl 1) : S43-S49, 2012.
 
11) Shimada K, et al : Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg 34 : 1908-1915, 2010.
PubMed
12) 大内田次男ほか : 通常型膵癌に対する長期生存因子の検討. 消化器内科 51 (2) : 195-202, 2010.
 
13) Schlieman MG, et al : Utility of tumor markers in determining respectability of pancreatic cancer. Arch Surg 138 : 951-955, 2003.
 
14) Waraya M, et al : Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol 16 : 1231-1240, 2009.
PubMed
15) La Torre M, et al : Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Gut Liver 8 : 102-108, 2014.
PubMed
P.189 掲載の参考文献
1) 日本膵臓学会 (編) : 膵癌取扱い規約, 第6版, 補訂版, p28, 金原出版, 2013.
 
2) Voong KR, et al : Resected pancreatic adenosquamous carcinoma : clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum Pathol 41 : 113-112, 2010.
PubMed
3) Boyd CA, et al : 415 patients with adenosquamous carcinoma of the pancreas : apopulation-based analysis of prognosis and survival. J Surg Res 174 : 12-19, 2012.
 
4) 田中雅夫 : 膵癌登録報告 2007. 膵臓 22 : e1-e427, 2007.
 
5) 日本膵臓学会膵癌登録委員会 : 日本膵臓学会膵癌登録20年間の総括. 膵臓 18 : 101-169, 2003.
Medical*Online
6) 北川裕久ほか : 膵腺扁平上皮癌. 日本臨牀別冊 膵臓症候群 (第2版), p296-298, 日本臨牀社, 2011.
 
7) 石渡裕俊ほか : 膵腺扁平上皮癌の画像所見の特徴. 膵臓 21 : 62-69, 2006.
Medical*Online
8) 鬼澤俊輔ほか : 膵腺扁平上皮癌. 肝胆膵 49 : 744-747, 2004.
Medical*Online
9) 伊藤達雄ほか : FDG-PETで高度集積を認めた膵腺扁平上皮癌の一例. 膵臓 46 : 616-621, 2009.
 
10) Katz MHG, et al : Adenosquamous versus adenocarcinoma of the pancreas : A population-based outcomes analysis. J Gastrointest Surg 15 : 165-174, 2011.
PubMed
11) 池井聡ほか : 膵腺扁平上皮癌の1切除例. 膵臓 8 : 545-551, 1993.
 
12) Smoot RL, et al : Adenosquamous carcinoma of the pancreas : a single-institution experience comparing resection and palliative care. J Am Coll Surg 207 : 368-370, 2008.
PubMed
13) 花本浩一ほか : 急速な増大を観察し得た膵頭部腺扁平上皮癌の一切除例. 膵臓 28 : 191-196, 2013.
Medical*Online
14) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン, 2013年版, p127-129, 金原出版, 2013.
 
P.193 掲載の参考文献
1) Fukushima N, et al : Ductal adenocarcinoma variant and mixed neoplasms of the pancreas. In : World Health Organization of Classification of Tumours of the Digestive System (ed by Bosman FT, et al), p292-294, International Agency for Research on Cancer (IARC), Lyon, 2010.
 
2) 日本膵臓学会 (編) : 膵癌取扱い規約, 第7版, 金原出版, 2013.
 
3) 松野正紀ほか : 膵癌登録20年間の総括. 膵臓 18 : 97-169, 2003.
 
4) Fukushima N, et al : Intraductal papillary tumors and mucinous cystic tumors of the pancreas. Clinicopathologic study of 38 cases. Hum Pathol 28 : 1010-1017, 1997.
PubMed
5) Sohn TA, et al. Intraductal papillary mucinous neoplasms of the pancreas : an updated experience. Ann Surg 239 : 788-797, 2004
PubMed
6) 住吉辰郎ほか : 膵管内乳頭粘液性腫瘍由来の浸潤癌との鑑別が問題となった膵粘液癌の一例. 日臨外会誌 68 (6) : 1550-1554, 2007.
 
7) 北田英貴ほか : 著明な石灰化をともなった膵粘液癌の1例. 日消誌 102 : 479-483, 2005.
Medical*Online
8) Yoon MA, et al: MRI features of pancreatic colloid carcinoma. AJR Am J Roentgenol 193 : W308-313, 2009.
PubMed
9) Adsay NV, et al : Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol 25: 26-42, 2012.
 
10) 島田和明ほか : 膵粘液癌-稀な膵外分泌腫瘍. 胆と膵 33 (8) : 685-690, 2012.
 
11) 浦田孝広ほか : 急性膵炎を契機に発見された粘液癌の一例. 日消誌 106 : 233-239, 2009.
 
12) 須田耕一ほか : 膵粘液癌の病理組織学的検討. 病理と臨床 9 : 933-937, 1991.
 
13) Poultsides GA, et al : Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg 251 : 470-476, 2010.
PubMed
14) Seidel G, et al : Almost all infiltrating colloid carcinomas of the pancreas and preampulalry region arise from in situ papillary neoplasms : astudy of 39 cases. Am J Surg Pathol 26 : 56-63, 2002.
 
P.197 掲載の参考文献
1) Sommers SC, Meissner WA : Unusual carcinoma of the pancreas. AMA Arch Pathol 58 : 101-111, 1954.
PubMed
2) 日本膵臓学会 (編) : 膵癌取扱い規約, 第6版, 補訂版, p24-31, 金原出版, 2009.
 
3) WHO Classification of Tumours of Digestive System, 4th ed (ed by Bosman Fr, et al), p280-295, The International Agency for Research on Cancer, Lyon, 2010.
 
4) Hruban R et al : Tumours of Pancreas (AFIP, Atlas of Tumor Pathology, 4th series), p23-25, p177-190, American Registry of Pathology Washington DC in collaboration With the Armed Force Institute of Pathology, Washington DC, 2007.
 
5) 日本膵臓学会 : 膵癌登録報告 2007. 膵臓 22 : e1-e425, 2007.
 
6) Clark CJ, et al : Clinical outcomes fbr anaplastic pancreatic cancer : apopulation-based study. J Am Coll Surg 215 : 627-634, 2012.
 
7) Strobel O, et al : A naplastic pancreatic cancer : presentation, surgical management, and outcome. Surgery 149 : 200-208, 2011.
 
8) Paal E, et al : A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of literature. Ann Diagn Pathol 5 : 129-140, 2001.
PubMed
9) 辻江正徳ほか : Gemcitabine投与により肝転移が消失した膵癌術後肝転移再発の1例. 癌と化学療法 30 : 297-301, 2003.
Medical*Online
10) 内田大輔ほか : EUS-FNABにて診断し, 化学療法にて加療した退形成性膵管癌の1例. 胆と膵 30 : 815-819, 2009.
Medical*Online
11) 阿部徹ほか : 肝転移再発に対する集学的治療により長期生存している破骨細胞型退形成性膵管癌の一例. 膵臓 26 : 629-635, 2011.
 
12) Yoshioka M, et al : Effective use of gemcitabine in the treatment of undifferentiated carcinoma with osteoclast-like giant cells of the pancreas with portal vein tumor thrombus. Intern Med 51 : 2145-2150, 2012.
PubMed
P.202 掲載の参考文献
1) Bosman FT, et al (ed) : WHO Classification of Tumours of the Digestive System, IARC, Lyon, 2010.
 
2) Klimstra DS, Adsay NV : Acinar cell carcinoma of the pancreas. A case associated with the lipase hypersecretion syndrome. Pathol Case Rev 6 : 121-126, 2001.
 
3) Toll AD, et al : Acinar cell carcinoma of the pancreas : clinical and cytomorphologic characterics. Korean J Pathol 47 : 93-99, 2013.
 
4) La Rosa S, et al : Clinicopathologic study of 62 acinar cell carcinomas of the pancreas. Insights into the morphology and immunophenotype and search for prognostic markers. Am J Surg Pathol 36 : 1782-1795, 2012.
PubMed
5) La Rosa S, et al : The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. Virchow Arch 454 : 133-142, 2009.
PubMed
6) Yasumoto M, et al : The utility of a novel antibody in the pathological diagnosis of pancreatic acinar cell carcinoma. J Clin Pathol 65 : 327-332, 2012.
PubMed
7) Moore PS, et al : Pancreatic tumours : molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 84 : 253-262, 2001.
PubMed
8) Terhune PG, et al : Evaluation of p53 mutation in pancreatic acinar cell carcinomas of humans and transgenic mice. Pancreas 16 : 6-12, 1998.
PubMed
9) Pellegata NS, et al : K-ras and p53 gene mutations in pancreatic cancer : ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54 : 1556-1560, 1994.
PubMed
10) Longnecker DS : Molecular pathology of invasive carcinoma. Ann NY Acad Sci 880 : 74-82, 1999.
PubMed
11) Abraham SC, et al : Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma : frequent alleic loss on chromosome 11p and alterations in the APC/β-catenin pathway. Am J Surg Pathol 160 : 953-962, 2002.
 
12) Rold C, et al : MicroRNA expression abnormalties in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 24 : 4677-4684, 2006.
 
13) Jiao Y, et al : Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J pathol 232 : 428-435, 2014.
PubMed
14) 古川徹ほか : 膵腺房細胞癌はBRCA2, FAT遺伝子異常を持つ. 第103回日本病理学会総会, 広島 2014.
 
P.205 掲載の参考文献
1) 大橋計彦ほか : 粘液産生膵癌の4例-特異な十二指腸所見を中心として-. Progressive of Digestive Endoscopy 20 : 348-351, 1982.
 
2) Suzuki Y, et al : Cystic neoplasm of the pancreas : a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28 : 241-246, 2004.
PubMed
3) Tanaka M, et al ; International Association of Pancreatology : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
4) Maguchi H, et al : Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas. A multicenter study in Japan. Pancreas 40 : 364-370, 2011.
PubMed
5) Yamaguchi K et al : Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 40 : 571-580, 2011.
PubMed
6) 丹野誠志ほか : 分枝型IPMN症例における膵管癌の危険因子-北海道多施設調査1181例の検討-. 消化器内科 55 : 86-90, 2012.
 
7) Capurso G, et al : Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas : a multicentre case-control study. Am J Gastroenterol 108 : 1003-1009, 2013.
PubMed
8) Larghi A, et al : Prevalence and risk factors of extrapancreatic malignancies in a large cohort of patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Oncol 24 : 1907-1911, 2013.
 
9) Jang JY, et al : Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas : is it possible to predict the malignancy before surgery? Ann Surg Oncol 12 : 124-132, 2005.
PubMed
10) Hwang DW, et al : Determination of malignant and invasive predictors of branch duct type intraductal papillary mucinous neoplasms of the pancreas : asuggested scoring formula. J Korean Med Sci 26 : 740-746, 2011.
PubMed
P.209 掲載の参考文献
1) Tanaka M, et al : International consensus guidelines for management of intraductal papillary mucinous neoplasm and mucinous cystic neoplasm of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
2) Tanaka M, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
3) Adsay V, et al : Intraductal neoplasm of the pancreas. In : World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System (ed by Bosman FT, et al), p304-313, IARC Press, Lyon, 2010.
 
4) Tamura K, et al : Treatment strategy for main duct intraductal papillary mucinous neoplasm of the pancreas based on the assessment of recurrence in the remnant pancreas after resection. Ann Surg 259 : 360-368, 2014.
PubMed
5) Ohtuska T, et al : An increase in the number of predictive factors augments the likelihood of malignancy in branch duct intraductal papillary mucinous neoplasm of the pancreas. Surgery 151 : 76-83, 2012.
 
6) Abdeljawad K, et al : Prevalence of malignancy in patients with pure main duct intraductal papillary mucinous neoplasm. Gastrointest Endosc 79 : 623-629, 2014.
PubMed
7) Jang JY, et al : Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. Br J Surg 101 : 686-692, 2014.
PubMed
8) Kobayashi G, et al : Natural history of branch duct intraductal papillary mucinous neoplasm with mural nodules : a Japan pancreas society multicenter study. Pancreas 43 : 532-538, 2014.
PubMed
9) Ohno E, et al : Intraductal papillary mucinous neoplasm of the pancreas ; differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules. Ann Surg 249 : 628-634, 2009.
PubMed
10) Aso T, et al : "High-Risk Stigmata" of the 2012 International Consensus Guidelines Correlate With the Malignant Grade of Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Pancreas 43 : 1239-1243, 2014.
PubMed
11) Ohtsuka T, et al : Role of endoscopic retrograde pancreatography to detect early pancreatic ductal carcinoma concomitant with intraductal papillary mucinous neoplasm of the pancreas. J Hepatobiliary Pancreat Sci 20 : 356-361, 2013.
PubMed
12) Ideno N, et al : Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 258 : 141-151, 2013.
PubMed
13) Ohtsuka T, et al : Follow-up study after resection of intraductal papillary mucinous neoplasm of the pancreas ; special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas. Am J Surg 204 : 44-48, 2012.
 
14) Possot G, et al : Recurrences after surgical resection of intraductal papillary mucinous neoplasm of the pancreas : asingle-center study of recurrence predictive factors. Pancreas 41 : 137-141, 2012.
 
P.213 掲載の参考文献
1) Adsay NV, et al : Intraductal neoplasms of the pancreas. In : WHO Classification of Tumours of the Digestive System (ed by Bosman FT, et al), p304-313, IARC, Lyon, 2010.
 
2) Tanaka M, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
3) Furukawa T et al : Classification of types of intraductal papillary-mucinous neoplasm of the pancreas : a consensus study. Virchows Arch 447 : 794-799, 2005.
PubMed
4) Furukawa T, et al : Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 60 : 509-516, 2011.
PubMed
5) Adsay NV, et al : Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms : delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol 28 : 839-848, 2004.
PubMed
6) Monzen M, et al : Usefulness of cell block cytology for preoperative grading and typing of intraductal papillary mucinous neoplasms. Pancreatology 13 : 369-378, 2013.
PubMed
7) Hara T, et al : Preoperative histological subtype classification of intraductal papillary mucinous neoplasms (IPMN) by pancreatic juice cytology with MUC stain. Ann Surg 257 : 1103-1111, 2013.
 
P.221 掲載の参考文献
1) 大橋計彦ほか : 総胆管-膵管瘻を形成した膵嚢胞状腺癌の1切除例. Progress of Digestive Endoscopy 17 : 261-264, 1980.
 
2) 大橋計彦ほか : 粘液産生膵癌の4例. Progress of Digestive Endoscopy 20 : 348-351, 1982.
 
3) Adsay N, et al : Intraductal neoplasms of the pancreas. In : WHO Classification of Tumours of the Digestive System, 4th ed (ed by Bosman FT, et al), p304-313, IARC Press, Lyon, 2010.
 
4) 日本膵臓学会 (編) : 膵癌取扱い規約, 第6版補訂版, 金原出版, 2013.
 
5) 清水道生, 伴慎一 : ムチンに関する最近の考え方膵腫瘍に関連して ムチンの概念の変遷病理学的な立場から. 胆と膵 26 : 429-433, 2005.
 
6) Thai P, et al : Regulation of airway mucin gene expression. Annu Rev Physiol 70 : 405-429, 2008.
PubMed
7) Yamada N, et al : MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res 68 : 2708-2716, 2008.
PubMed
8) Shimizu M, Manabe T : Mucin-producing pancreatic tumors : historical review of its nosological concept. Zentralbl Pathol 140 : 211-223, 1994.
PubMed
9) Osako M, et al : Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer 71 : 2191-2199, 1993.
PubMed
10) Nakamura A, et al : New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression : its relationshipwith potential for malignancy. J Pathol 197 : 201-210, 2002.
 
11) Yonezawa S, et al : Mucins in human neoplasms : clinical pathology, gene expression and diagnostic application. Pathol Int 61 : 697-716, 2011.
PubMed
12) Furukawa T, et al : Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 60 : 509-516, 2011.
PubMed
13) Ban S, et al : Intraductal papillary mucinous neoplasm (IPMN) of the pancreas : its histopathologic difference between 2 major types. Am J Surg Pathol 30 : 1561-1569, 2006.
PubMed
14) Adsay NV, et al : Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms : delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol 28 : 839-848, 2004.
PubMed
15) Adsay NV, et al : Intraductal oncocytic papillary neoplasms of the pancreas. Am J Surg Pathol 20 : 980-994, 1996.
PubMed
16) Yamaguchi H, et al : Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 33 : 1164-1172, 2009.
PubMed
17) Nagata K, et al : Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg 14 : 243-254, 2007.
PubMed
P.225 掲載の参考文献
1) Hruban RH, et al : An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28 : 977-987, 2004.
PubMed
2) Crippa S, et al : Intraductal papillary mucinous neoplasms of the pancreas. In : Surgery of Pancreatic Tumors (ed by Shrikhande SV, et al), p289-298, BI Publications, New Delhi, 2008.
 
3) Tanaka M, et al : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
4) Salvia R, et al : Main-duct intraductal papillary mucinous neoplasms of the pancreas : clinical predictors of malignancy and long-term survival following resection. Ann Surg 239 : 678-685, 2004.
PubMed
5) Jang JW, et al : Clinical characteristics of intraductal papillary mucinous neoplasm manifesting as acute pancreatitis or acute recurrent pancreatitis. J Gastroenterol Hepatol 28 : 731-738, 2013.
PubMed
6) Hata T, et al : Dilated papilla with mucin extrusion is a potential predictor of acute pancreatitis associated with intraductal papillary mucinous neoplasms of pancreas. Pancreatology 13 : 615-620, 2013.
PubMed
7) 鈴木裕ほか : IPMT, MCTにおける全国症例調査の分析と現状における問題点. 膵臓 18 : 653-663, 2003.
Medical*Online
8) 堤宏介ほか : 膵炎を発症した膵管内乳頭粘液性腫瘍 (IPMN) 切除症例の検討. 日腹部救急医会誌 30 : 671-676, 2010.
 
9) Bassi C, et al : Natural history of intraductal papillary mucinous neoplasms (IPMN) : current evidence and implications for management. J Gastrointest Surg 12 : 645-650, 2008.
PubMed
10) Partelli S, et al : Invasive intraductal papillary mucinous carcinomas of the pancreas : predictors of survival and the role of lymph node ratio. Ann Surg 251 : 477-482, 2010.
PubMed
11) Salvia R, et al : Dfferences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg 2 : 342-346, 2010.
 
12) Rodriguez JR, et al : Brach-duct intraductal papillary mucinous neoplasms : observations in 145 patients who underwent resection. Gastroenterology 133 : 72-79, 2007.
 
13) Ingkakul T, et al : Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 25 : 70-75, 2010.
 
14) Roch AM, et al : Abnormal serum pancreatic enzymes, but not pancreatitis, are associated with an increased risk of malignancy in patients with intraductal papillary mucinous neoplasms. Surgery 156 : 923-929, 2014.
 
15) Waters JA, et al : Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma : a multi-institutional comparison according to America Joint Committee on Cancer Stage. J Am Coll Surg 213 : 275-283, 2011.
 
16) Yopp AC, et al : Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas : a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg 253 : 968-974, 2011.
PubMed
17) Furukawa T, et al : Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 1 : 161, 2011.
PubMed
18) Wu J, et al : Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 108 : 21188-21193, 2011.
PubMed
19) Murtaza M, et al : Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497 : 108-112, 2013.
PubMed
P.233 掲載の参考文献
1) 大橋計彦ほか : 粘液産生膵癌の4例-特異な十二指腸乳頭所見を中心として-. Prog Digest Endosc 20 : 348-351, 1982.
 
2) Tanaka M, et al : International Association of Pancreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
3) 田中雅夫 : IPMN/MCN国際診療ガイドライン, 医学書院, 2006.
 
4) Tanaka M, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
5) 田中雅夫 : IPMN/MCN国際診療ガイドライン 2012年版, 医学書院, 2012.
 
6) 金子真紀ほか : MDCT, DWI, EUSによる小膵癌の診断. 膵臓 26 : 37-42, 2011.
Medical*Online
7) Hirono S, et al : The carcinoembryonic antigen level in the pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 255 : 517-522, 2012.
PubMed
8) Wu J, et al : Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst deveropment. Sci Transl Med 3 : 92ra63, 2011.
 
9) Yamao K, et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma : A multi-institutional study of Japan Pancreas Society. Pancreas 40 : 67-71, 2011.
PubMed
10) Hirooka Y, et al : Case of intraductal papillary mucinous tumor in which endosonography-guided fine-needle aspiration biopsy caused dissemination. J Gastroenterol Hepatol 18 : 1323-1327, 2003.
PubMed
11) 日本膵臓病学会 (編) : 膵癌取扱い規約, 第6版, 金原出版, 2009.
 
12) Kang MJ, et al : Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol 9 : 87-93, 2011.
PubMed
13) Levy P, et al : Natural history of intraductal papillary mucinous tumors of the pancreas : actuarial risk of malignancy. Clin Gastroenterol Hepatol 4 : 460-468, 2006.
PubMed
14) Maguchi H, et al : Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas. A multicenter study in Japan. Pancreas 40 : 364-370, 2011.
PubMed
15) Zhang J, et al : Correlation between CT patterns and pathological classification of intraductal papillary mucinous neoplasm. Eur J Radiol 73 : 96-101, 2010.
PubMed
16) 里井俊平ほか : 最近5年間におけるIPMN症例の解析-手術術式決定における主膵管径の重要性-. 膵臓 23 : 481-485, 2008.
Medical*Online
17) 真口宏介 : 粘液産生膵腫瘍の臨床病理学的および診断学的研究. 日消誌 91 : 1003-1015, 1994.
Medical*Online
18) 小林剛ほか : EUSによる膵疾患の診断. 消化器外科 25 : 1931-1940, 2002.
 
19) 山口幸二ほか : IPMN由来浸潤癌とIPMN併存膵癌膵臓 27 : 563-571, 2012.
 
20) 白倉克也ほか : 比較的若年に発生し診断に苦慮したIPMN分枝型由来の膵粘液癌の1例. 膵臓 25 : 503-511, 2010.
Medical*Online
21) 小林剛ほか : 粘液産生膵腫瘍の超音波所見と病理組織所見. 日消誌 87 : 235-242, 1990.
 
22) 真口宏介ほか : 分枝型IPMNの自然史-日本における多施設共同研究-. 膵臓 27 : 167-174, 2012.
Medical*Online
23) Kobayashi G, et al : Lateral spread along the main pancreatic duct in branch-duct intraductal papillary mucinous neoplasms of the pancreas : usefulness of intraductal ultrasonography for its evaluation. Dig Endosc 23 : 62-68, 2011.
PubMed
24) Kobayashi G, et al : Intraductal papillary mucinous neoplasms of the pancreas showing fistula formation into other organs. J Gastroenterol 45 : 1080-1089, 2010.
PubMed
P.238 掲載の参考文献
1) Yamaguchi K, et al : Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 40 (4) : 571-580, 2011.
PubMed
2) Tanaka M, et al : International consensus guidelines, 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 (3) : 183-197, 2012.
PubMed
3) Kim KW, et al : Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas : a meta-analysis. Ann Surg 259 (1) : 72-81, 2014.
PubMed
4) Anand N, et al : Cyst features and risk of malignancy in intraductal papillary mucinous neoplasms of the pancreas : a meta-analysis. Clin Gastroenterol Hepatol 11 (8) : 913-921 ; quiz e59-60, 2013.
 
5) Thomton GD, et al : Endoscopic ultrasound guided丘ne needle aspiration for the diagnosis of pancreatic cystic neoplasms : a meta-analysis. Pancreatology 13 (1) : 48-57, 2013.
 
6) Suzuki R, et al : Diagnostic yield of endoscopic retrograde cholangiopancreatography-based cytology for distinguishing malignant and benign intraductal papillary mucinous neoplasm : systematic review and meta-analysis. Dig Endosc 26 (4) : 586-593, 2014.
PubMed
7) Ngamruengphong S, et al : Cyst carcinoembryonic antigen in differentiating pancreatic cysts : a meta-analysis. Dig Liver Dis 45 (11) : 920-926, 2013.
PubMed
8) Nissim S, et al : Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas : a meta-analysis. Pancreas 41 (8) : 1195-1205, 2012.
PubMed
9) Fukushima N, et al : Invasive carcinoma derived from intraductal papillary-mucinous carcinoma of the pancreas : clinicopathologic and immunohistochemical study of eight cases. Virchows Arch 439 (1) : 6-13, 2001.
PubMed
10) Poultsides GA, et al : Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg 251 (3) : 470-476, 2010.
PubMed
11) Koh YX, et al : Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma. Ann Surg Oncol 21 (8) : 2782-2800, 2014.
PubMed
12) Waters JA, et al : Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma : a multi-institutional comparison according to American Joint Committee on Cancer Stage. J Am Coll Surg 213 (2) : 275-283, 2011.
PubMed
13) Sadakari Y, et al : Invasive carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type. Surgery 147 (6) : 812-817, 2010.
 
14) Mino-Kenudson M, et al : Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 60 (12) : 1712-1720, 2011.
PubMed
15) Yopp AC, et al : Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pan creas : a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg 253 (5) : 968-974, 2011.
 
16) Nakata K, et al : Invasive carcinoma derived from intestinal-type intraductal papillary mucinous neoplasm is associated with minimal invasion, colloid carcinoma, and less invasive behavior, leading to abetter prognosis. Pancreas 40 (4) : 581-587, 2011.
 
17) Yamaguchi K, et al : Intraductal papillary-mucinous tumor of the pancreas concomitant with ductal carcinoma of the pancreas. Pancreatology 2 (5) : 484-490, 2002.
PubMed
18) Kamisawa T, et al : Malignancies associated with intraductal papillary mucinous neoplasm of the pancreas. World J Gastroenterol 11 (36) : 5688-5690, 2005.
PubMed
19) Tanno S, et al : Incidence of synchronous and metachronous pancreatic carcinoma in 168 patients with branch duct intraductal papillary mucinous neoplasm. Pancreatology 10 (2-3) : 173-178, 2010.
 
20) Ingkakul T, et al : Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 251 (1) : 70-75, 2010.
PubMed
21) Kanno A, et al : Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas. J Gastroenterol 45 (9) : 952-959, 2010.
PubMed
22) Tada M, et al : Pancreatic cancer in patients with pancreatic cystic lesions : a prospective study in 197 patients. Clin Gastroenterol Hepatol 4 (10) : 1265-1270, 2006.
PubMed
23) Uehara H, et al : Development of ductal carcinoma of the pancreas during follow-upof branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 57 (11) : 1561-1565, 2008.
 
24) Tanno S, et al : Pancreatic ductal adenocarcinomas in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms. Pancreas 39 (1) : 36-40, 2010.
PubMed
25) Ohtsuka T, et al : Follow-up study after resection of intraductal papillary mucinous neoplasm of the pancreas ; special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas. Am J Surg 204 (1) : 44-48, 2012.
 
26) Ideno N, et al : Intraducta1 papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 258 (1) : 141-151, 2013.
PubMed
27) He J, et al : Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg 216 (4) : 657-665 ; discussion 65-67, 2013.
 
28) Tamura K, et al : Unresectable pancreatic ductal adenocarcinoma in the remnant pancreas diagnosed during every-6-month surveillance after resection of branch duct intraductal papillary mucinous neoplasm : a case report. JOP 14 (4) : 450-453, 2013.
PubMed
29) Mori Y, et al : Intraoperative irrigation cytology of the remnant pancreas to detect remnant distinct pancreatic ductal adenocarcinoma in patients with intraductal papillary mucinous neoplasm undergoing partial pancreatectomy. Surgery 155 (1) : 67-73, 2014.
PubMed
P.243 掲載の参考文献
1) Tanaka M, et al : International Consensus Guidelines 2012 for the Management of IPMN and MCN of the Pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
2) 長谷部修ほか : 胆管・膵管拡張を呈する疾患の診断. 消化器内視鏡 25 : 178-185, 2013.
Medical*Online
3) 北野雅之ほか : ここまで進んだ内視鏡診断. 早期膵癌. 消化器内視鏡 22 : 1933-1940. 2010.
 
4) Maguchi H : The role of endoscopic ultrasonography in the diagnosis of pancreatic tumors. J Hepatobiliary Pancreat Surg 11 : 1-3, 2004.
 
5) 一二三倫郎ほか : 膵漿液性嚢胞腺腫の肉眼形態の多様性に関する検討. 胆と膵 22 : 91-98, 2001.
Medical*Online
6) 真口宏介ほか : 膵管内乳頭粘液性腫瘍 (IPMN) ・粘液性嚢胞性腫瘍 (MCN). その他の嚢胞性腫瘍. 日内会誌 101 : 93-99, 2012.
 
7) 真口宏介ほか : 膵腫瘍の超音波診断. J Med Ultrasonics 37 : 425-433, 2010.
 
P.246 掲載の参考文献
1) 多田稔ほか : IPMNからの発癌. 日消誌 109 (2) : 178-182, 2012.
Medical*Online
2) Kawakubo K, et al : Disease-secific mortality among patients with intraductal papillary mucinous neoplasm of the pancreas. Clin Gastroenterol Hepatol 12 : 486-491, 2014.
 
3) Tanaka M, et al : International consensus guidelines, 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
4) Tada M, et al : Pancreatic cancer in patients with pancreatic cystic lesions : a prospective study in 197 patients. Clin Gastroenterol Hepatol 4 : 1265-1270, 2006.
PubMed
5) Uehara H, et al : Development of ductal carcinoma of the pancreas during follow-upof branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 57 : 1561-1565, 2008.
 
6) Tanno S, et al : Pancreatic ductal adenocarcinoma in long-term follow-uppatients with branch duct intraductal papillary mucinous neoplasms. Pancreas 39 : 36-40, 2010.
 
7) Kawakubo K, et al : Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. Gut 60 : 1249-1253, 2011.
PubMed
8) Kamata K, et al : Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy 46 (1) : 22-29, 2014.
PubMed
P.250 掲載の参考文献
1) 木村理, 渡邊利広 : IPMN国際診療ガイドライン2012の解説と残された課題 膵臓 28 : 163-172, 2013.
 
2) Yamaguchi K, et al : Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 40 : 571-580, 2011.
PubMed
3) Ito T, et al : The distribution of atypical epithelium in main-duct type intraductal papillary mucinous neoplasms of the pancreas. J Hepatobilisry Pancreat Sci 18 : 241-246, 2011.
PubMed
4) Kimura W, Nagai H : Study of surgical anatomy for duodenum-preserving resection of the head of the pancreas. Ann Surg 221 : 359-363, 1995.
PubMed
5) 木村理ほか : IPMNに対する外科治療指針の現況. 膵臓 23 : 473-480, 2008.
Medical*Online
6) Kimura W, et al : A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system : the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg 259 : 773-780, 2014.
PubMed
7) Kimura W : Strategies for the treatment of invasive ductal carcinoma of the pancreas and how to achieve zero mortality for pancreaticoduodenectomy. J Hepatobiliary Pancreat Surg 15 : 270-277, 2008.
PubMed
8) Kimura W, et al : Surgical anatomy of arteries running transversely in the pancreas, with special reference to the superior transverse pancreatic artery. Hepatogastroenterology 51 : 973-979, 2004.
 
9) Nakata K, et al : Invasive carcinoma derived from intestinal-type intraductal papillary mucinous neoplasm is associated with minimal invasion, colloid carcinoma, and less invasive behavior, leading to abetter prognosis. Pancreas 40 : 581-587, 2011.
 
10) Kimura W, et al : Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein. Surgery 120 : 885-890, 1996.
PubMed
11) 木村理ほか : 脾温存膵体尾部切除術の意義. 臨床外科 64 : 437-440, 2009.
 
12) 木村理 : 膵消化酵素補充薬 パンクレリパーゼ 日医師会誌 142 : 2468-2469, 2014.
 
13) 木村理 : 膵体尾部切除術. 外科治療 104 : 941-946, 2011.
Medical*Online
P.255 掲載の参考文献
1) Beger HG, et al : Erfahrung mit einer das Duodenum erhaltenden Pankreaskopfresektion bei chronischer Pancreatitis. Chirurg 51 : 303-309, 1980.
PubMed
2) 今泉俊秀ほか : 膵と胆管を十二指腸吻合で再建しえた十二指腸温存膵頭全切除の新術式. 胆と膵 11 : 621-626, 1990.
 
3) 梁英樹ほか : 十二指腸温存膵頭全切除の新術式. 手術44 : 447-451, 1990.
 
4) 羽鳥隆ほか : 十二指腸温存膵頭切除術. 日外会誌 113 : 223-225, 2012.
 
5) 羽鳥隆ほか : 十二指腸温存膵頭切除 (DPPHR). 手術 67 : 915-919, 2013.
 
6) Hatori T, et al : Duodenum-preserving total pancreatectomy for pancreatic neoplasms. J Hepatobiliary Pancreat Sci 17 : 824-830, 2010.
PubMed
7) Ichimura T, et al : Total parenchymal pancreatectomy preserving the duodenum, choledochus and spleen for widespread intraductal papillary mucinous neoplasm : report of a case. Hepatogastroenterology 57 : 8-11, 2010.
PubMed
8) 羽鳥隆ほか : 十二指腸温存膵切除術. 消化器外科 35 : 740-743, 2012.
 
9) Warshaw AL : Conservation of the spleen with distal pancreatectomy. Arch Surg 123 : 550-553, 1988.
PubMed
10) Kimura W, et al : Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein. Surgery 120 : 885-890, 1996.
PubMed
11) Mabrut JY, et al : Laparoscopic pancreatic resection : results of a multicenter European study of 127 patients. Surgery 137 : 597-605, 2005.
PubMed
P.259 掲載の参考文献
1) Tanaka M, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
2) Ohtsuka T, Tanaka M : Chapter 16-Postoperative surveillance of branch duct IPMN. In : Intraductal Papillary Mucinous Neoplasm of the Pancreas (ed by Tanaka M), p189-199, Springer, Tokyo, 2014.
 
3) Ohtsuka T, Tanaka M : Chapter 15-Postoperative surveillance of main duct IPMN. In : Intraductal Papillary Mucinous Neoplasm of the Pancreas (ed by Tanaka M), p181-188, Springer, Tokyo, 2014.
 
4) Tamura K, et al : Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of the recurrences in the remnant pancreas after resection : a retrospective review. Ann Surg 259 : 306-308, 2014.
 
5) Rodriguez JR, et al : Branch-duct intraductal papillary mucinous neoplasms : observations in 145 patients who underwent resection. Gastroenterology 133 : 72-79, 2007.
PubMed
6) Sadakari Y, et al : Invasive carcinoma derived from non-intestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from intestinal type. Surgery 147 : 812-817, 2010.
 
7) Yamaguchi K, et al : Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 40 : 571-580, 2011.
PubMed
8) Ohtsuka T, et al : Follow-upstudy after resection of intraductal papillary mucinous neoplasm of the pancreas : special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas. Am J Surg 204 : 44-48, 2012.
 
9) Ingkakul T, et al : Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 251 : 70-75, 2010.
PubMed
10) Kamata K, et al : Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy 46 : 22-29, 2014.
PubMed
11) Ohtsuka T, et al : Role of endoscopic retrograde pancreatography for early detection of pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm of the pancreas. J Hepatobiliary Pancreat Sci 20 : 356-361, 2013.
PubMed
12) Ideno N, et al : Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 258 : 141-151, 2013.
PubMed
13) Yamagchi K : Chapter 10-Development of extrapancreatic malignancy. In : Intraductal Papillary Mucinous Neoplasm of the Pancreas (ed by Tanaka M), p129-135, Springer, Tokyo, 2014.
 
P.263 掲載の参考文献
1) Tanaka M, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
2) D'Angelica M, et al : Intraductal papillary mucinous neoplasms of the pancreas : an analysis of clinicopathologic features and outcome. Ann Surg 239 : 400-408, 2004.
PubMed
3) Sohn TA, et al : Intraductal papillary mucinous neoplasms of the pancreas : an updated experience. Ann Surg 239 : 788-797 ; discussion 797-799, 2004.
 
4) Ohtsuka T, et al : Follow-up study after resection of intraductal papillary mucinous neoplasm of the pancreas ; special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas. Am J Surg 204 : 44-48, 2012.
 
5) Schnelldorfer T, et al : Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg 143 : 639-646 ; discussion 646, 2008.
PubMed
6) 羽鳥隆ほか : 分枝型IPMNの外科治療戦略 残膵の観察方針と外科治療戦略. 胆と膵 31 : 479-484, 2010.
 
7) He J, et al : Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg 216 : 657-665 ; discussion 665-667, 2013.
 
8) Poultsides GA, et al : Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg 251 : 470-476, 2010.
PubMed
9) Sadakari Y, et al : Invasive carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type. Surgery 147 : 812-817, 2010.
 
10) Wasif N, et al : Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adeno-carcinoma : a stage-matched comparison of outcomes. Cancer 116 : 3369-3377, 2010.
 
11) Yopp AC, et al : Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas : a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg 253 : 968-974, 2011.
PubMed
12) Yamaguchi K, et al : Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 40 : 571-580, 2011,
PubMed
13) Uehara H, et al : Development of ductal carcinoma of the pancreas during follow-upof branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 57 : 1561-1565, 2008.
 
14) Maguchi H, et al : Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas : a multicenter study in Japan. Pancreas 40 : 364-370, 2011.
PubMed
15) 小山内学ほか : IPMNにおける「国際診療ガイドライン」の検証 IPMNの自然史とfollow-up. 胆と膵 30 : 263-270, 2009.
 
P.266 掲載の参考文献
1) Compagno J, Oertel JE : Mucinous cystic neoplasms of the pancreas With overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol 69 : 573-580, 1978.
PubMed
2) Kloppel G, et a1 (ed) : World Health Organization Classification of Tumours. In : Histological Typing of Tumours of the Exocrine Pancreas (World Health Organization-International histologic classification of tumors), Springer, Geneva, 1996.
 
3) Solcia E, et al : Tumor of the pancreas. In : Atlas of Tumor Pathology, Series III, fascicle 20, Armed Forces Institute of Pathology, Washington DC, 1997.
 
4) Suzuki Y, et al : Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor : Cystic neoplasm of the pancreas : aJapanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28 : 241-246, 2004.
PubMed
5) 山雄健次ほか : 卵巣型間質を伴うMCNの臨床病理学的特徴と予後. 膵臓 27 : 9-16, 2012.
 
P.270 掲載の参考文献
1) Zamboni G, et al : Mucinous cystic tumors of the pancreas : clinicopathological features, prognosis, and relationshipto other mucinous cystic tumors. Am J Surg Pathol 23 : 410-422, 1999.
 
2) Thompson LD, et al : Mucinous cystic neoplasm (mucinous cystadenoma of low-grade malignant potential) of the pancreas : a clinicopathologic study of 130 cases. Am J Surg Pathol 23 : 1-16, 1999.
 
3) Nishimura H : Atlas of Human Prenatal Histology, Igaku-Shoin, Tokyo-Newyork, 1983.
 
4) Campbell F, Verbeke CS : Embryology, anatomy, and histology. In : Pathology of the Pancreas. A Practical Approach, p3-4, Springer-Verlag, London, 2013.
 
5) Albores-Saavedra J, et al : Mucinous cystadenocarcinoma of the pancreas. Morphologic and immunohistochemical observations. Am J Surg Pathol 11 : 11-20, 1987.
PubMed
6) Gourley WK, et al : Cystadenoma and cystadenocarcinoma with mesenchymal stroma of the liver. Immunohistochemical analysis. Arch Pathol Lab Med 116 : 1047-1050, 1992.
PubMed
7) Tenti P, et al : Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreatobiliary epithelial cells. Cancer 69 : 2131-2142, 1992.
PubMed
8) Tenti P, et al : Primary retoperitoneal mucinous cystadenocarcinomas : an immunohistochemical and molecular study. Virchows Arch 424 : 53-57, 1994.
 
9) 山雄健次ほか : 卵巣型間質を伴うMCNの臨床病理学的特徴と予後-日本膵臓学会多施設共同研究から-. 膵臓 27 : 9-16, 2012.
 
9) Bosman FT, et al (ed) : WHO Classification of Tumours of the Digestive System, IARC, Lyon, 2010.
 
10) Singhi AD, et al : Preoperative GNAS and KRAS Testing in the Diagnosis of Pancreatic Mucinous Cysts. Clin Cancer Res 20 : 4381-4389, 2014.
PubMed
P.279 掲載の参考文献
1) Compagno J, Oertel JE : Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol 69 : 573-580, 1978.
PubMed
2) Ohashi K, et al : Four cases of mucin-secreting pancreatic cancer. Prog Dig Endosc 20 : 348-351, 1982.
 
3) Hruban RH, et al : Tumors of the Exocrine Pancreas, 4th ed, World Health Organization, p300-303, IARC Press, Lyon, 2010.
 
4) Yamao K, et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian type stroma : a multi-institutional study of the Japan pancreas society. Pancreas 40 : 67-71, 2011.
PubMed
5) Tajiri T, et al : Mucinous cystadenoma of the pancreas 17 years after excision of gallbladder because of a choledochal cyst. J Gastroenterol 39 : 181-187, 2004.
PubMed
6) 福嶋敬宜 : Mucinous Cystic Neoplasm悪性例の病理像および頻度. 肝胆膵 63 : 731-735, 2011.
Medical*Online
7) Lewis GH, et al : Prognosis of minimally invasive carcinoma arising in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 37 : 601-605, 2013.
PubMed
8) Adsay NV : Cystic lesions of the pancreas. Mod Pathol 20 : 71-93, 2007.
 
9) Nitta T, et al : Pancreatic ductal adenocarcinomas with multiple large cystic structures : A clinicopathologic and immunohistochemical study of the seven cases. Pancreatology 13 : 401-408, 2013.
PubMed
10) Tajiri T, et al : Sequential progression and intraductal spread of invasive ductal adenocarcinoma of the pancreas arising from around the main pancreatic duct. Hepatogastroenterology 52 : 745-748, 2005.
PubMed
11) Zamboni G, et al : Mucinous cystic tumors of the pancreas : clinicopathological features, prognosis, and relationshipto other mucinous cystic tumors. Am J Surg Pathol 23 : 410-422, 1999.
 
12) Tanaka M, et a1 ; International Association of Pancreatology : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
 
P.282 掲載の参考文献
1) Zamboni G, et al : Mucinous cystic neoplasms of the exocrine pancreas. In : WHO Classification of Tumours of the Digestive System, 4th ed, LARC Press, Lyon, 2010.
 
2) Tanaka M, et al : International Association of Pancreatology : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
3) Suzuki Y, et al : Cystic neoplasm of the pancreas : a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28 : 241-246, 2004.
PubMed
4) Yoon WJ, et al : Cystic neoplasms of the exocrine pancreas : an update of a nationwide survey in Korea. Pancreas 37 : 254-258, 2008.
PubMed
5) Crippa S, et al : Mucinous cystic neoplasm of the pancreas is not an aggressive entity : lessons from 163 resected patients. Ann Surg 247 : 571-579, 2008.
 
6) Moriya T, Traverso LW : Clinocopathologic feature of mucinous cystic neoplasm of the pancreas vs. side branch duct type IPMN. 45th Annual Pancreas Club Meeting, Chicago, USA ; May 6-7, 2011.
 
7) Yamao K, et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovariantype stroma : a multi-institutional study of the Japan pancreas society. Pancreas 40 : 67-71, 2011.
PubMed
8) Kimura W, et al : Multicenter study of serous cystic neoplasm of the Japan pancreas society. Pancreas 41 : 380-387, 2012.
PubMed
P.286 掲載の参考文献
1) Compagno L, Oertel JE : Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol 69 : 573-580, 1978.
 
2) Zamboni G, et al : Mucinous cystic tumors of the pancreas : clinicopathological features, prognosis, and relationshipto other mucinous cystic tumors. Am J Surg Pathol 23 : 410-422, 1999.
 
3) Yamao K, et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma : a multi-institutional study of the Japan Pancreas Society. Pancreas 40 : 67-71, 2011.
PubMed
4) Yamao K, et al : Endoscopic diagnosis and staging of mucinous cystic neoplasms and intraductal papillary-mucinous tumors. J Hepatobiliary Pancreat Surg 10 : 142-146, 2003.
PubMed
5) Crippa S, et al : Mucinous cystic neoplasm of the pancreas is not an aggressive entity : lessons from 163 resected patients. Ann Surg 247 : 571-579, 2008.
 
6) Suzuki Y, et al : Cystic neoplasm of the pancreas : a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28 : 241-246, 2004.
PubMed
7) van der Waaij LA, et al : Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions : a pooled analysis. Gastrointest Endosc 62 : 383-389, 2005.
PubMed
8) Tanaka M, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
P.290 掲載の参考文献
1) Wada K, et al : Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg 189 : 632-636, 2005.
PubMed
2) Kloppel G, et al : World Health Organization International Histological Typing of Tumors of the Exocrine Pancreas, 2nd ed, p12, Springer-Verlag, Berlin, 1996.
 
3) Tanaka M, et al : International consensus guidelines for intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
4) Tanaka M, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
5) Yamao K et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma : a multi-institutional study of the Japan pancreas society. Pancreas 40 : 67-71, 2011.
PubMed
6) Garcia-Carracedo D, et al : PIK3CA mutations in mucinous cystic neoplasms of the pancreas. Pancreas 43 : 245-249, 2014.
PubMed
7) Nikiforova MN, et al : Integration of KRAS testing in the diagnosis of pancreatic cystic lesions : a clinical experience of 618 pancreatic cysts. Mod Pathol 26 : 1478-1487, 2013.
PubMed
8) Lee LS, et al : Investigating MicroRNA Expression Profiles in Pancreatic Cystic Neoplasms. Clin Transl Gastroenterol 5 : e47, 2014.
PubMed
9) Yamaguchi K, Tanaka M : Radiologic imagings of cystic neoplasms of the pancreas. Pancreatology 1 : 633-636, 2001.
PubMed
10) Oh HC, et al : Cyst Fluid Amylase and CEA Levels in the Differential Diagnosis of Pancreatic Cysts : A Single-Center Experience with Histologically Proven Cysts. Dig Dis Sci 59 : 3111-3116, 2014.
PubMed
11) Wu J, et al : Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3 : 92ra66, 2011.
PubMed
12) Brugge WR, et al : Diagnosis of pancreatic cystic neoplasms : areport of the cooperative pancreatic cyst study. Gastroenterology 126 : 1330-1336, 2004.
 
13) Allen PJ, et al : Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm. Ann Surg 250 : 754-760, 2009.
PubMed
P.293 掲載の参考文献
1) Thompson LD, et al : Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas : aclinicopathologic study of 130 cases. Am J Surg Pathol 23 (1) : 1-16, 1999.
 
2) 国際膵臓学会ワーキンググループ : IPMN/MCN国際診療ガイドライン・2012年版 <日本語版・解説> (田中雅夫訳), p17, 医学書院, 2012.
 
3) Park JW, et al : Mucinous cystic neoplasm of the pancreas : is surgical resection recommended for all surgically fit patients? Pancreatology 14 (2) : 131-136, 2014.
PubMed
4) Yamao K et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma : a multi-institutional study of the Japan pancreas society. Pancreas 40 (1) : 67-71, 2011.
PubMed
5) Lewis GH, et al : Prognosis of minimally invasive carcinoma arising in nucinous cystic neoplasms of the pancreas. Am J Surg Pathol 37 (4) : 601-605, 2013.
PubMed
6) Goh BK, et al : A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma : clinicopathological features of 344 patients. World J Surg 30 (12) : 2236-2245, 2006.
PubMed
7) Crippa S, et al : Mucinous cystic neoplasm of the pancreas is not an aggressive entity : lessons from 163 resected patients. Ann Surg 247 (4) : 571-579, 2008.
 
8) Gil E, et al : Mucinous cystic neoplasms of the pancreas with ovarian stroma. ANZ J Surg 83 (12) : 985-990, 2013.
PubMed
9) Nakagohri T, et al : Surgical outcome of intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol 14 (11) : 3174-3180, 2007.
PubMed
10) Murakami Y, et al : Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery 140 (3) : 448-453, 2006.
PubMed
P.296 掲載の参考文献
1) Compagno J, Oertel JE : Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol 69 : 573-580, 1978.
PubMed
2) Kloppel G, Gibson JB : World Helth Organization : Histological Typing of Tumors of Exocrine Pancreas 2nd ed, Springer, Berline, New York, 1996.
 
3) Solcia E, et al : Tumors of the pancreas. Atlas of Tumor Pathology, 3rd Series, Fascicle 20, AFIP, Washinton DC, 1997.
 
4) Tanaka M, et al : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
5) Zamboni G, et al : Mucinous cystic neoplasm of the pancreas. In : WHO Classification of Tumours of the Digestive System ; World Hearth Organization of Tumours, 4th ed (ed by Bosman FT, et al), p236-238, IARC Press, Lyon, 2010.
 
6) 日本膵臓学会 (編) : 膵癌取扱い規約, 2009年7月, 第6版, 金原出版, 2009.
 
7) Suzuki Y, et al : Cystic neoplasm of the pancreas : aJapanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 28 (3) : 241-246, 2004.
PubMed
8) Yamao K, et al : Clinicopathological featUres and prognosis of mucinous cystic neoplasm with ovarian-type stroma : a multi-institutional study of the Japan pancreas society. Pancreas 40 (1) : 67-71, 2011.
PubMed
9) Tanaka M, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
P.303 掲載の参考文献
1) Compagno J, Oertel JE : Microcystic adenomas of the pancreas (glycogen-rich cystadenomas). A clinicopathologic study of 34 cases. Am J Clin Pathol 69 : 289-298, 1978.
PubMed
2) Hodgkinson DJ, et al : Pancreatic cystadenoma. A clinicopathologic study of 45 cases. Arch Surg 113 : 512-519, 1978.
PubMed
3) 一二三倫郎ほか : 膵漿液性嚢胞腺腫の肉眼形態の多発性に関する検討. 胆と膵 22 : 91-98, 2001.
 
4) Tseng JF, et al : Serous cystadenoma of the pancreas : tumor growth rates and recommendations for treatment. Ann Surg 242 : 413-421, 2005.
PubMed
5) Galanis C, et al : Resected serous cystic neoplasms of the pancreas : a review of 158 patients with recommendations for treatment. J Gastrointest Surg 11 : 820-826, 2007.
PubMed
6) Le Borgne J, et al : Cystadenomas and cystadenocarcinomas of the pancreas : amultiinstitutional retrospective study of 398 cases. French Surgical Association. Ann Surg 230 : 152-161, 1999.
PubMed
7) Bassi C, et al : Management of 100 consecutive cases of pancreatic serous cystadenoma : wait for symptoms and see at imaging or vice versa? World J Surg 27 : 319-323, 2003.
PubMed
8) Kimura W, et al : Multicenter study of serous cystic neoplasm of the Japan pancreas society. Pancreas 41 : 380-387, 2012.
PubMed
9) Terris B, et al : Serous neoplasms of the pancreas. In : WHO classification of tumours of the digestive system 4th ed, p296-299, IARC Press, Lyon, 2010.
 
10) Hruban RH, et al : Tumor of the pancreas. Atlas of tumor pathology 4th series, Fascicle 6, p33-50, Armed Forces Institute of Pathology, Washington DC, 2007.
 
11) Hifumi N, et al : Serous cystic tumor of the pancreas-diagnostic value of CT and MRI imagings. Tan to Sui 24 : 245-253, 2003. (in Japanese)
 
12) Lee SE, et al : The morphological classification of a serous cystic tumor (SCT) of the pancreas and evaluation of the preoperative diagnosis accuracy of computed tomography. Ann Surg Oncol 15 : 2089-2095, 2008.
PubMed
13) Watanabe G, et al : Operative indication of serous cystic tumor. Tan to Sui 24 : 303-310, 2003. (in Japanese)
 
14) 渡邊利広, 木村理 : 漿液性嚢胞腺腫超音波/超音波内視鏡. 見て診て学ぶ膵腫瘍の画像診断, p93-100, 永井書店, 2009.
 
15) 渡邊利広, 木村理 : Serous cystic neoplasm診断 (分類) と治療外科手術の適応は. 肝胆膵 61 : 367-381, 2010.
 
16) Hamilton S, Aaltonen LA : WHO classification of tumours of pathology and genetics of tumors of the digestive system, IARC Press, Lyon, 2000.
 
17) Khashab MA, et al : Tumor size and location correlate with behavior of pancreatic serous cystic neoplasms. Am J Gastroenterol 106 : 1521-1526, 2011.
PubMed
18) 渡邊利広, 木村理 : 膵嚢胞性腫瘍の全国調査で明らかにされた新知見の要点 SCNの全国調査で何が明らかになったか? 肝胆膵 63 : 771-777, 2011.
 
19) Philips CA, et al : Unique presentation of giant metastatic microcystic serous adenocarcinoma of the pancreas. Case Rep Gastrointest Med 2014 : 913745, 2014.
PubMed
20) Franko J, et al : Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. Am J Clin Oncol 31 : 624-625, 2008.
PubMed
21) Kimura W, Makuuchi M : Operative indications for cystic lesions of the pancreas with malignant potential-our experience-. Hepatogastroenterolgy 46 : 483-491, 1999.
 
22) Buscarini E, et al : Italian consensus guidelines for the diagnostic work-upand follow-upof cystic pancreatic neoplasms. Dig Liver Dis 46 : 479-493, 2014.
 
P.309 掲載の参考文献
1) Frantz VK : Tumors of the pancreas. Atlas of tumor pathology 1st series, Fascicles 27 and 28, p32-33, Amed Forces Institute of Pathology, Washington DC, 1959.
 
2) Cubilla AL, Fitzgerald PJ : Tumor of the exocrine pancreas. Atlas of tumor pathology, p201-207, Fascicles 19, Armed Forces Institute of Pathology, Washington DC, 1984.
 
3) 日本膵臓学会 (編) : 膵癌取扱い規約, 第4版, 金原出版, 1993.
 
4) 蒲田敏文ほか : SPNの画像-CT, MRI所見を中心に. 肝胆膵画像 11 : 381-385, 2009.
 
5) Romics L Jr, et al : Solid pseudopapillary neoplasm of the pancreas-proposed argorithms for diagnosis and surgical treatment. Langenbecks Arch Surg 395 : 747-755, 2010.
PubMed
6) 柳澤昭夫ほか : SPNの病理. 肝胆膵画像 11 : 373-379, 2009.
 
7) 祖父尼淳ほか : 膵疾患における造影超音波の有用性と鑑別診断. 肝・胆・膵 60 : 465-477, 2010.
Medical*Online
8) Lee JH, et al : Solid pseudopapillary carcinoma of the pancreas : differentiation from benign solid pseudopapillary tumor using CT and MRI. Clin Radiol 63 : 1006-1014, 2008.
PubMed
9) Chung YE, et al : Differentiation of benign and malignant solid pseudopapillary neoplasms of the pancreas. J Comput Assist Tomogr 33 : 689-694, 2009.
PubMed
10) Wang DB, et al : Imaging features of solid pseudopapillary tumor of the pancreas on multi-detector row computed tomography. World J Gastroenterol 21 : 829-835, 2009.
 
11) Guevendi M, et al : Papillary cystic and solid tumors. In : Surgical Diseases of the Pancreas, 3rd ed (ed by Howard J, et al), p681-693, Williams & Willkins, Baltimore, 1998.
 
12) 吉岡正智ほか : 膵solid-pseudopapillary tumorの臨床病理学的特徴と外科的治療-本邦報告302例と自験6例について. 胆と膵 22 : 45-52, 2001.
 
13) Yu PF, et al : Solid pseudopapillary tumor of the pancreas : A review of 553 cases in Chinese literature. World J Gastroenterol 16 : 1209-1214, 2010.
PubMed
14) Kang CM, et al : Predicting recurrence of pancreatic solid pseudopapillary tumors after surgical resection : Analysis in Korea. Ann Surg 260 : 348-355, 2014.
PubMed
15) Yang F, et al : Solid pseudopapillary tumor of the pancreas : a case series of 26 consecutive patients. Am J Surg 198 : 210-215, 2009.
PubMed
16) Lee SE, et al : Clinical featUres and outcome of solid pseudopapillary neoplasm-Difference between adults and children. Arch Surg 143 : 1218-1221, 2008.
PubMed
17) Reddy S, et al : Surgical management of solid-pseudopapillary neoplasms of the pancreas (Franz or Hamoudi tumors) : a large single-institutional series. Am J Coll Surg 208 : 957-959, 2009.
PubMed
18) Morikawa T, et al : Solid pseudopapillary neoplasms of the pancreas : an 18-year experience at a single Japanese institution. Surg Today 43 : 26-32, 2013.
 
19) 間下直樹ほか : 20年の経過で局所再発を来した膵solid-pseudopapillary neoplasmの1切除例. 日消外会誌 43 : 948-952, 2010.
 
P.315 掲載の参考文献
1) Kerr AA : Cysts and pseudocysts of the pancreas. Surg Gynecol Obset 27 : 40-44, 1918.
 
2) 恩田真二ほか : 膵臓 に発生したdermoid cystの1例. 日消外会誌 43 : 431-436, 2010.
 
3) 浦田孝広ほか : 膵dermoid cystの1例. 日消誌 109 : 1791-1798, 2012.
Medical*Online
4) 熊野正士ほか : 膵の嚢胞性腫瘍. 臨床画像 22 : 1010-1018, 2006.
Medical*Online
5) 井村仁郎ほか : 膵内副脾に発生した類上皮嚢胞の1例. 胆と膵 34 : 257-262, 2013.
Medical*Online
6) 篠原芙美ほか : 粘液性嚢胞腫瘍と鑑別困難であった膵内副脾に発生したepidermoid cystの1例. 日消誌 111 : 566-575, 2014.
Medical*Online
7) 白石治ほか : 膵内副脾epidermoid cystの1症例. 日外科連合雑誌 33 : 213-217, 2008.
 
8) Luchtrath H, Schriefers KH : A pancreatic Cyst With features of a so-called branchiogenic Cyst Pathologe 6 : 217-219, 1985.
PubMed
9) Truong LD, et al : Lymphoepithelial cyst of the pancreas. Am J Surg Pathol 11 : 899-903, 1987.
PubMed
10) 松本祐介ほか : 慢性膵炎にみられた膵リンパ上皮嚢胞 (Lymphoepithelial cyst) の1例. 日臨外会誌 69 : 1786-1790, 2008.
 
11) 加茂田泰久ほか : 術前診断しえた膵lymphoepithelial cystの1例. 膵臓 22 : 123-129, 2007.
Medical*Online
12) 佐々木翔ほか : 4年2ヵ月の経過で増大した膵リンパ上皮嚢胞の1例. 日消誌 111 : 326-333, 2014.
Medical*Online
13) Ahlawat SK : Lymphoepithelial cyst of pancreas. Role of endoscopic ultrasound guided fine needle aspiration. JOP 9 : 230-234, 2008.
PubMed
14) Hirooka Y, et al : Case of intraductal papillary mucinous tumor in which endosonography-guided fine-needle aspiration biopsy caused dissemination. J Gastroenterol Hepatol 18 : 1323-1324, 2003.
PubMed
P.319 掲載の参考文献
1) Metz DC, Jensen RT : Gastrointestinal neuroendocrine tumors. Gastroenterology 135 : 1469-1492, 2008.
PubMed
2) Yao JC, et al : One hundred years after 'carcinoid' : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26 : 3063-3072, 2008.
PubMed
3) Modlin IM, et al : Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9 : 61-72, 2008.
PubMed
4) Ito T, et al : Therapy of metastatic pancreatic neuroendocrine tumors (pNETs) : recent insights and advances. J Gastroenterol 47 : 941-960, 2012.
PubMed
5) Ito T, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
6) Ito T, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 50 : 58-64, 2015.
PubMed
7) Bosman FT, et al : WHO World Health Organization classification of tumors and genetics of the digestive system, IARC press, Lyon, 2010.
 
8) Ishikawa T, et al : Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc 71 : 951-959, 2010.
PubMed
9) Itokawa F, et al : EUS elastography combined with the strain ratio of tissue elasticity for diagnosis of solid pancreatic masses. J Gastroenterol 46 : 843-853, 2011.
PubMed
10) Haba S, et al : Diagnostic ability and factors affecting accuracy of endoscopic ultrasound-guided fine needle aspiration for pancreatic solid lesions : Japanese large single center experience. J Gastroenterol 48 : 973-981, 2013.
PubMed
11) Hosoda W, et al : Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration. Pathol Int 60 : 358-364, 2010.
PubMed
12) Gastrointestinal Pathology Study Groupof Korean Society of Pathologists ; Cho MY, et al : Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009 : Multicenter Study. Cancer Res Treat 44 : 157-165, 2012.
 
13) Ito T, et al : Causes of death and prognostic factors in multiple endocrine neoplasia type 1 : a prospective study : comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 92 : 135-181, 2013.
PubMed
14) Niina Y, et al : The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. Gut Liver 6 : 287-294, 2012.
PubMed
15) Igarashi H, et al : Pancreatic involvement in Japanese patients with von Hippel-Lindau disease : results of a nationwide survey. J Gastroenterol 49 : 511-516, 2014.
PubMed
16) Jensen RT, et al : ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms : functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95 (2) : 98-119, 2012.
PubMed
17) Oberg K, Eriksson B : Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19 : 753-781, 2005.
 
18) Yao JC, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 : 514-523, 2011.
PubMed
19) Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumours : a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol 42 : 903-911, 2012.
PubMed
20) Raymond E, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364 : 1082, 2011.
 
21) Ito T, et al : Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 31 : 1265-1274, 2013.
 
22) Rinke A, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 27 : 4656-4663, 2009.
 
23) Ito T, et al : Pancreatic neuroendocrine tumors : clinical features, diagnosis and medical treatment : advances. Best Pract Res Clin Gastroenterol 26 : 737-753, 2012.
PubMed
24) Tsutsumi K, et al : Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production, J Gastroenterol 47 : 678-685, 2012.
PubMed
25) Ito T, et al : Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 42 : 497-500, 2007.
PubMed
26) Imamura M : Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol 16 : 4519-4525, 2010.
PubMed
P.326 掲載の参考文献
1) Yao JC, et al : One hundred years after "carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26 : 3063-3072, 2008.
PubMed
2) Ito T, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
3) Bosman FT, et al : Pathology and Genetics Tumor of the Digestive system (World Health Organization Classification of Tumors). IARC Press, Lyon, 2010.
 
4) Rindi G, et al : TNM staging of midgut and hindgut (neuro) endocrine tumors : a consensus proposal including a grading system. Virchows Arch 451 : 757-762, 2007.
PubMed
5) Volante M, et al : The pathological diagnosis of neuroendocrine tumor : common questions and tentative answers. Virchows Arch 458 : 393-402, 2011.
PubMed
6) Sorbye H, et al : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : the NORDIC NEC study. Ann Oncol 24 : 152-160, 2013.
 
P.330 掲載の参考文献
1) Jiao Y, et al : DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331 : 1199-1203, 2011.
PubMed
2) Jones S, et al : Core signaling Pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 : 1801-1806, 2008.
PubMed
3) Chandrasekharappa SC, et al : Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 : 404-407, 1997.
PubMed
4) Yokoyama A, et al : The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123 : 207-218, 2005.
PubMed
5) Corbo V, et al : MEN1 in pancreatic endocrine tumors : analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer 17 : 771-783, 2010.
PubMed
6) Lewis PW, et al : Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci USA 107 : 14075-14080, 2010.
PubMed
7) Marinoni I, et al : Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146 : 453-460, 2014.
PubMed
8) Li J, et al : PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 : 1943-1947, 1997.
PubMed
9) Inoki K, et al : TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 : 648-657, 2002.
PubMed
10) Samuels Y, et al : High frequency of mutations of the PIK3CA gene in human cancers. Science 304 : 554, 2004.
PubMed
11) Missiaglia E, et al : Pancreatic endocrine tumors : expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28 : 245-255, 2010.
PubMed
12) Yao JC, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 : 514-523, 2011.
PubMed
13) Cao Y, et al : Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat Commun 4 : 2810, 2013.
PubMed
14) Yachida S, et al : Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36 : 173-184, 2012.
PubMed
15) Libutti SK, et al : Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery 128 : 1022-1027, 2000.
PubMed
16) Hanahan D : Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian Virus 40 oncogenes. Nature 315 : 115-122, 1985.
PubMed
17) Crabtree JS, et al : A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 98 : 1118-1123, 2001.
PubMed
18) Stiles BL, et al : Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol 26 : 2772-2781, 2006.
PubMed
P.337 掲載の参考文献
1) 土井隆一郎ほか : MEN-I型合併消化管ホルモン産生腫瘍の治療方針. 内分泌外科 19 : 91-97, 2002.
 
2) 土井隆一郎ほか : MEN-I型に合併する膵内分泌腫瘍の治療方針. 外科 62 : 1040-1045, 2000.
 
3) 土井隆一郎ほか : 多発性内分泌腺腫症1型に発生する膵島腫瘍の診断と手術法に関する新たな展開, 外科 68 : 808-814, 2006.
 
4) Oberg K, Eriksson B : Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19 : 753-781, 2005.
 
5) Plockinger U, et al : Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80 : 394-424, 2004.
 
6) Ito T, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
7) Gibril F, et al : Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome : a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 83 : 43-83, 2004.
PubMed
8) Trump D, et al : Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89 : 653-669, 1996.
PubMed
9) Sakurai A, et al : Clinical features of insulinoma in patients with multiple endocrine neoplasia type 1 : analysis of the database of the MEN Consortium of Japan. Endocr J 59 : 859-866, 2012.
PubMed
10) Brandi ML, et al : Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 : 5658-5671, 2001.
PubMed
11) Goudet P, et al : Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34 : 249-255, 2010.
 
12) Imamura M, et al : Clinicopathological characteristics of duodenal microgastrinomas. World J Surg 16 : 703-709 : discussion 709-710, 1992.
 
13) 土井隆一郎, 塚田俊彦 : 消化性潰瘍とガストリノーマ. 総合臨床 57 : 525-532, 2008.
Medical*Online
14) 土井隆一郎, 塚田俊彦 : ガストリノーマの診断と治療. 内分泌外科 24 : 69-73, 2007.
 
15) 土井隆一郎 : ガストリノーマ. 日本臨牀 69 (増刊号2) : 589-592, 2011.
 
16) 土井隆一郎 : 膵内分泌腫瘍. 消化器外科 31 : 1141-1152, 2008.
 
17) 土井隆一郎 : 神経内分泌腫瘍. 消化器外科 34 : 1239-1246, 2011.
 
18) Sakurai A, et al : Multiple endocrine neoplasia type 1 in Japan : establishment and analysis of a multicentre database. Clin Endocrinol (Oxf) 76 : 533-539, 2012.
PubMed
19) Plockinger U, et al : ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors. Neuroendocrinology 90 : 159-161, 2009.
PubMed
20) Glascock MJ, Carty SE : Multiple endocrine neoplasia type 1 : fresh perspective on clinical features and penetrance. Surg Oncol 11 : 143-150, 2002.
PubMed
21) Schaefer S, et al : Natural course of small adrenal lesions in multiple endocrine neoplasia type 1 : an endoscopic ultrasound imaging study. Eur J Endocrinol 158 : 699-704, 2008.
PubMed
22) Imamura M, et al : Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. Wo rld J Gastroenterol 17 : 1343-1353, 2011.
 
23) Bartsch DK, et al : Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242 : 757-764 ; discussion 764-756, 2005.
 
24) Fraker DL, et al : Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 220 : 320-328 ; discussion 328-330, 1994.
 
25) Norton JA, et al : Surgery increases survival in patients with gastrinoma. Ann Surg 244 : 410-419, 2006.
PubMed
26) 今村正之 : NET臨床の変遷 : 局在診断法の進歩と病態解明. 医学のあゆみ 224 : 753-756, 2008.
Medical*Online
27) Gibril F, et al : Prospective study of the natural history of gastrinoma in patients with MEN1 : definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 86 : 5282-5293, 2001.
 
28) Jethwa P, et al : Diabetic control after total pancreatectomy. Dig Liver Dis 38 : 415-419, 2006.
PubMed
29) Maeda H, Hanazaki K : Pancreatogenic diabetes after pancreatic resection. Pancreatology 11 : 268-276, 2011.
PubMed
30) Steinmuller T, et al : Consensus guidelines for the management of patients with liver metastases from digestive (neuro) endocrine tumors : foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87 : 47-62, 2008.
PubMed
31) Cardinal JW, et al : A report of a national mutation testing service for the MEN1 gene : clinical presentations and implications for mutation testing. J Med Genet 42 : 69-74, 2005.
PubMed
32) Kihara M, et al : MEN1 gene analysis in patients with primary hyperparathyroidism : 10-year experience of a single institution for thyroid and parathyroid care in Japan. Endocr J 56 : 649-656, 2009.
PubMed
33) Tham E, et al : Clinical testing for mutations in the MEN1 gene in Sweden : a report on 200 unrelated cases. J Clin Endocrinol Metab 92 : 3389-3395, 2007.
 
P.342 掲載の参考文献
1) 伊藤鉄英ほか : 日本における内分泌腫瘍の疫学. 膵臓 23 : 654-659, 2008.
 
2) de Herder WW, et al : Well-differentiated pancreatic tumor/carcinoma : insulinoma. Neuroendocrinology 126 : 183-188, 2006.
 
3) 都築義和, 石井裕正 : インスリノーマ-本邦の1991-2000年における358例の臨床統計的観察-. 日本臨牀 59 : 121-131, 2001.
Medical*Online
4) Placzkowski KA, et al : Secular Trends in the Presentation and Management of Functioning Insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab 94 : 1069-1073, 2009.
 
5) Service FJ, et al : Hypoglycemic disorders. N Engl J Med 332 : 1144-1152, 1995.
PubMed
6) Gouya H, et al : CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. Am J Roentgenol 181 : 987-992, 2003.
 
7) Grant CS, et al : Insulinoma. The value of intraoperative ultrasonography. Arch Surg 123 : 843-848, 1988.
PubMed
8) Noone TC, et al : Imaging and localization of islet-cell tumors of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Netab 19 : 195-211, 2005.
 
9) Imamura M : Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol 16 : 4519-4525, 2010.
PubMed
10) Doppman JL, et al : Insulinoma ; Localization with selective intraarterial injection of calcium. Radiology 178 : 237-241, 1991.
PubMed
11) Oberg K, et al : Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15 : 966-973, 2004.
PubMed
12) Service FJ, et al : Functioning insulinoma-incidence, recurrence, and long-term survival of patients : a 60-year study. Mayo Clin Proc 66 : 711-719, 1991.
PubMed
13) Espana-Gomez MN, et al : Pancreatic insulinoma : a surgical experience. World J Surg 33 : 1996-1970, 2009.
 
P.351 掲載の参考文献
1) Croughs RJ, et al : Glucagonoma as part of the polyglandular adenoma syndrome. Am J Med 52 : 690-698, 1972.
PubMed
2) Roggli VL, et al : Duodenal glucagonoma : acase report. Hum Pathol 10 : 350-353, 1979.
 
3) Hunstein W, et al : Glucagonoma syndrome and bronchial carcinoma. Ann Intern Med 109 : 920-921, 1988.
PubMed
4) Ito T, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.
PubMed
5) Doi R, et al : Pancreatic Endocrine Tumor in Japan. Pancreas 28 : 247-252, 2004.
PubMed
6) Guillausseau PJ, et al : Les Glucagonomes. Aspects cliniques, biologiques, anatomopathologiques et therapeutiques (revue generale de 130 cases). Gastroenterol Clin Biol 6 : 1029-1041, 1982.
PubMed
7) Mallinson CN, et al : A glucagonoma syndrome. Lancet 2 : 1-5, 1974.
PubMed
8) Fjallskog ML, et al : Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92 : 1101-1107, 2001.
PubMed
9) Kulke MH, et al : A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51 : 1033-1038, 2006.
PubMed
10) Wynick D, et al : Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 319 : 605-607, 1988.
PubMed
P.354 掲載の参考文献
1) Zollinger RM, Ellison EH : Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142 : 709-728, 1955.
PubMed
2) Eiseman B, Maynard RM : A noninsulin producing islet cell adenoma associated with progregsive peptic ulceration (the Zollinger-Ellison syndrome). Gastroenterology 31 : 296-304, 1956.
PubMed
3) Gregory RM, et al : Extraction of a gastrin-like substance from a pancreatic tumour in a case of Zollinger-Ellison syndrome. Lancet 1 (7133) : 1045-1048, 1960.
 
4) Isenberg JI, et al : Zollinger-Ellison syndrome. Gastroenterology 65 : 140-165, 1973.
PubMed
5) Yeung MJ, Pasieka JL : Gastrinomas : a historical perspective. J Surg Oncol 100 : 425-433, 2009.
PubMed
6) Wu PC, et al : A prospective analysis of the frequency, location, and curability of ectopic (nonpancreaticoduodenal, nonnodal) gastrinoma. Surgery 122 : 1176-1182, 1997.
PubMed
7) Stabile BE, et al : The gastrinoma triangle : Operative implications. Am J Surg 147 : 25-31, 1984.
PubMed
8) Soga J, Yakuwa Y : The gastrinoma/Zollinger-Ellison syndrome : statistical evaluation of a Japanese series of 359 cases. J Hepatobiliary Pancreat Surg 5 : 77-85, 1998.
 
9) 泉山肇ほか : 膵内分泌腫瘍の画像診断. 膵臓 23 : 665-670, 2008.
Medical*Online
10) Imamura M, et al : Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 17 : 1343-1353, 2011.
PubMed
11) Ito T, et al : Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 42 : 497-500, 2007.
PubMed
12) Jensen RT, et al : ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms : functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95 : 98-119, 2012.
PubMed
13) 土井隆一郎 : ガストリノーマ. 日本臨牀 69 (増刊号2) : 585-592, 2011.
Medical*Online
14) Wada M, et al : Intravenous calcium injection test is a novel complementary procedure in differential diagnosis for gastrinoma. World J Surg 26 : 1291-1296, 2002.
PubMed
15) Sigh S, et al : Chromogranin A : a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 6 : 313-314, 2012.
 
16) Imamura M, et al : Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg 205 : 230-239, 1987.
PubMed
17) Krenning EP, et al : Somatostatin receptor scintigraphy with [111In-DTPA-D-Phel]-and [123I-Tyr3]-octreotide : the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20 : 716, 1993.
PubMed
18) van Essen M, et al : Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumors. Acta Oncol 46 : 723-734, 2007.
PubMed
19) Yu F, et al : Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 17 : 615-630, 1999.
PubMed
P.357 掲載の参考文献
1) Oberndorfer S : Karzinoide Tumoren des DUnndarmes. Frankf Z Pathol 1 : 426-429, 1907.
 
2) Bosman FT, et al : Tumours of the pancreas. Neuroendocrine neoplasm. In : WHO Classification of Tumours of the Digestive System. IARC press, Lyon, 2010.
 
3) Modlin IM, et al : A 5-dicade analysis of 13,715 carcinoid tumors. Cancer 97 : 934-959, 2003.
PubMed
4) Soga J : Carcinoids of the pancreas : an analysis of 156 cases. Cancer 105 : 1180-1187, 2005.
 
5) Bilimoria KY, et al : Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors : analysis of 9,821 patients. J Gastrointesti Surg 11 : 1460-1467, 2007.
 
6) Mao C, et al : Carcinoid tumor of the pancreas. Status report based on two cases and review of the world's literature. Int J Pancreatol 23 : 153-164, 1998.
PubMed
7) Puli SR, et al : Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors : a systematic review and meta analysis. World J Gastroenterol 19 : 3678-3684, 2013.
 
8) Maurer CA, et al : Carcinoid of the pancreas : clinical characteristics and morphological features. Eur J Cancer 32a : 1109-1116, 1996.
PubMed
9) La Rosa S, et al : Serotonin-producing enterochromaffin cell tumors of the pancreas : clinicopathologic study of 15 cases and comparison with intestinal enterochromaffin cell tumors. Pancreas 40 : 883-895, 2011.
PubMed
10) Kunz PL et al : Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 42 : 557-577, 2013.
PubMed
P.360 掲載の参考文献
1) Adachi Y, et al : A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers. World JGastroenterol 16 : 5779-5789, 2010.
PubMed
2) Min Y, et al : Genetic blockade of the insulin-like growth factor-I receptor : a oromising strategy for human pancreatic cancer. Cancer Res 63 : 6432-6441, 2003.
PubMed
3) Chung JO, et al : Hypoglycemia associated with the production of insulin-like growth factor II in a pancreatic islet cell tumor : a case report. Endocr J 55 : 607-612, 2008.
 
4) Wulbrand U, et al : mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur J Clin Invest 30 : 729-739, 2000.
PubMed
5) Hoog A, et al : Insulin-like growth factor-II in endocrine pancreatic tumours. Immunohistochemical, biochemical and in situ hybridization findings. APMIS 109 : 127-140, 2001.
PubMed
6) 吉嵜友之ほか : 先端巨大症を来したGH-RH産生膵内分泌腫瘍の一例. 内分泌会誌 86 (Suppl) : 32-35, 2010.
 
7) 緑川早苗ほか : MEN1型に合併した膵内分泌腫瘍からのGHRH産生による先端巨大症とその治療経験. 内分泌会誌87 (Suppl) : 69-71, 2011.
 
8) Vitale L, et al : Differential expression of alternatively spliced mRNA forms of the insulin-like growth factor 1 receptor in human neuroendocrine tumors. Oncol Rep 15 : 1249-1256, 2006.
PubMed
9) Hantel C, et al : Anti insulin-like growth gactor I receptor immunoliposomes : a single formulation combining two anticancer treatments with enhanced therapeutic efficiency. J Clin Endocrinol Metab 95 : 943-952, 2010.
 
10) Vitale G, et al : Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. Am J Physiol Endocrinol Metab 296 : E559-E566, 2009.
PubMed
11) Strosberg JR et al : A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer 20 : 383-390, 2013.
PubMed
12) Ida T, et al : Gastric neuroendocrine carcinoma with non-islet cell tumor hypoglycemia associated with enhanced production of insulin-like growth factor II. Intern Med 52 : 757-760, 2013.
PubMed
13) Sturrock ND, et al : Spontaneous hypoglycaemia in a noninsulin-dependent diabetes mellitus patient with disseminated pancreatic carcinoma. Diabet Med 14 : 324-326, 1997.
 
14) Mizuta Y, et al : Acinar cell carcinoma of the pancreas associated with hypoglycemia : Involvement of "big" insulin-like growth factor-II. J Gastroenterol 33 : 761-765, 1998.
PubMed
15) 福田いずみ : IGF-II産生腫瘍中のIGF-IIの性質に関する研究. 東京女子医大誌 61 : 289-299, 1991.
 
P.367 掲載の参考文献
1) Donowitz, et al : Evaluation of patients with chronic diarrhea. N Engl J Med 332 : 725-729, 1995.
PubMed
2) American Gastroenterological Association medical position statement : guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 116 : 1461-1463, 1999.
PubMed
3) Kirkwood KS, Debas HT : Neuroendocrine tumors : Common presentations of uncommon diseases. Compr Ther 21 : 719-725, 1995.
PubMed
4) Soga J, Yakuwa Y : Somatostatinoma/inhibitory syndrome : a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 18 : 13-22, 1999.
 
5) Mao C, et al : Von Recklinghausen's disease associated with duodenal somatostatinoma : Contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 59 : 67-73, 1995.
PubMed
6) O'Brien TD, et al : Clinical features of duodenal somatostatinomas. Surgery 114 : 1144-1147, 1993.
PubMed
7) Angeletti S, et al : Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 42 : 792-794, 1998.
PubMed
8) Doga M, et al : Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors : relevant clinical aspects. Ann Oncol 12 (Suppl 2) : S89-94, 2001.
 
9) Alexandraki KI, Grossman AB : Ectopic ACTH syndrome. Rev Endocr Metab Disord 11 : 117-126, 2010.
PubMed
P.370 掲載の参考文献
1) Yao JC, et al : One hundred years after carcinoid : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26 : 3063-3072, 2008.
PubMed
2) 伊藤鉄英ほか : 日本における膵内分泌腫瘍の現状と治療戦略. 福岡医学雑誌 103 : 131-137, 2012.
Medical*Online
3) Friesen SR, Tomita T : The APUD concept of islet cell tumors. In : Surgical Disease of the Pancreas (ed by Howard JM), p803-813, Lea & Febiger, Philadelphia. 1987.
 
4) Kimura W, et al : Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 36 : 933-942, 1991.
PubMed
5) Modlin IM, et al : Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9 : 61-72, 2008.
PubMed
6) Dromain C, et al : Detection of liver metastases from endocrine tumors : a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23 : 70-78, 2005.
PubMed
7) Kann P, et al : Endosonography of insulin-secreting and clinically non-functioning neuroendocrine tumors of the pancreas : criteria for benignancy and malignancy. Eur J Med Res 6 : 385-390, 2001.
PubMed
8) Gibril F, Jensen RT : Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis 36 (Suppl 1) : S106-120, 2004.
 
9) 日本膵臓学会 (編) : 膵癌取り扱い規約, 第6版補訂版, 金原出版, 2013.
 
10) Falconi M, et al : Surgical strategy in the treatment of pancreatic neuroendocrine tumors. JOP 7 : 150-156, 2006.
PubMed
11) 五十嵐久人ほか : 膵神経内分泌腫瘍に対する薬物療法. 腫瘍内科 7 : 198-204, 2011.
 
12) Rinke A, et al ; PROMID Study Group : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 27 : 4656-4663, 2009.
 
13) Raymond E, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364 : 501-513, 2011.
PubMed
14) 五十嵐久人ほか : 膵神経内分泌腫瘍 1. 疫学・症候・診断. 日内誌 101 : 100-108, 2012.
 
15) 木村理 : 非機能性膵内分泌腫瘍の診断と治療の現状. 日消誌 101 : 373-381, 2004.
 
P.375 掲載の参考文献
1) Adler H, et al : Pancreatectomy for metastatic disease : a systematic review. Eur J Surg Oncol 40 : 379-386, 2014.
PubMed
2) Reddy S, Wolfgang CL : The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol 10 : 287-293, 2009.
 
3) 小塚貞夫ほか : 転移性膵癌の病理学的研究. 胆と膵 1 : 1531-1535, 1980.
 
4) 遠藤健ほか : 下行結腸癌切除後の転移性膵腫瘍の1例. 日臨外会誌 65 : 2464-2467, 2004.
 
5) Palmowski M, et al : Metastasis to the pancreas : characterization by morphology and contrast Pancreatology 8 : 199-203, 2008.
 
6) 多田知子ほか : 腎癌の多発性膵転移に対し, 膵全摘術を施行した1例. 日消誌 8 : 199-203, 2008.
 
7) Layfield IJ, et al : Metastatic disease to the pancreas documented by endoscopic ultrasound guided Diagn Cytopathol 40 : 228-233, 2012.
 
8) 里見佳昭 : 腎がんの治療の現況と今後の課題. 日泌尿会誌 81 : 1-13, 1990.
 
9) Tanis PJ, et al : Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 96 : 579-592, 2009.
PubMed
10) Abe H, Kamai T : Recent advances in the treatment of metastatic renal cell carcinoma Int J Urol 20 : 944-955, 2013.
PubMed
11) Minni F, et al : Pancreatic metastases : observations of three cases and review of the literature. Pancreatology 4 : 509-520, 2004.
PubMed
12) Sperti C, et al : Metastasis to the pancreas from colorectal cancer : is there a place for pancreatic resection? Dis Colon Rectum 52 : 1154-1159, 2009.
 
13) 篠藤浩一ほか : 直腸癌異時性膵転移の1例. 日臨外会誌 72 : 438-443, 2011.
 
14) 葛西智徳 , 堀蝦 : 肺癌剖検症例の遠隔転移に対する検討. 青森県立中央病院医誌 40 : 93-97, 1995.
 
15) Ettinger DS, et al : Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw 11 : 645-653, 2013.
PubMed
P.379 掲載の参考文献
1) Horie A, et al : Morphogenesis of pancreatoblastoma, infantile carcinoma of the pancreas : report of two cases. Cancer 39 : 247-254, 1977.
PubMed
2) Morohoshi T, et al : Pancreatoblastoma With marked elevation of serum alpha-fetoprotein. An autopsy case report with immunocytochemical study. Virchows Arch A Pathol Anat Histopathol 416 : 265-270, 1990.
PubMed
3) Cingolani N, et al : Alpha-fetoprotein production by pancreatic tumors exhibiting acinar cell differentiation : study of five cases, one arising in a mediastinal teratoma. Hum Pathol 31 : 938-944, 2000.
 
4) Cavallini A, et al : Pancreatoblastoma in adults : a review of the literature. Pancreatology 9 : 73-80, 2009.
PubMed
5) Nakatani Y, et al : Biotin-rich, optically clear nuclei express estrogen receptor-beta : tumors with morules may developunder the influence of estrogen and aberrant beta-catenin expression. Hum Pathol 35 : 869-874, 2004.
PubMed
6) Abraham SC, et al : Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastoma : frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 159 : 1619-1627, 2001.
PubMed
7) Kerr NJ, et al : Pancreatoblastoma is associated with chromosome 11p loss of heterozygosity and IGF2 overexpression. Med Pediatr Oncol 39 : 52-54, 2002.
PubMed
8) Abraham SC, et al : Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma : frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol 160 : 953-962, 2002.
PubMed
9) Furlan D, et al : APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of the pancreas, mainly through gene loss and promoter hypermethylation. Virchows Arch 464 : 553-564, 2014.
PubMed
10) Marchegiani G, et al : Pancreatic hepatoid carcinoma : a review of the literature. Dig Surg 30 : 425-433, 2013.
PubMed
11) Matsueda K et al : Hepatoid carcinoma of the pancreas producing protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP). J Gastroenterol 41 : 1011-1019, 2006.
PubMed
12) Hameed O, et al : Hepatoid carcinoma of the pancreas : a case report and literature review of a heterogeneous group of tumors, Am J Surg Pathol 31 : 146-152, 2007.
PubMed
13) Wilentz RE, et al : Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas : A newly described and characterized entity. Am J Pathol 156 : 1641-1651, 2000.
PubMed
14) Goggins M, et al : Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 152 : 1501-1507, 1998.
PubMed
15) Banville N, et al : Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. Hum Pathol 37 : 1498-1502, 2006.
 
P.384 掲載の参考文献
1) Dawson IM, et al : Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg 49 : 80-89, 1961.
PubMed
2) Nayer H, et al : Primary pancreatic lymphomas : a cytopathologic analysis of a rare malignancy. Cancer 102 : 315-321, 2004.
PubMed
3) Du X, et al : Primary pancreatic lymphoma : a clinical quandary of diagnosis and treatment. Pancreas 40 : 30-36, 2011.
PubMed
4) Nishimura R et al : Primary pancreatic lymphoma : clinicopathological analysis of 19 cases from Japan and review of the literature. Oncology 60 (4) : 322-329, 2001.
 
5) Saif MW : Primary pancreatic lymphomas. JOP 7 : 262-273, 2006.
PubMed
6) Merkle EM, et al : Imaging findings in pancreatic lymphoma : differential aspects. AJR Am J Roentgenol 174 (3) : 671-675, 2000.
PubMed
7) Teefey SA, et al : CT appearance of primary pancreatic lymphoma. Gastrointest Radiol 11 (1) : 41-43, 1986.
PubMed
8) Flamenbaum M, et al : Endoscopic ultrasonography of a pancreatic lymphoma. Endoscopy 30 (3) : 43, 1998.
 
9) 永山雅子ほか : 消化器MRIの読み方 膵悪性リンパ腫. 臨消内科 22 : 1661-1667, 2007.
 
10) Pezzilli R, et al : A case of primary pancreatic lymphoma. JOP 5 (2) : 105-106, 2004.
PubMed
11) Binn M, et al : Surgical resection plus chemotherapy versus chemotherapy alone : comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol 14 (12) : 1751-1757, 2003.
 
12) Koch P, et al : Primary gastrointestinal non-Hodgkin's lymphoma : II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 19 (18) : 3874-3883, 2001.
 
13) Battula N, et al : Primary pancreatic lymphoma : diagnostic and therapeutic dilemma. Pancreas 33 (2) : 192-194, 2006.
PubMed
14) Koniaris LG, et al : Is there a role for surgical resection in the treatment of early-stage pancreatic lymphoma? : J Am Coll Surg 190 (3) : 319-330, 2000.
 
15) Grimison PS, et al : Primary pancreatic lymphoma-pancreatic tumours that are potentially curable without resection, a retrospective review of four cases. BMC Cancer 6 : 117, 2006.
PubMed
P.389 掲載の参考文献
1) Bosman FT, et al : WHO classification of tumours of the digestive system. International Agency for Research on Cancer, Lyon, 2010.
 
2) Hruban RH, et al : AFIP Atlas of Tumor Pathology Series 4. Tumors of the Pancreas, ARP, Washington DC, 2007.
 
3) Goldszmidt D, et al : Kasabach-Merritt syndrome with pancreatic hemangioma in an infant Arch Fr Pediatr 50 : 593-597, 1993.
 
4) Schulz AS, et al : Anaemia, thrombocytopenia and coagulopathy due to occult diffUse infantile haemangiomatosis of spleen and pancreas. Eur J Pediatr 158 : 379-383, 1999.
PubMed
5) Igarashi A, et al : Huge cystic lymphangioma of the pancreas : report of a case. Surg Today 31 : 743-746, 2001.
PubMed
6) Sun LF, et al : A giant hemolymphangioma of the pancreas in a 20-year-old girl : a report of one case and review of the literature. World J Surg Oncol 7 : 31, 2009.
 
7) Zalatnai A, et al : Pancreatic leiomyosarcoma. Case report with immunohistochemical and flow cytometric studies. Virchows Arch 432 : 469-472, 1998.
PubMed
8) Pascal RR, et al : Primary malignant fibrous histiocytoma of the pancreas. Hum Pathol 20 : 1215-1217, 1989.
PubMed
9) Mizukami H, et al : Pancreatic malignant fibrous histiocytoma, inflammatory myofibroblastic tumor, and inflammatory pseudotumor related to autoimmune pancreatitis : characterization and differential diagnosis. Virchows Arch 448 : 552-560, 2006.
PubMed
10) Tan G, et al : Cystic schwannoma of the pancreas. Ann Diagn Pathol 7 : 285-291, 2003.
PubMed
11) Raut CP, Fernandez-del Castillo C : Giant lipoma of the pancreas : case report and review of lipomatous lesions of the pancreas. Pancreas 26 : 97-99, 2003.
PubMed
12) Chandrasoma P, Fitzgibbons P : Granular cell tumor of the intrapancreatic common bile duct. Cancer 53 : 2178-2182, 1984.
PubMed
13) Zamboni G, et al : Clear cell "sugar" tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cells. Am J Surg Pathol 20 : 722-730, 1996.
PubMed
14) Luttges J, et al : Solitary fibrous tumour of the pancreas : a new member of the small groupof mesenchymal pancreatic tumours. Virchows Arch 435 : 37-42, 1999.
 
15) Movahedi-Lankarani S, et al : Primitive neuroectodermal tumors of the pancreas : areport of seven cases of a rare neoplasm. Am J Surg Pathol 26 : 1040-1047, 2002.
 
P.399 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン作成小委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2006年版, 金原出版, 2006.
 
2) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2009年版, 金原出版, 2009.
 
3) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2013年版, 金原出版, 2013.
 
4) Maeda A, et al : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer : Japan Adjuvant Study Groupof Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol 38 (3) : 227-229, 2008.
 
5) Minds診療ガイドライン選定部会 (編) : Minds診療ガイドライン作成の手引き2007, 医学書院, 2007.
 
6) Yamaguchi K Tanaka M : EBM-based Clinical Guidelines for Pancreatic Cancer, 2009 from the Japan Pancreas Society : a synopsis. Jpn J Clin Oncol 41 (7) : 836-840, 2011.
PubMed
7) Yamaguchi K et al : EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society : a synopsis. Jpn J Clin Oncol 44 : 883-888, 2014.
PubMed
8) 日本膵臓学会ホームページ : 膵癌診療ガイドライン2013年版の一部改訂について. [http://www.suizou.org/2014/news-11.html]
 
P.404 掲載の参考文献
1) Tanaka M, et al : International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6 : 17-32, 2006.
PubMed
2) Tanaka M, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 : 183-197, 2012.
PubMed
3) Terris B, et al : Serous neoplasms of the pancreas, Tumors of the Exocrine Pancreas 4th ed, World Health Organization. p296-299, IARC Press, Lyon, 2010.
 
4) Tamura K, et al : Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection : a retrospective review. Ann Surg 259 : 360-368, 2014.
PubMed
5) Park WG, et al : Diagnostic performance of cyst且uid carcinoembryonic antigen and amylase in histologically confirmed pancreatic cysts. Pancreas 40 : 42-45, 2011.
 
6) Cizginer S, et al : Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas 40 : 1024-1028, 2011.
PubMed
7) van der Waaij LA, et al : Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions : a pooled analysis. Gastrointest Endosc 62 : 383-389, 2005.
PubMed
8) Yamao K, et al : Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma : a multi-institutional study of the Japan pancreas society. Pancreas 40 : 67-71, 2011.
PubMed
9) Hirooka Y, et al : Case of intraductal papillary mucinous tumor in which endosonography-guided fine-needle aspiration biopsy caused dissemination. J Gastroenterol Hepatol 18 : 1323-1327, 2003.
PubMed
10) Yoon WJ, et al : Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration : the PIPE Study. Endoscopy 46 : 382-387, 2014.
PubMed
11) Aso T, et al : "High-risk stigmata" of the 2012 international consensus guidelines correlates with the malignant grade of branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas 43 : 1239-1243, 2014.
PubMed
12) Mori Y, et al : Intraoperative irrigation cytology of the remnant pancreas to detect remnant distinct pancreatic ductal adenocarcinoma in patients with intraductal papillary mucinous neoplasm undergoing partial pancreatectomy. Surgery 155 : 67-73, 2014.
PubMed
13) Hara T, et al : Preoperative histological subtype classification of intraductal papillary mucinous neo-plasms (IPMN) by pancreatic juice cytology with MUC stain. Ann Surg 257 : 1103-1111, 2013.
 
14) Ideno N, et al : Intraducta1 papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 258 : 141-151, 2013.
PubMed
15) Ohtsuka T, et al : Follow-upstudy after resection of intraductal papillary mucinous neoplasm of the pancreas : special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas. Am J Surg 204 : 44-48, 2012.
 
P.408 掲載の参考文献
1) Burris HA 3rd, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 15 : 2403-2413, 1997.
 
2) Conroy T, et al ; Groupe Tumeurs Digestives of Unicancer ; PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 : 1817-1825, 2011.
PubMed
3) 池田公史ほか : 化学療法未治療の遠隔転移を有する膵癌に対するFOLFIRINOX併用療法の第II相臨床試験 (O15-1口演), 第51回日本癌治療学会学術集会 (2013年10月24日京都市). 日本癌治療学会誌 48 (3) : 979, 2013.
 
4) Von Hoff DD, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 : 1691-1703, 2013.
PubMed
5) 池田広史ほか : A phase I/II trial of weekly nab-paclitaxel (nab-P)+Gemcitabine (G) with metastatic pancreatic cancer (MPC). 切除不能進行・再発膵癌患者に対するABI-007+Gemcitabine療法 第I/II相試験. O2-13-13一般口演), 第12回日本臨床腫瘍学会学術集会 (2014年7月18日福岡市), 2014.
 
6) NCCN Clinical Practice Guidelines in Oncology, Pancreatic Adenocarcinoma, Version 2, 2014. [http://www.nccn.org/default.aspx]
 
7) Jarboe J, Saif MW : First line therapy for metastatic pancreatic cancer. JOPO 14 : 340-343, 2013.
 
P.412 掲載の参考文献
1) Conroy T, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 : 1817-1825, 2011.
PubMed
2) Von Hoff DD, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 : 1691-1703, 2013.
PubMed
3) Van Cutsem E, et al : Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22 : 1430-1438, 2004.
PubMed
4) Kindler HL et al : Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer : phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28 : 3617-3622, 2010.
 
5) Kindler HL, et al : Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma : a double-blind randomised phase 3 study. Lancet Oncol 12 : 256-262, 2011.
PubMed
6) Van Cutsem E, et al : Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27 : 2231-2237, 2009.
PubMed
7) Philip PA, et al : Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma : Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28 : 3605-3610, 2010.
 
8) Moore MJ, et al : Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 : 1960-1966, 2007.
 
9) 日本膵臓学会膵癌診療ガイドライン改定委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン, 2013年版, 金原出版, 2013.
 
10) Raymond E, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364 : 501-513, 2011.
PubMed
11) Yao JC, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 : 514-523, 2011.
PubMed
12) 日本神経内分泌腫瘍研究会 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン作成委員会 (編) : 膵・消化管神経内分泌腫瘍 (NET), 診療ガイドライン第1版, 2013.
 
13) Okusaka T, et al : Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102 : 425-431, 2011.
PubMed
14) The National Comprehensive Cancer Network : NCCN clinical practice guidelines in oncology-pancreatic adenocarcinoma version 2, 2014. [www.nccn.org]
PubMed
15) Ito T, et al : Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 31 : 1265-1274, 2013.
 
P.418 掲載の参考文献
1) 跡見裕 (監) : 膵上皮内癌フォーラム (高折恭一編), メディカルトリビューン社, 2005.
 
2) Hruban RH, et al : An illustrated consensus on the classification of pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasms (IPMNs). Am J Surg Pathol 28 (8) : 977-987, 2004.
PubMed
3) Wada K, et al ; Clinical importance of Familial Pancreatic Cancer Registry in Japan : a report from kick-off meeting at International Symposium on Pancreas Cancer, 2012. J Hepatobiliary Pancreat Sci, 2013. [Epub ahead of print]
 
4) MacDermott RP, Kramer P : Adenocarcinoma of the pancreas in four siblings. Gastroenterology 65 : 137-139, 1973.
PubMed
5) Friedman JM, Fialkow PJ : Carcinoma of the pancreas in four brothers. Birth Defects Orig Artic Ser 12 : 145-150, 1976.
PubMed
6) Reimer RR, et al : Pancreatic cancer in father and son. Lancet 1 : 911, 1977.
PubMed
7) Dat NM, Sontag SJ : Pancreatic carcinoma in brothers. Ann Intern Med 97 : 282, 1982.
 
8) Katkhouda N, Mouiel J : Pancreatic cancer in mother and daughter. Lancet 2 : 747, 1986.
PubMed
9) Klein AP, et al : Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds, Cancer Res 64 : 2634-2638, 2004.
PubMed
10) Canto MI, et al : Screening for early pancreatic neoplasia in high-risk individuals : aprospective controlled study. Clin Gastroenterol Hepato14 : 766-781, 2006.
 
11) Canto MI, et al : International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62 : 339-347, 2013.
 
P.422 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改訂委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン 2013年版, p25-29, 金原出版, 2013.
 
2) 日本膵臓学会膵癌登録委員会 : 膵癌登録報告 2007. 膵臓 22 : e1-94, 2007.
 
3) 佐藤江里ほか : 膵癌危険因子としての耐糖能異常をどうとらえるか. 膵臓 27 : 139-144 : 2012.
Medical*Online
4) Huxley R, et al : Type II diabetes and pancreatic cancer : a meta-analysis of 36 studies. Br J Cancer 92 : 2076-2083, 2005.
PubMed
5) 舩越顕博 : 2型糖尿病に発症する膵癌-その機序と特徴. 胆と膵 35 : 373-377, 2014.
Medical*Online
6) Li D, et al : Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterol 137 : 482-488, 2009.
 
7) 新名雄介ほか : 経過を追えた小膵癌-この所見に気をつけろ! 症例呈示. 糖尿病と膵癌肝胆膵画像 13 : 261-267, 2011.
 
8) Ben Q, et al : Diabetes mellitus and risk of pancreatic cancer : a meta-analysis of cohort studies. Eur J Cancer 47 : 1928-1937, 2011.
PubMed
9) Pannala R, et al : Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 104 : 2318-2325, 2009.
PubMed
10) World Cancer Research Fund/American Institute for Cancer Research : Food, Nutrition, Physical Activity and the Prevention of Cancer : a Global Perspective. Second Expert Report, AICR, Washington DC, 2007.
 
11) 林櫻松ほか : 肥満と膵癌, 胆道癌の関連. 胆と膵 33 : 1221-1226, 2012.
Medical*Online
12) Lin Y, et al : Obesity, physical activity and the risk of pancreatic cancer in a large Japanese cohort. Int J Cancer 120 : 2665-2671, 2007.
 
13) Secretan B, et al : A review of human carcinogens-Part E : tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 10 : 1033-1034, 2009.
PubMed
14) 井上真奈美, 津金昌一郎 : 喫煙と胆・膵癌のリスク. 胆と膵 33 : 1217-1219, 2012.
Medical*Online
15) Pericleous M, et al : Nutrition and pancreatic cancer. Anticancer Res 34 : 9-22, 2014.
PubMed
P.427 掲載の参考文献
1) Egawa S, et al : Japan Pancreatic Cancer Registry ; 30th Year Anniversary. Pancreas 41 : 985-992, 2012.
PubMed
2) 花田敬士, 飯星知博 : 膵がん早期診断の新たな展開. 日消誌 110 : 2051-2059, 2013.
Medical*Online
3) 日本膵臓学会膵癌診療ガイドライン改定委員会 (編) : 膵癌診療ガイドライン 2013年版, 金原出版, 2013.
 
4) Maguchi H, et al : Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas : amulticenter study in Japan. Pancreas 40 : 364-370, 2011.
 
5) Yamaguchi K, et al : Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant from IPMN. Pancreas 40 : 571-580, 2011.
PubMed
6) Kamata K, et al : Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy 46 : 22-29, 2014.
PubMed
7) Klein AP : Identifying people at a high risk of developing pancreatic cancer. Nat Rev 13 : 66-74, 2013.
 
8) Tanaka S, et al : Periodic ultrasonography checkupfor the early detection of pancreatic cancer : preliminary report. Pancreas 28 : 268-272, 2004.
PubMed
9) Tanaka S, et al : Slight dilatation of main pancreatic duct and presence of pancreatic cysts as predictive signs of pancreatic cancer. Radiology 254 : 956-972, 2010.
 
10) Kobayashi T, et al : A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomarkers Prev 22 : 571-579, 2013.
PubMed
11) Iiboshi T, et al : Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer : establishing a new method for the early detection of pancreatic carcinoma in situ. Pancreas 41 : 523-529, 2012.
PubMed
12) 進藤浩子ほか : 分枝型IPMNに併存した膵上皮内癌の1例. 膵臓 29 : 742-748, 2014.
Medical*Online
13) 木村公一ほか : ENPDチューブ留置での連続膵液採取による細胞診の小膵癌診断への有用性. 日消誌 108 : 928-936, 2011.
Medical*Online
14) 深澤光晴ほか : 膵癌早期診断を目指す地域連携. 肝胆膵 66 : 277-284, 2013.
 
P.432 掲載の参考文献
1) 田中雅夫ほか : 膵癌登録報告 2007. 膵臓 22 : e1-427, 2007.
 
2) Egawa S, et al : Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 41 : 985-992, 2012.
PubMed
3) Gillen S, et al : Preoperative/neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS Med 7 : e1000267, 2010.
PubMed
4) 伊佐地秀司ほか : 局所進行/切除不能膵癌に対する化学放射線療法後の根治切除の意義. 臨外 67 : 66-72, 2012.
 
5) Vauthey JN, Dixon E : AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer : rationale and overview of the conference. Ann Surg Oncol 16 : 1725-1726, 2009.
PubMed
6) Tseng JF, et al : Pancreaticoduodenectomy with vascular resection : margin status and survival duration. J Gastrointest Surg 8 : 935-949, 2004.
PubMed
7) National Comprehensive Cancer Network : Clinical practice guidelines in oncology. Pancreatic Adenocarcinoma. Version 2, 2014. Available from : [http://www.nccn.org/professionnals/physcian_gls/f_guidelines.asp], Accessed on May 27, 2014.
 
8) Katz MH, et al : Borderline resectable pancreatic cancer : need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 20 : 2787-2795, 2013.
PubMed
9) Seufferlein T, et al : Pancreatic adenocarcinoma : ESMO-ESDO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 23 (Suppl 7) : vii33-40, 2012.
 
10) Bockhorn M, et al : Borderline resectable pancreatic cancer : a consensus statement by the International Study Groupof Pancreatic Surgery (ISGPS). Surgery 155 : 977-988, 2014.
 
11) 日本膵臓学会膵癌診療ガイドライン改定委員会 (編) : 科学的根拠に基づく膵癌診療ガイドライン, 2013年版, 金原出版, 2013.
 
12) Hirano S, et al : Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer : long-term results. Ann Surg 246 : 46-51, 2007.
PubMed
13) 伊佐地秀司, 加藤宏之 : 第37回日本膵切研究会 第22回膵切研究会アンケート調査報告書, 2010. [http://web.me.com/shujiisajil/PanSurg/]
 
14) Kato H, et al : Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer : a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20 : 601-610, 2013.
 
15) 岸和田昌之ほか : Borderline resectable膵癌の臨床的特徴と治療成績-膵切研究会アンケート調査結果と当科の化学放射線療法の比較-. 癌の臨床 60 : 247-257, 2014.
Medical*Online
P.436 掲載の参考文献
1) Osawa R, et al : Identification of HLA-A24-restricted novel T Cell epitope peptides derived from P-cadherin and kinesin family member 20A. J Biomed Biotechnol 2012 : 848042, 2012.
 
2) Suda T, et al : Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 98 (11) : 1803-1808, 2007.
PubMed
3) Kanehira M, et al : Involvement of upregulation of DEPDC 1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 26 (44) : 6448-6455, 2007.
 
4) Yokomine K, et al : The forkhead box M1 transcription factor as a candidate of target for anticancer immunotherapy. Int J Cancer 126 : 2153-2163, 2010.
PubMed
5) Ishizaki H, et al : Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 12 (19) : 5841-5849, 2006.
 
6) Wada S, et al : Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 65 (11) : 4939-4946, 2005.
PubMed
7) Miyazawa M, et al : Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 101 (2) : 433-439, 2010.
PubMed
8) Yamaue H, et al : Phase II/III clinical trial with VEGFR2-epitope peptide and gemcitabine for patients with locally advanced, metastatic, or unresectable pancreatic cancer : PEGASUS-PC study. J Clin Oncol 30 (Suppl 34) : Abstr 223, 2012.
 
9) Zucker DM, Yang S : Inference for a family of survival models encompassing the proportional hazards and proportional odds models. Stat Med 25 : 995-1014, 2006.
PubMed
10) Middleton GW, et al : A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer. J Clin Oncol 31 (Suppl) : Abstr LBA4004, 2013.
 
11) Hodi FS, et al : Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 : 711-723, 2010.
PubMed
12) Topalian SL, et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (26) : 2443-2454, 2012.
PubMed
P.441 掲載の参考文献
1) 袴田健一ほか : 膵癌に対するロボット支援膵体尾部切除術. 消化器ダビンチ手術のすべて (土田明彦, 宇山一朗編), p193-202, 医学図書出版, 2013.
 
2) Gagner M, Pomp A : Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc 8 : 408-410, 1994.
PubMed
3) Cuschieri A : Laparoscopic surgery of the pancreas. J R Coll Surg Edinb 39 : 178-184, 1994.
PubMed
4) 北野正剛ほか : 内視鏡外科手術に関するアンケート調査-第11回集計結果報告. 日内視鏡外会誌 17 : 571-694, 2012.
 
5) Giulianotti PC, et al : Robotics in general surgery : personal experience in a large community hospital. Arch Surg 138 : 777-784, 2003.
 
6) Zureikat AH, et al : 250 robotic pancreatic resections : safety and feasibility. Ann Surg 258 : 554-559 ; discussion 559-562, 2013.
 
7) Nigri GR, et al : Metaanalysis of trials comparing minimally invasive and open distal pancreatectomies. Surg Endosc 25 : 1642-1651, 2011.
PubMed
8) Mesleh MG, et al : Minimally invasive surgical techniques for pancreatic cancer : ready for prime time? J Hepatobiliary Pancreat Sci, 2013. [Epub ahead of print]
 
9) Nakamura M, Nakashima H : Laparoscopic distal pancreatectomy and pancreatoduodenectomy : is it worthwhile? A meta-analysis of laparoscopic pancreatectomy. J Hepatobiliary Pancreat Sci 20 : 421-428, 2013.
PubMed
10) Sui CJ, et al : Laparoscopic versus open distal pancreatectomy : a meta-analysis. Asian J Surg 35 : 1-8, 2012.
PubMed
11) Venkat R, et al : Laparoscopic distal pancreatectomy is associated with sigriificantly less overall morbidity compared to the open technique : a systematic review and meta-analysis. Ann Surg 255 : 1048-1059, 2012.
 
12) Drymousis P, et al : Laparoscopic versus open pancreas resection for pancreatic neuroendocrine tumours : a systematic reView and meta-analysis. HPB (Oxford) 16 : 397-406, 2014.
PubMed
13) Rosales-Velderrain A, et al : National trends in resection of the distal pancreas. World J Gastroenterol 18 : 4342-4349, 2012.
PubMed
14) Zhang J, et al : Robotic versus open pancreatectomy : a systematic review and meta-analysis. Ann Surg Oncol 20 : 1774-1780, 2013.
PubMed
15) Daouadi M, et al : Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg 257 : 128-132, 2013.
 
P.445 掲載の参考文献
1) Callery MP, et al : Pretreatment assessment of resectable and borderline resectable pancreatic cancer : expert consensus statement. Ann Surg Oncol 16 : 1727-1733, 2009.
PubMed
2) Ceha HM, et al : Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 89 : 2222-2229, 2000.
PubMed
3) Abelson JA, et al : Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 82 (4) : e595-601, 2012.
PubMed
4) Koong AC, et al : Phase II study to assess the efflcacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63 : 320-323, 2005,
PubMed
5) Ben-Josef E, et al : Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 59 : 454-459, 2004.
PubMed
6) Oonishi K, et al : Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiother Oncol 105 (2) : 258-265, 2012.
 
7) Schulz-Ertner D, Tsujii H : Particle radiation therapy using Proton and heavier ion beams. J Clin Oncol 25 : 953-964, 2007.
 
8) 寺嶋広太郎ほか : 膵癌の重粒子線治療の現状と今後の展望. 膵・胆道癌FRONTIER 3 : 110-113, 2013.
 
9) Chen Y, et al : Combined radiochemotherapy in patients with locally advanced pancreatic cancer : a meta-analysis. World J Gastroenterol 19 (42) : 7461-7471, 2013.
 
10) Loehrer PJ, et al : Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer : an Eastern Cooperative Oncology Grouptrial. J Clin Oncol 29 (31) : 4105-4112, 2011.
 
11) Sa Cunha A, et al : Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg 201 (3) : 359-365, 2005.
PubMed
12) Golcher H, et al : Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol 34 (7) : 756-764, 2008.
PubMed
13) Shinoto M, et al : Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer 119 (1) : 45-51, 2013.
PubMed

胆道癌

P.452 掲載の参考文献
1) Albores-Saavedra J, et al : Carcinoma of the gallbladder and extrahepatic bile ducts. In : WHO classification of tumours of the digestive system. IARC Press, Lyon, 2010.
 
2) 日本肝胆膵外科学会 (編) : 胆道癌取扱い規約, 第6版, p45, 金原出版, 2013.
 
3) Zen Y, et al : Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma : preliminary report based on interobserver agreement. Pathol Int 55 : 180-188, 2005.
PubMed
4) 佐藤保則, 中沼安二 : 胆管内腫瘍の組織分類とそのエビデンス. 胆と膵 32 : 1331-1338, 2011.
Medical*Online
5) Zen Y, et al : Biliary intraepithelial neoplasia : an intemational interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 20 : 701-709, 2007.
 
6) Zen Y, et al : Biliary papillary tumors share pathological featUres With intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44 : 1333-1343, 2006.
PubMed
7) AdsayV, et al : Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are≧1.0 cm) : clinicopathologic and immunohistochemical analysis of 123 cases. Am J Surg Pathol 36 : 1279-1301, 2012.
 
8) 鬼島宏 : 胆嚢・胆管. 外科病理学, 第4版 (向井清ほか編), 文光堂, p665-698, 2006.
 
9) Kijima H, et al : Histogenesis of gallbladder carcinoma form investigation of early carcinoma and microcarcinoma Acta Pathol Jpn 39 : 235-244, 1989.
 
P.460 掲載の参考文献
1) 中沼安二 : 胆道の病理-胆道と膵臓の潜在的可塑性からの観察-. 胆道 12 : 287-295, 2010.
 
2) Nakanuma Y, et al : Proposal of a new disease concept "biliary diseases with pancreatic counterparts". Anatomical and pathological bases. Histol Histopathol 29 : 1-10, 2014.
PubMed
3) Gandou C, et al : Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar immunophenotypes, and development-related molecules. Hum Pathol 44 (5) : 811-821, 2013.
PubMed
4) Nakanuma Y : A novel approach to biliary tract pathology based on similarities to pancreatic counterparts : is the biliary tract an incomplete pancreas? Pathol Int 60 (6) : 419-429, 2010.
PubMed
5) Larsen WJ : Human Embryology, Chruchill Livingstone, New York, 1997.
 
6) Cardinale V, et al : The biliary tree-a reservoir of multipotent stem cells. Nat Rev Gastroenterol Hepatol 9 (4) : 231-240, 2012.
PubMed
7) Zen Y, et al : Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44 (5) : 1333-1343, 2006.
PubMed
8) Cardinale V, et al : Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology 54 : 2159-2172, 2011.
PubMed
9) Carpino G, et al : Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts : an anatomical in situ study yielding evidence of maturational lineages. J Anat 220 : 186-199, 2012.
PubMed
10) op den Dries S, et al : Injury to peribiliary glands and vascular plexus before liver transplantation predicts formation of non-anastomotic biliary strictures. J Hepatol 60 : 1172-1179, 2014.
PubMed
11) Sumazaki R, et al : Conversion of biliary system to pancreatic tissue in Hes1-deficient mice. Nat Genet 36 : 83-87, 2004.
PubMed
12) Nakanuma Y, et al : Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply. Microsc Res Tech 38 : 552-570, 1997.
PubMed
13) Terada T, et al : Glandular elements around the intrahepatic bile ducts in man ; their morphology and distribution in normal livers. Liver 7 : 1-8, 1987.
PubMed
14) Terada T, et al : Extrahepatic peribiliary glands express alpha-amylase isozymes, trypsin and pancreatic lipase : an immunohistochemical analysis. Hepatology 18 : 803-808, 1993.
PubMed
15) Terada T, et al : Pathologic observations of intrahepatic peribiliary glands in 1000 consecutive autopsy livers. Heterotopic pancreas in the liver. Gastroenterology 98 : 1333-1337, 1990.
PubMed
16) Zen Y, et al : IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis : do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol 28 : 1193-1203, 2004.
PubMed
17) Zen Y, et al : Follicular cholangitis and pancreatitis-clinicopathological features and differential diagnosis of an under-recognized entity. Histopathology 60 : 261-269, 2012.
PubMed
18) Matsubara T, et al : Alcohol-related injury to peribiliary glands is a cause of peribiliary cysts : based on analysis of clinical and autopsy cases. J Clin Gastroenterol 48 (2) : 153-159, 2014.
 
19) Nakanuma Y, et al : Intrahepatic cholangiocarcinoma. In : WHO Classification of Tumours : Tumours of the Digestive System, 4th ed (ed by Fr Bosman, et al), p217-224, IARC, Lyon, 2010.
 
P.464 掲載の参考文献
1) Ishihara S, et al : StatUs of surgical treatment of biliary tract cancer. Dig Surg 24 : 131-136, 2007.
PubMed
2) 厚生労働省ホームページ. [http://www.mhlw.go.jp/file/05-Shingikai-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka/0000037672.pdf]
 
3) Furuse J, et al : Role of chemotherapy in treatments for biliary tract cancer. J Hepatobiliary Pancreat Sci 19 : 337-341, 2012.
 
4) Nagakawa T, et al : Biliary tract cancer treatment : results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 9 : 569-575, 2002.
PubMed
5) Morine Y, et al : Clinical features of pancreaticobiliary maljunction : update analysis of 2nd Japan-nationwide survey. J Hepatobiliary Pancreat Sci 20 : 472-480, 2013.
PubMed
6) Hundal R, Shaffer EA : Gallbladder cancer : epidemiology and outcome. Clin Epidemiol 6 : 99-109, 2014.
PubMed
7) Dutta U : Gallbladder cancer : can newer insights improve the outcome? J Gastroenterol Hepatol 27 : 642-653, 2012.
PubMed
8) Agrawal V, et al : p53, carcinoembryonic antigen and carbohydrate antigen 19.9 expression in gall bladder cancer, precursor epithelial lesions and xanthogranulomatous cholecystitis. J Postgrad Med 56 : 262-266, 2010.
PubMed
9) Wistuba II, Gazdar AF : Gallbladder cancer : lessons from a rare tumour. Nat Rev Cancer 4 : 695-706, 2004.
PubMed
10) Wistuba II, Albores-Saavedra J : Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 6 : 237-244, 1999.
PubMed
11) Ajiki T, et al : K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut 38 : 426-429, 1996.
PubMed
12) Hanada K, et al : K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 77 : 452-458, 1996.
 
13) Ueki T, et al : Alterations of p16 and prognosis in biliary tract cancers from a population-based study in China. Clin Cancer Res 10 : 1717-1725, 2004.
PubMed
14) Sun XN, et al : Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma. Tumour Biol 32 : 1183-1190, 2011.
PubMed
15) Kiguchi K, et al : Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5. ErbB-2 mice. Mol Cancer Ther 6 : 1709-1717, 2007.
PubMed
16) Yang S, et al : Inhibition of SCAMP1 suppresses cell migration and invasion in human pancreatic and gallbladder cancer cells. Tumour Biol 34 : 2731-2739, 2013.
PubMed
17) Tan X, et al : Prognostic factors of distal cholangiocarcinoma after curative surgery : a series of 84 cases. Hepatogastroenterology 60 : 1892-1895, 2013.
PubMed
18) Andersen JB, et al : Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142 : 1021-1031, e15, 2012.
 
19) Ong CK et al : Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 44 : 690-693, 2012.
PubMed
20) Arumugam T, et al : Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 98 : 1806-1818, 2006.
PubMed
21) Hamada S, et al : Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci 102 : 150-156, 2011.
PubMed
22) El-Khoueiry AB, et al : S0941 : a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110 : 882-887, 2014.
PubMed
23) Ramanathan RK, et al : A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 64 : 777-783, 2009.
PubMed
24) Zhu AX, et al : Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome : a phase 2 study. Lancet Ohcol 11 : 48-54, 2010.
PubMed
25) Gruenberger B, et al : Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer : a phase 2 study. Lancet Oncol 11 : 1142-1148, 2010.
PubMed
26) Chen SC, et al : Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas. HPB (Oxford) 15 : 951-957, 2013.
PubMed
27) Kim WS, et al : Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol 105 : 266-272, 2012.
 
28) Hsu HP, et al : Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms. J Surg Oncol 101 : 356-362, 2010.
PubMed
29) Guo R, et al : Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Hum Pathol 45 : 1015-1023, 2014.
PubMed
30) Hsu HP, et al : Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival. Cancer Biol Ther 10 : 144-154, 2010.
PubMed
P.470 掲載の参考文献
1) Ferlay J, et al : GLOBOCAN, 2012 v1.0, Cancer Incidence and Mortality Worldwide : IARC CancerBase No.11 [Internet]. International Agency for Research on Cancer, Lyon, 2013. [http://globocan.iarc.fr] (August 29, 2014, date last accessed).
 
2) Randi G, et al : Epidemiology of biliary tract cancers : an update. Ann Oncol 20 : 146-159, 2009.
PubMed
3) WHO : Cancer Mortality Database. [http://www-dep.iarc.fr/WHOdb/WHOdb.htm] (August 30, 2014, date last accessed).
 
P.475 掲載の参考文献
1) Sobin LH, et al (ed) : UICC TNM classincation of malignant tumors, 7th ed, Wiley-Blackwell, 2009.
 
2) DeOliveira ML, et al : New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 53 : 1363-1371, 2011.
 
3) Razumilava N, Gores GJ : Cholangiocarcinoma. Lancet 383 : 2168-2179, 2014.
PubMed
4) Cardinale V, et al : Cholangiocarcinoma : increasing burden of classifications. Hepatobiliary Surg Nutr 2 : 272-280, 2013.
PubMed
5) Kato A, et al : Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer : a retrospective single-center study. Ann Surg Oncol 20 : 318-324, 2013.
PubMed
6) 日本肝胆膵外科学会 (編) : 臨床・病理 胆道癌取扱い規約, 第6版, 金原出版, 2013.
 
7) Okuda K, et al : Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma : a study of 57 autopsy-proven cases. Cancer 39 : 232-246, 1977.
PubMed
8) Nakanuma Y, et al : Clinicopathological characterization of so-called "cholangiocarcinoma with intraductal papillary growth" with respect to "intraductal papillary neoplasm of bile duct (IPNB)". Int J Clin Exppathol 7 : 3112-3122, 2014.
 
9) Nakanuma Y, et al : Intrahepatic cholangiocarcinoma. In : WHO Classification of Tumours of the Digestive System ; World Health Organization of Tumours, 4th ed (ed by FT Bosman, et al), p217-224, LARC, Lyon, 2010.
 
10) Nakanuma Y, et al : Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2 : 419-427, 2010.
PubMed
P.480 掲載の参考文献
1) Gonda TA, et al : Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. Gastrointest Endosc 75 : 74-79, 2012.
PubMed
2) Tannapfel A, et al : Frequency of p16INK4A alteration and k-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47 : 721-727, 2000.
 
3) Nehls O, et al : Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 24 : 139-154, 2004.
PubMed
4) 甲斐真弘ほか : 胆汁中腫瘍マーカーと胆道疾患. 胆と膵 29 : 717-722, 2008.
Medical*Online
5) Goldin RD, Roa JC : Gallbladder cancer : a morphological and molecular update. Histopathology 55 : 218-229, 2009.
PubMed
6) Ito R, et al : UsefUlness of K-ras gene mutation at codon 12 in bile for diagnosing biliary strictures. Int J Oncol 12 : 1019-1023, 1998.
PubMed
7) Chuang SC, et al : Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg 28 : 995-1000, 2004.
PubMed
8) Wang J, et al : p53 status and its prognostic role in extrahepatic bile duct cancer : A meta-analysis of published studies. Dig Dis Sci 56 : 655-662, 2011.
 
9) Park JS, et al : P16 hypermethylation predicts surgical outcome following curative resection of Mid/Distal bile duct cancer. Ann Surg Oncol 20 : 2511-2517, 2013.
PubMed
10) Tascilar M, et al : Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. Am J Clin Patol 116 : 831-837, 2001.
 
11) Kang YK et al : Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol 33 : 877-883, 2002.
PubMed
12) McCarthy DM, et al : Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater : analysis of 140 cases. Mod Pathol 16 : 272-278, 2003.
PubMed
13) Itoi T, et al : Detection of telomerase reverse transcriptase mRNA in biopsy specimens and bile for diagnosis of biliary tract cancers. Int J Mol Med 7 : 281-287, 2001.
PubMed
14) Kawahara R, et al : Analysis of hTERT mRNA expression in biliary tract and pancreatic cancer. J Hepatobiliary Pancreat Surg 14 : 189-193, 2007.
PubMed
15) Leelawat K, et al : Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J Gastroenterol 12 : 4195-4198, 2006.
PubMed
P.484 掲載の参考文献
1) 厚生労働省大臣官房統計情報部 (編) : 人口動態統計.
 
2) 丹野誠志ほか : ゲムシタビンの感受性と耐性化に関する因子. 肝胆膵 55 (5) : 1143-1148, 2007.
Medical*Online
3) Murata A, et al : Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. World J Surg Oncol 11 : 117, 2013.
PubMed
4) Kobayashi H, et al : Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann Surg 256 : 288-296, 2012.
PubMed
5) Matsuda A, et al : Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma. Hepatology 52 (1) : 174-182, 2010.
PubMed
P.490 掲載の参考文献
1) Valle J, et al : Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. N Engl J Med 362 : 1273-1281, 2010.
PubMed
2) Okusaka T, et al : Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer 103 : 469-474, 2010.
 
3) Morizane C, et al : Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer : a Japan Clinical Oncology Grouptrial (JCOG 0805). Cancer Sci 104 : 1211-1216, 2013.
 
4) 秋田弘俊, 木下一郎 : 化学療法に対する反応性の分子生物学的予測因子. Medical Practice 25 : 106-109, 2008.
Medical*Online
5) 綾部悦里好ほか : 肺癌. 癌と化学療法 36 : 21-25, 2009.
Medical*Online
6) Alberts B, et al : Molecular biology of THE CELL 5th edition, p295-304, Garland Science, New York, 2012.
 
7) Gazdar AF : DNA repair and survival in lung cancer-the two faces of Janus. N Engl J Med 22 : 771-773, 2007.
 
8) Olaussen KA, et al : DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 : 983-991, 2006.
PubMed
9) Friboulet L, et al : ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368 : 1101-1110, 2013.
PubMed
10) Uemura S, et al : ERCC1 mRNA Expression as a Postoperative Prognostic Marker in Extrahepatic Bile Duct Cancer. Ann Surg Oncol, 2014. [Epub ahead of print]
 
11) Hwang IG, et al : Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients. Cancer Chemother Pharmacol 68 : 935-944, 2011.
PubMed
12) Ojima H, et al : Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. Cancer Sci 101 : 882-888, 2010.
PubMed
P.494 掲載の参考文献
1) Numata K, et al : Differential diagnosis of gallbladder diseases with contrast-enhanced harmonic gray scale ultrasonography. J Ultrasound Med 26 : 763-774, 2007.
PubMed
2) Inoue T, et al : Diagnosis of gallbladder diseases by contrast-enhanced phase-inversion harmonic ultrasonography. Ultrasound Med Biol 33 : 353-361, 2007.
PubMed
3) Kim SH, et al : Four-dimensional volume contrast ultrasound imaging of the gallbladder compared with tissue harmonic imaging : preliminary experience. Eur Radiol 14 : 1657-1664, 2004.
PubMed
4) Lee HJ, et al : Three-dimensional uutrasonography using the minimum transparent mode in obstructive biliary diseases : early experience. J Ultrasound Med 21 : 443-453, 2002.
PubMed
5) 三原修一ほか : 集団検診における胆嚢癌診断の現状. 胆と膵 26 : 801-804, 2005.
 
6) Segawa K, et al : Prevalence of gallbladder polyps among apparently healthy Japanese : ultrasonographic study. Am J Gastroenterol 87 : 630-633, 1992.
PubMed
7) Mangel AW : Management of gallbladder polyps. South Med J 90 : 481-483, 1997.
PubMed
8) Sinkai H, et al : Surgical indications for small polypoid lesions of the gallbladder. Am J Surg 175 : 114-117, 1998.
 
9) 乾和郎, 芳野純治 : エコーで10mm以下の胆嚢隆起性病変は必ずしも良性とは限らない. 肝胆膵 87 : 1155-1157, 2005.
 
10) Kubota K, et al : How should polypoid lesions of the gallbladder be treated in the era of laparoscopic cholecystectomy? Surgery 117 : 481-487, 1995.
PubMed
11) 田中幸子ほか : 腹部超音波がん健診基準. 日消がん検診誌 49 : 667-685, 2011.
 
12) Hirooka Y, et al : Differential diagnosis of gallbladder masses using colour doppler ultrasonography. J Gastroenterol Hepatol 11 : 840-846, 1996.
PubMed
13) 服部昌志ほか : 胆嚢隆起性病変の質的診断における造影超音波検査の有用性と病理組織学的検討, 日消誌 104 : 790-798, 2007.
Medical*Online
14) Xie XH, et al : Differential diagnosis between benign and malignant gallbladder diseases with real-time contrast-enhanced ultrasound. Eur Radiol 20 : 239-248, 2010.
PubMed
P.505 掲載の参考文献
1) 蒲田敏文ほか : 肝門部胆管癌のMD-CTによる診断. 胆道 21 (2) : 204-214, 2007.
Medical*Online
2) Katabathina VS, et al : Adult bile duct strictures : role of MR cholangiopancreatography in characterization. Radiographics 34 : 565-586, 2014.
PubMed
3) 西尾秀樹ほか : 手術適応基準から考える胆道癌の読影ポイント. 画像診断 26 : 544-553. 2006.
 
4) 蒲田敏文ほか : 胆嚢腺筋腫症の典型画像. 肝胆膵画像 10 (4) : 305-310, 2008.
 
5) 蒲田敏文, 松井修 : 膵・胆道癌の遠隔転移診断 : MDCTによる肝転移, リンパ節転移診断. 胆と膵 30 (9) : 919-927, 2009.
Medical*Online
6) 小坂一斗ほか : IPNBの画像診断と粘液産生. 粘液産生性胆道系腫瘍の再出発-エビデンスとしての画像と病理. 胆と膵 34 (5) : 381-387, 2013.
 
P.509 掲載の参考文献
1) 日本肝胆膵外科学会 (編) : 臨床・病理胆道取扱い規約, 第6版, 金原出版, 2013.
 
2) 真口宏介 : 肝外胆管癌の術前診断. 胆道 22 : 140-148, 2008.
Medical*Online
3) 真口宏介ほか : 胆管癌に対する進展度診断-最近の動向-. 日消誌 107 : 1089-1095, 2010,
Medical*Online
4) 真口宏介, 安保義恭 : 胆管癌に対する進展度診断-ビデオによる実際-. 胆道 26 : 176-184, 2012.
Medical*Online
5) Makuuchi M, et al : Preoperative portal embolization to increase safety of major hapetectomy for hilar bile duct carcinoma : a preliminary report. Surgery 107 : 521-527, 1990.
PubMed
6) Nagino M, et al : Selective percutaneous transhepatic embolization of the portal vein in preparation for extensive liver resection : the ipsilateral approach. Radiology 200 : 559-563, 1996.
PubMed
7) 近藤哲ほか : 肝門部の外科解剖-術式決定に必要なこと. 消化器画像 6 : 337-343, 2004.
 
8) 蒲田敏文ほか : 肝門部胆管癌のMD-CTによる診断. 胆道 21 : 204-214, 2007.
Medical*Online
9) 小山内学ほか : 胆嚢管癌8切除例の臨床像と画像診断. 胆道 20 : 17-25, 2006.
Medical*Online
10) 糸井隆夫ほか : 内視鏡的経鼻胆嚢ドレナージチューブによる洗浄細胞診の意義. 胆と膵26 : 847-853, 2005.
 
11) Harano M, et al : Clinical impact of endoscopic papillectomy for benign-malignant borderline lesions of the major duodenal papilla. J Hepatobiliary Pancreat Sci 18 : 190-194, 2011.
PubMed
P.514 掲載の参考文献
1) Niwa K, et al : Comparison of image quality between electronic and mechanical radial scanning echoendoscopes in pancreatic diseases. J Gastroenterol Hepatol 19 : 454-459, 2004.
 
2) Ishikawa H, et al : A comparison of image quality betWeen tissue harmonic imaging and fundamental imaging with an electronic radial scanning echoendoscope in the diagnosis of pancreatic diseases. Gastrointest Endosc 57 : 931-936, 2003.
PubMed
3) Hirooka Y, et al : Diagnosis of pancreatic disorders using contrast-enhanced endoscopic ultrasonography and endoscopic elastography. Clin Gastroenterol Hepatol 7 : S63-67, 2009.
PubMed
4) Hirooka Y, et al : Contrast-enhanced endoscopic ultrasonography in digestive diseases. J Gastroenterol 47 : 1063-1072, 2012.
PubMed
5) Catalano MF, et al : Endosonographic featUres predictive of lymph node metastasis. Gastrointest Endosc 40 : 442-446, 1994.
PubMed
6) Kojima S, et al : Differentiation of benign and malignant lymph nodes with contrast-enhanced echolymphography using endoscopic ultrasound-guided puncture. Hepatogastroenterology 50 : 1285-1291, 2003.
PubMed
7) Kanamori A, et al : Usefulness of contrast-enhanced endoscopic ultrasonography in the differentiation between malignant and benign lymphadenopathy. Am J Gastroenterol 101 : 45-51, 2006.
PubMed
8) Kuroiwa M, et al : New technique using intraductal ultrasonography for the diagnosis of bile duct cancer. J Ultrasound Med 13 : 189-195, 1994.
PubMed
9) Kawashima H, et al : Progress of endoscopic ultrasonography and intraductal ultrasonography in the diagnosis of malignant biliary diseases. J Hepatobiliary Pancreat Surg 13 : 69-74, 2006.
PubMed
10) Kawashima H, et al : Diagnostic and prognostic value of immunohistochemical expression of S100P and IMP3 in transpapillary biliary forceps biopsy samples of extrahepatic bile duct carcinoma. J Hepatobiliary Pancreat Sci 20 : 441-447, 2013.
PubMed
11) 日本肝胆膵外科学会 (編) : 胆道癌取扱い規約, 第6版, 金原出版, 2013.
 
12) Itoh A, et al : Intraductal ultrasonography in diagnosing tumor extension of cancer of the papilla of Vater. Gastrointest Endosc 45 : 251-260, 1997.
PubMed
13) 廣岡芳樹ほか : 十二指腸乳頭部癌進展度診断におけるUS/EUSの役割. 日本胆道学会雑誌 23 : 797-805, 2009.
 
P.518 掲載の参考文献
1) Annunziata S, et al : Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma : a meta-analysis. Biomed Res Int 2014 : 247693, 2014.
PubMed
2) Petrowsky H, et al : Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 45 (1) : 43-50, 2006.
PubMed
3) Moon CM, et al : UsefUlness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol 23 (5) : 759-765, 2008
PubMed
4) 山本久, 海野倫 : 外科医に必要なPET検査の知識 その有用性と問題点 胆嚢癌・胆管癌におけるPET検査の意義. 臨床外科 65 (2) : 238・-242, 2010.
 
5) Kim JY, et al : Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma : a prospective study compared with conventional imaging. Am J Gastroenterol 103 (5) : 1145-1151, 2008.
PubMed
6) Anderson CD, et al : Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 8 (1) : 90-97, 2004.
PubMed
7) Prytz H, et al : Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 44 (6) : 1572-1580, 2006.
PubMed
8) Maldjian PD, et al : Adenomyomatosis of the gallbladder : another cause for a "hot" gallbladder on 18F-FDG PET. AJR Am J Roentgenol 189 (1) : W36-38, 2007.
PubMed
9) Kitazono MT, Colletti PM : FDG PET imaging of acute cholecystitis. Clin Nucl Med 31 (1) : 23-24, 2006.
PubMed
10) Oe A, et al : Distinguishing benign from malignant gallbladder wall thickening using FDG-PET. Ann Nucl Med 20 (10) : 699-703, 2006.
PubMed
11) Makino I, et al : Xanthogranulomatous cholecystitis mimicking gallbladder carcinoma with a false-positive result on fluorodeoxyglucose PET. World J Gastroenterol 15 (29) : 3691-3693, 2009.
PubMed
12) Lee SW, et al : Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 45 (5) : 560-566, 2010.
PubMed
13) Corvera CU, et al : 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 206 (1) : 57-65, 2008.
PubMed
14) Kitajima K, et al : Clinical impact of whole body FDG-PET for recurrent biliary cancer : a multicenter study. Ann Nucl Med 23 (8) : 709-715, 2009.
PubMed
15) Strong VE, et al : A novel method to localize antibody-targeted cancer deposits intraoperatively using handheld PET beta and gamma probes. Surg Endosc 22 (2) : 386-391, 2008.
PubMed
P.523 掲載の参考文献
1) 胆道癌診療ガイドライン作成出版委員会 (編) : 胆道癌診療ガイドライン, 第1版, 医学図書出版, 2007.
 
2) Nakajima M, et al : Peroral cholangiopancreatoscopy (PCPS) under duodenoscopic guidance. Am J Gastroenterol 66 : 241-247, 1976.
 
3) Larghi A, Waxman I : Endoscopic direct cholangioscopy by using an ultra-slim upper endoscope : a feasibility study. Gastrointest Endosc 63 : 853-857, 2006.
PubMed
4) Doi S, et al : Carbon dioxide insufflation vs. conventional saline irrigation for peroral video cholangioscopy. Endoscopy 43 : 1070-1075, 2011.
PubMed
5) Fukuda Y, et al : Diagnostic utility of peroral cholangioscopy for various bile-duct lesions. Gastrointest Endosc 62 : 374-382, 2005.
PubMed
6) Tsuyuguchi T, et al : Peroral cholangioscopy for the diagnosis and treatment of biliary diseases. J Hepatobiliary Pancreat Surg 13 (2) : 94-99, 2006.
PubMed
7) Nishikawa T, et al : Comparison of the diagnostic accuracy of peroral video-cholangioscopic visual findings and cholangioscopy-guided fbrceps biopsy findings for indeterminate biliary lesions : a prospective study. Gastrointest Endosc 77 : 219-226, 2013.
PubMed
8) Nishikawa T, et al : Preoperative assessment of longitudinal extension of cholangiocarcinoma with peroral video-cholangioscopy : A prospective study. Dig Endosc 26 : 450-457, 2014.
PubMed
P.528 掲載の参考文献
1) 広岡保明ほか : 胆汁細胞診の採取判定方法に関する研究 (第1報)-貯留胆汁細胞診の細胞判定基準-. 日臨細胞会誌 49 : 7-14, 2010.
 
2) Yagioka Y, et al : Clinical significance of bile cytology via an endoscopic nasobiliary drainage tube for pathological diagnosis of malignant biliary strictures. J Hepatobiliary Pancreat Sci 18 : 211-215, 2011.
 
3) Noda Y, et al : Prospective randomized controlled study comparing cell block method and conventional smear method for bile cytology. Dig Endosc 25 : 444-452, 2013.
PubMed
4) Nishikawa T, et al : Factors affecting the accuracy of endoscopic transpapillary sampling methods for bile duct cancer. Dig Endosc 26 : 276-281, 2014.
PubMed
5) Yasuda I, et al : Diagnostic value of transpapillary biopsy using double lumen introducer for determination of mucosal extent in extrahepatic bile duct cancer. Dig Endosc 15 : 200-206, 2003.
 
6) Noda Y, et al : Intraductal ultrasonography before biliary drainage and transpapillary biopsy in assessment of the longitudinal extent of bile duct cancer. Dig Endosc 20 : 73-78, 2008.
 
7) 野田裕ほか : 胆汁の効果的採取法と保存法. 胆と膵 29 : 689-695, 2008.
Medical*Online
8) Itoi T, et al : Preoperative diagnosis and management of thick-walled gallbladder based on bile cytology obtained by endoscopic transpapillary gallbladder drainage tube. Gastrointest Endosc 64 : 512-519, 2006.
PubMed
9) 木村公一ほか : ENBDチューブ留置での胆汁細胞診の回数別・疾患別検討. Gastroenterol Endosc 53 : 3510-3517, 2011.
 
10) 古旗淳, 広岡保明 : 胆汁処理法の標準化のための工夫. 日臨細胞会誌 49 : 443-448, 2010.
 
11) 高橋久美子ほか : 胆嚢組織像と粘膜擦過および胆汁中細胞の形態の比較-点計測による核・細胞質面積の推定を基に-. J Jap Soc Clin Cytolol 49 : 99-107, 2010.
 
12) 三浦弘守ほか : セルブロックの正しい作り方. 病理と臨床 20 : 32-39, 2002.
 
13) 坂東美奈子, 広川満良 : コロジオンバッグを用いたセルブロック作製法. 臨床検査 38 : 1335-1338, 1994.
 
14) 佐野順司ほか : アルギン酸ナトリウムを用いたセルブロック法の有用性についての検討. 日臨細胞会誌 44 : 291-297, 2005.
 
15) Noda Y, et al : Diagnostic efficacy of the cell block method in comparison with smear cytology of tissue samples obtained by endoscopic ultrasound-guided fine-needle aspiration. J Gastroenterol 45 : 868-875, 2010.
PubMed
P.537 掲載の参考文献
1) Rabenstein T, et al : Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 59 : 606-613, 2004.
 
2) de Bellis M, et al : Tissue sampling at ERCP in suspected malignant biliary stricture (Part 1). Gastrointest Endosc 56 : 552-561, 2002.
PubMed
3) de Bellis M, et al : Tissue sampling at ERCP in suspected malignant biliary stricture (Part 2). Gastrointest Endosc 56 : 720-730, 2002.
PubMed
4) Hattori M, et al : Prospective study of biliary cytology in suspected perihilar cholangiocarcinoma. Br J Surg 98 : 704-709, 2011.
PubMed
5) Parasher VK, Huibregste K : Endoscopic retrograde wire-guided cytology of malignant biliary stricture using a novel scraping brush. Gastrointest Endosc 48 : 288-290, 1998.
 
6) 山崎滋孝ほか : 悪性胆道狭窄のPTCD胆汁細胞診. 消化器科 28 : 377-380, 1999.
 
7) 川井俊郎 : 胆汁細胞診の陽性率に関与する因子について. 日本臨床細胞学会東京都支部会報 18 : 21-24, 2000.
 
8) Mohandas KM, et al : Diagnosis of malignant obstructive jaundice by cytology : results improved by dilating the bile duct stricture. Gastrointest Endosc 40 : 150-154, 1994.
PubMed
9) Ornellas LC, et al : Comparison between endoscopic brush cytology performed before and after biliary stricture dilation for cancer detection. Arq Gastroenterol 43 : 20-23, 2006.
PubMed
10) Mansfield JC, et al : A prospective evaluation of cytology from biliary strictures. Gut 40 : 671-677, 1997.
PubMed
11) Ponchon T, et al : Value of endoscopic brush cytology and biopsies for the diagnosis of malignant bile duct stenosis : results of a prospective study. Gastrointest Endosc 42 : 565-572, 1995.
PubMed
12) Pugliese V, et al : Endoscopic retrograde forceps biopsy and brush cytology of biliary stricture : a prospective study. Gastrointest Endosc 42 : 520-526, 1995.
PubMed
13) Jaiwala J, et al : Triple tissue sampling at ERCP in malignant biliary obstruction. Gastrointest Endosc 51 : 383-390, 2000.
 
14) Burnett AS, et al : Sensitivity of endoscopic retrograde cholangiopancreatography standard cytology : 10-yreview of the literature. J Surg Res 184 : 304-311, 2013.
PubMed
15) Farrell RJ, et al : The combination of stricture dilation, endoscopic needle aspiration, and biliary brushing significantly improves diagnostic yield from malignant bile duct stricture. Gastrointest Endosc 54 : 584-594, 2001.
 
16) Vasilieva LE, et al : Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 11 : 349-359, 2012.
PubMed
17) Victor DW, et al : Current endoscopic approach to indeterminate biliary strictures. World J Gastroenterol 18 : 6197-6205, 2012.
PubMed
18) Kubota Y, et al : Endoscopic transpapillary biopsy for diagnosis of patients with pancreaticobiliary ductal stricture. Am J Gastroenterol 88 : 1700-1704, 1993.
PubMed
19) Sugiyama M, et al : Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary stricture : A prospective comparative study with bile and brush cytology. Am J Gastroenterol 91 : 465-467, 1996.
PubMed
20) Schoefl R, et al : Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenoses. Scand J Gastroenterol 32 : 363-368, 1997.
PubMed
21) 長谷部修ほか : 経乳頭的胆管生検・ブラッシング細胞診・胆汁細胞診の比較と併用の意義. 胆と膵 24 : 403-408, 2003.
Medical*Online
22) Dragnov PV, et al : Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP : a prospective, long-term follow-upstudy. Gastrointest Endosc 75 : 347-353, 2012.
 
23) Osanai M, et al : Peroral video cholangioscopy to evaluate indeterminate bile duct lesions and preoperative mucosal cancerous extension : a prospective multicenter study. Endoscopy 45 : 635-642, 2013.
PubMed
24) Fritscher-Ravens A, et al : EUS-guided fine-needle aspiration of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. Am J Gastroenterol 99 : 45-51, 2003.
 
25) Roesch T, et al : ERCP or EUS for tissue diagnosis of biliary stricture? A prospective comparative study. Gastrointest Endosc 60 : 390-396, 2004.
 
26) Oppong K, et al : EUS-FNA versus biliary brushings and assessment of simultaneous performance in jaundiced patients with suspected malignant obstruction. J Pancreas 11 : 560-567, 2010.
 
27) Hijioka S, et al : Diagnostic yield of endoscopic retrograde cholangiography and EUS-guided fine needle aspiration sampling in gallbladder carcinomas. J Hepatobiliary Pancreat Sci 19 : 650-655, 2012.
 
28) Ohshima Y, et al : EUS-FNA for suspected malignant biliary strictures after negative endoscopic transpapillary brush cytology and forceps biopsy. J Gastroenterol 46 : 921-928, 2011.
PubMed
29) Ogura T, et al : Can endoscopic ultrasound-guided fine needle aspiration offer clinical benefit for thick-walled gallbladders. Dig Dis Sci 59 : 1917-1924, 2014.
PubMed
P.544 掲載の参考文献
1) 乾和郎 : 超音波検診による膵・胆道がんの早期診断. 日消がん検診誌 50 : 409-414, 2012.
 
2) 雑賀公美子ほか : 日本のがん罹患の将来推計. がん・統計白書2012-データに基づくがん対策のために (祖父江友孝監), p63-81, 篠原出版新社, 2012.
 
3) 石原慎ほか : 胆嚢癌フロントライン 胆道癌全国登録データよりみた胆嚢癌の動向. 肝胆膵 64 : 461-466, 2012.
 
4) Tominaga S, et al : Epidemiologic aspects of bniary tract cancer in Japan. Natl Cancer Inst Monogr 53 : 25-34, 1979.
PubMed
5) 山本正治ほか : 主要臓器癌の疫学研究の現状 胆道癌. 癌と化学療法 28 : 155-158, 2001.
 
6) 松田彩子, 片野田耕太 : 都道府県別がん死亡. がん・統計白書2012-データに基づくがん対策のために (祖父江友孝監), p15-42, 篠原出版新社, 2012.
 
7) 菊池正悟, 黒澤美智子 : 喫煙, 飲酒習慣と膵がん, 胆嚢がんの関係. 日消がん検診誌 47 : 431-435, 2009.
 
8) 辻一郎 : 肥満と発がんリスクとの関連. 日消がん検診誌 48 : 199-207, 2010.
 
9) Yagyu K, et al : Bowel movement frequency, medical history and the risk of gallbladder cancer death : a cohort study in Japan. Cancer Sci 95 : 674-678, 2004.
 
P.547 掲載の参考文献
1) Ferlay J, et al : GLOBOCAN, 2012 v1.0, Cancer Incidence and Mortality Worldwide : IARC CancerBase No.11 [Internet] , Lyon, France : International Agency for Research on Cancer, 2013. available from : [http://globocan.iarc.fr], accessed on 01/09/2014.
 
2) Randi G, et al : Gallbladder cancer worldwide : geographical distribution and risk factors. Int J Cancer 118 (7) : 1591-1602, 2006.
PubMed
3) Wistuba II, Gazdar AF : Gallbladder cancer : lessons from a rare tumour. Nat Rev Cancer 4 (9) : 695-706, 2004.
PubMed
4) World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer : Global Perspective. available from : [http://www.dietandcancerreport.org/expert_report/report_contents/index.php], accessed on 01/09/2014.
 
5) Gourgiotis S, et al : Gallbladder cancer. Am J Surg 196 (2) : 252-264, 2008.
PubMed
6) Boutros C, et al : Gallbladder cancer : past, present and an uncertain future. Surg Oncol 21 (4) : e183-191, 2012.
 
7) Stinton LM, Shaffer EA : Epidemiology of gallbladder disease : cholelithiasis and cancer. Gut Liver 6 (2) : 172-187, 2012.
PubMed
8) Shrikhande SV, et al : Cholelithiasis in gallbladder cancer : coincidence, cofactor, or cause! Eur J Surg Oncol 36 (6) : 514-519, 2010.
PubMed
9) Diehl AK : Gallstone size and the risk of gallbladder cancer. JAMA 250 (17) : 2323-2326, 1983.
PubMed
10) Lazcano-Ponce EC, et al : Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51 (6) : 349-364, 2001.
PubMed
11) Caygill CP, et al : Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet 343 (8889) : 83-84, 1994.
PubMed
12) Prasad TL, et al : Mirizzi syndrome and gallbladder cancer. J Hepatobiliary Pancreat Surg 13 (4) : 323-326, 2006.
PubMed
P.551 掲載の参考文献
1) 日本肝胆膵外科学会 (編) : 胆道癌取扱い規約 (第6版補訂版), 金原出版, 2013.
 
2) Albores-Saavedra J, et al : Carcinoma of the gallbladder and extrahepatic bile ducts. In : World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System (ed by Bosman FT, et al), p266-273, IARC Press, Lyon, 2010.
 
3) Zen Y, et al : Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44 : 1333-1343, 2006.
PubMed
4) Zen Y, et al : Biliary intraepithelial neoplasia : an intemational interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 20 : 701-709, 2007.
 
5) Adsay V, et al : Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are≧1.0 cm) : clinicopathologic and immunohistochemical analysis of 123 cases. Am J Surg Pathol 36 : 1279-1301, 2012.
 
6) Adsay V, et al : International consensus study on the terminology and diagnosis of tumoral intraepithelial neoplasms ("adenomas" and "intracystic papillary neoplasms" of WHO-2010) of the gallbladder. Mod Pathol 26 : 422A, 2013.
 
7) Wakai T, et al : Mode of hepatic spread from gallbladder carcinoma : an immunohistochemical analysis of 42 hepatectomized specimens. Am J Surg Pathol 34 : 65-74, 2010.
PubMed
P.555 掲載の参考文献
1) 江川直人ほか : 胆石症と胆嚢癌の関係にみられる性差についての臨床的検討. 胆道 17 : 86-91, 2003.
Medical*Online
2) Sheth A, et al : Primary gallbladder cancer : recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol 95 : 1402-1410, 2000.
 
3) Hsing AW, et al : Family history of gallstones and the risk of biliary tract cancer and gallstones : a population-based study in Shanghi, China. Int J Cancer 121 : 832-838, 2007.
 
4) Gracie WA, Ransohoff DF : The natural history of silent gallstones : the innocent gallstone is not a myth. N Engl J Med 307 : 798-800, 1982.
 
5) 胆道癌診療ガイドライン作成出版委員会 (編) : エビデンスに基づいた胆道癌診療ガイドライン, p39, 医学図書出版, 2007.
 
6) Misra S, et al : Carcinoma of the gallbladder. Lancet Oncol 4 : 167-176, 2003.
PubMed
7) Piantino P, et al : Increased levels of CA19-9, CA50 and CA125 in patients with benign disease of biliary tract and the pancreas. J Nucl Med Allied Sci 34 : 97-102, 1990.
 
8) Patel AH, et al : The utility of CA19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95 : 204-207, 2000.
PubMed
9) Nichols JC, et al : Diagnostic role of senlm CA19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 68 : 874-879, 1993.
 
10) Khan SA, et al : Guidelines for the diagnosis and treatment of cholangiocarcinoma : consensus document. Gut 51 : 1-9, 2002.
 
11) Pasanen PA, et al : Clinical value of serum tumor marker CEA, CA50 ad CA242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis ; results from a prospective study. Anticancer Res 12 : 1687-1693, 1992.
 
12) Vij U, Baskaran V : Value of serum CEA and AFP in the diagnosis and prognosis of carcinoma gallbladder. Trop Gastroenterol 22 : 227-229, 2001.
PubMed
P.560 掲載の参考文献
1) 永川宅和, 萱原正都 : 胆道癌登録成績が教える胆道癌の診断と治療のあり方, 金原出版, 2005.
 
2) 土屋貴愛ほか : 臓器別最新データ 胆道癌 胆道癌の診断. 臨床外科 67 : 186-197, 2012.
 
3) 吉富秀幸ほか : 胆道癌診療ガイドラインの現状と改訂へ向けての課題-ガイドライン利用アンケート調査結果を中心に-. 胆と膵 32 : 263-269, 2011.
Medical*Online
4) エビデンスに基づいた胆道癌診療ガイドライン (改訂第2版) (胆道癌診療ガイドライン作成出版委員会編), 医学図書出版, 2014.
 
5) 森根裕二ほか : 全国集計からみた先天性胆道拡張症, 膵・胆管合流異常の胆道癌発生率とその特徴. 胆と膵 31 : 1923-1929, 2010,
 
6) 栗田亮ほか : 胆道癌の画像診断-US・CT・MRI-. 消化器外科 32 : 1683-1695, 2009.
 
7) Hayakawa S, et al : Color Doppler-guided spectral analysis of gall-bladder wall flow. J Gastroenterol Hepatol 13 : 181-185, 1998.
 
8) Tsuji S, et al : Contrast-enhanced ultrasonography in the diagnosis of gallbladder disease. Hepatogastroenterology 59 : 336-340, 2012.
PubMed
9) Inoue T, et al : Diagnosis of gallbladder diseases by contrast-enhanced phase-inversion harmonic ultrasonography. Ultrasound Med Biol 33 : 353-361, 2007.
PubMed
10) 胆道癌の画像診断 (CT, MRI, PET). コンセンサス癌治療 8 : 18-23, 2009.
 
11) 吉満研吾ほか : MRIによる胆膵の診断. 画像診断 27 : 1334-1343, 2007.
 
12) Lee SW, et al : Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 45 : 560-566, 2010.
PubMed
13) 若井俊文ほか : 胆嚢癌. 臨床外科 66 : 1342-1347, 2011.
 
14) Hijioka S, et al : Diagnostic yield of endoscopic retrograde cholangiography and of EUS-guided fine needle aspiration sampling in gallbladder carcinomas. J Hepatobiliary Pancreat Sci 19 : 650-655, 2012.
 
15) Itoi T, et al : Preoperative diagnosis and management of thick-walled gallbladder based on bile cytology obtained by endoscopic transpapillary gallbladder drainage tube. Gastrointest Endosc 64 : 512-519, 2006.
PubMed
P.565 掲載の参考文献
1) 胆道癌診療ガイドライン作成出版委員会 (編) : エビデンスに基づいた胆道癌診療ガイドライン, 改訂第2版, 医学図書出版, 2014,
 
2) 石原慎ほか : 胆嚢癌フロントライン 疫学 胆道癌全国登録データよりみた胆嚢癌の動向. 肝胆膵 64 (4) : 146-159, 2009.
 
3) 島田光生ほか : 膵・胆管合流異常の診療ガイドライン (日本膵・胆管合流異常研究会・日本胆道学会編). 胆道 26 : 678-690, 2012.
Medical*Online
4) 土屋貴愛ほか : 外科医のための癌診療データ 臓器別最新データ 胆道癌 胆道癌の診断. 臨床外科 67 : 186-197, 2012.
 
5) Mann DV, et al : Elevated tumor marker CA19-19, clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26 : 474-479, 2000.
 
6) 大倉久直 : シリアルルイスA糖鎖抗原. 基準値と異常値の間-その判定と対策第6版 (河合忠編), p369-372, 中外医学社, 2006.
 
7) De Groen PC, et al : Biliary tract cancers. N Engl J Med 341 : 1368-1378, 1999.
PubMed
8) 黒住昌弘ほか : 胆道癌の画像診断 (CT, MRI, PET). コンセンサス癌治療 8 : 18-23, 2009.
 
9) Lopera JE, et al : Malignant hilar and perihilar biliary obstruction : use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology 220 : 90-96, 2001.
PubMed
10) 吉満研吾ほか : MRIによる胆膵の診断. 画像診断 27 : 1334-1343, 2007.
 
11) 北島一宏ほか : 胆道がんにおけるFDG-PET/CTの臨床的有用性. インナービジョン 25 : 12-17, 2010.
Medical*Online
12) 糸井隆夫ほか : EUS画像診断. 胆膵内視鏡の診断・治療の基本手技, 改訂2版, p90-98, 羊土社, 2012.
 
13) 日本肝胆膵外科学会 (編) : 外科・病理 胆道癌取り扱い規約, 第6版, 金原出版, 2013.
 
14) 石川卓哉ほか : 胆嚢癌に対する超音波内視鏡および造影超音波内視鏡の有用性について. 肝胆膵 66 : 197-203, 2013.
Medical*Online
15) Itoi T, et al : Preoperative diagnosis and management of thick-walled gallbladder based on bile cytology obtained by endoscopic transpapillary gallbladder drainage tube. Gastrointest Endosc 64 : 512-519, 2006.
PubMed
P.570 掲載の参考文献
1) 藤井義郎ほか : 胆嚢小隆起性病変の実態-特にコレステロールポリープと腺腫について-. 胆道 13 : 327-331, 1999.
Medical*Online
2) 胆道癌診療ガイドライン作成委員会 : エビデンスに基づいた胆道癌診療ガイドライン (高田忠敬編), 第1版, p33, 医学図書出版, 2007.
 
3) 社団法人日本超音波医学会用語・診断基準委員会 : 胆嚢癌の超音波診断基準の公示. Jpn J Med Ultrasonics 37 : 329-332, 2002.
 
4) 日本消化器がん検診学会超音波部会委員会超音波検診基準作成のワーキンググループ : 腹部超音波がん検診 基準. 日消がん検診誌 49 : 667-685, 2011.
 
5) Thorbjarnarson B : Carcinoma of the gallbladder and acute cholecystitis. Ann Surg 151 : 241-244, 1960.
PubMed
6) 須藤幸一, 木村理 : 胆道感染症. 日本臨牀 60 : 284-288, 2002.
Medical*Online
7) 名取志保ほか : 胆嚢癌との鑑別が困難であった黄色肉芽腫性胆嚢炎の1例. 胆と膵 18 : 593-596, 1997.
Medical*Online
8) 遠藤格ほか : 黄色肉芽腫性胆嚢炎の診断と治療戦略-過大な手術を回避するための術前・術中の方策-. 胆道 27 : 712-719, 2013.
Medical*Online
9) 五十嵐誠治ほか : 胆嚢の病理. 画像診断 31 : 252-264, 2011.
 
10) 日本膵・胆管合流異常研究会, 日本胆道学会 (編) : II. 診断 CQ-II-1膵・胆管合流異常の診断基準は? 膵・胆管合流異常診療ガイドライン, p19, 医学図書出版, 2012.
 
P.574 掲載の参考文献
1) エビデンスに基づいた胆道癌診療ガイドライン (第1版) (胆道癌診療ガイドライン作成出版委員会編), 医学図書出版, 2007.
 
2) 胆道癌取扱い規約 (第6版) (日本肝胆膵外科学会編), 金原出版, 2013.
 
3) Lamarca A, et al : Efficacy and safety of cisplatin and gemcitabine (CG) chemotherapy for advanced biliary tract cancer (ABC) in jaundiced patients (pts). J Clin Oncol 32 (Suppl 3 ; Abstr 294), 2014.
 
P.578 掲載の参考文献
1) エビデンスに基づいた胆道癌診療ガイドライン (第1版) (胆道癌診療ガイドライン作成出版委員会編), 医学図書出版, 2007.
 
2) 臨床・病理 胆道癌取扱い規約 (第6版) (日本肝胆膵外科学会編), 金原出版, 2013.
 
3) Wakai T, et al : Morphological features of early gallbladder carcinoma. Hepatogastroenterology 59 : 1013-1017, 2012.
PubMed
4) You DD. et al : What is an adequate extent of resection for T1 gallbladder cancers? Ann Surg 247 : 835-838, 2008.
PubMed
5) Jensen EH, et al : Lymph node evaluation is associated with improved surVival after surgery for early stage gallbladder cancer. Surgery 146 : 706-711, 2009.
PubMed
6) Goetze TO, Paolucci V : Immediate re-resection of T1 incidental gallbladder carcinomas : a survival analysis of the German Registry. Surg Endosc 22 : 2462-2465, 2008.
 
7) Tsukada T, et al : Lymph node spread from carcinoma of the gallbladder. Cancer 80 : 661-667, 1997.
 
8) Horiguchi A, et al : Gallbladder bed resection or hepatectomy of segments 4a and 5 for pT2 gallbladder carcinoma : analysis of Japanese registration cases by the study groupfor biliary surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20 : 518-524, 2013.
PubMed
9) Shimizu Y, et al : Should the extrahepatic bile duct be resected for locally advanced gallbladder cancer? Surgery 136 : 1012-1017, 2004.
PubMed
10) Pawlik TM, et al : Incidence of finding residual disease for incidenta1 gallbladder carcinoma : implications for re-resection. J Gastrointest Surg 11 : 1478-1486, 2007.
PubMed
11) Nishio H, et al : Aggressive surgery for stage IV gallbladder carcinoma ; what are the contraindications? J Hepatobiliary Pancreat Surg 14 : 351-357, 2007.
PubMed
12) Higuchi R, et al : Surgical approaches to advanced gallbladder cancer : a 40-year single-institution study of prognostic factors and resectability. Ann Surg Oncol 21 : 4308-4316, 2014.
PubMed
P.583 掲載の参考文献
1) 胆道癌診療ガイドライン作成出版委員会 (編) : エビデンスに基づいた胆道癌診療ガイドライン, p76-77, 医学図書出版, 2007.
 
2) Ouchi K et al : Organizing Committee, The 30th Annual Congress of the Japanese Society of Biliary Surgery : Laparoscopic cholecystectomy for gallbladder carcinoma : results of a Japanese survey of 498 patients. J Hepatobiliary Pancreat Surg 9 (2) : 256-260, 2002.
 
3) 内視鏡外科手術に関するアンケート調査-第11回集計結果報告-. 日鏡外会誌 17 : 571-694, 2012.
 
4) 新井田達雄ほか : 胆嚢癌の進展度に応じた治療の選択. 消化器科 45 : 330-337, 2007.
 
5) 本田五郎ほか : 早期胆嚢癌に対する腹腔鏡下胆嚢全層切除のコツとその剥離層の組織学的検討. 胆道 27 : 705-711, 2013.
Medical*Online
6) Cho A, et al : Total laparoscopic resection of the gallbladder together with the gallbladder bed. J Hepatobiliary Pancreat Surg 15 (6) : 585-588, 2008.
PubMed
7) Cho A, et al : Laparoscopic major hepato-biliary-pancreatic surgery : formidable challenge to standardization. J Hepatobiliary Pancreat Surg 16 (6) : 705-710, 2009.
PubMed
8) Takahashi M, et al : Pure laparoscopic right hepatectomy by anterior approach with hanging maneuver for large intrahepatic cholangiocarcinoma. Surg Endosc 27 (12) : 4732-4733, 2013.
PubMed
9) Machado MA, et al : Totally laparoscopic right hepatectomy with Roux-en-Y hepaticojejunostomy for right-sided intraductal papillary mucinous neoplasm of the bile duct. Ann Surg Oncol 21 (6) : 1841-1843, 2014.
PubMed
10) 平井健次郎ほか : 切除標本にてsevere dysplasiaと診断されport site recurrenceをきたした胆嚢上皮内癌の1例. 日臨外会誌 69 : 427-432, 2008.
 
11) 腰塚靖之ほか : 術後5年目にポート部再発巣を切除した腹腔鏡下胆嚢摘出後偶発胆嚢癌の1例. 日臨外会誌 69 : 433-437, 2008.
 
12) Paolucci V, et al : Tumor seeding following laparoscopy : international survey. World J Surg 23 (10) : 989-995, 1999.
PubMed
13) Hirabayashi Y, et al : Port-site metastasis after CO2 pneumoperitoneum : role of adhesion molecules and prevention with antiadhesion molecules. Surg Endosc 18 (7) : 1113-1117, 2004.
PubMed
P.589 掲載の参考文献
1) Miyakawa S, et al : Biliary tract cancer treatment 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16 : 1-7, 2009.
PubMed
2) Ikeda M, et al : A Phase II Trial of Uracil-Tegafur (UFT) in Patients with Advanced Biliary Tract Carcinoma. Jpn J Clin Oncol 35 : 439-443, 2005.
 
3) Furuse J, et al : A phase II study of uraci1-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol 65 : 113-120, 2009.
PubMed
4) Okusaka T, et al : Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57 : 647-653, 2006.
PubMed
5) Furuse J, et al : S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer : a multicenter phase II study. Cancer Chemother Pharmacol 62 : 849-855, 2008.
PubMed
6) Eckel F, Schmid RM : Chemotherapy in advanced biliary tract carcinoma : apooled analysis of clinical trials. Br J Cancer 96 : 896-902, 2007.
PubMed
7) Valle JW, et al : Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours : a multicenter randomized phase II study-The UK ABC-01 Study. Br J Cancer 101 : 621-627, 2009.
 
8) Valle J, et al : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 : 1273-1281, 2010.
PubMed
9) Okusaka T, et al : Gemcitbine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicenter study in Japan. Br J Cancer 103 : 469-474, 2010.
PubMed
10) Valle JW, et al : Cisplatin and gemcitabine for advanced biliary tract cancer : a meta-analysis of two randomized trials. Ann Oncol 25 : 391-398, 2014.
PubMed
11) Morizane C, et al : Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer : a Japan Clinical Oncology Group trial (JCOG0805). Cancer Sci 104 : 1211-1216, 2013.
 
12) Sasaki T, et al : Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 30 : 708-713, 2012.
PubMed
13) Suzuki E, et al : A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 71 : 1141-1146, 2013.
PubMed
14) Valle JW, et al : ABC-03 : A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC). J Clin Oncol 32 (Suppl) ; abstract 4002, 2014.
 
15) Takada T, et al : Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 : 1685-1695, 2002.
PubMed
P.593 掲載の参考文献
1) Jarnagin WR, et al : Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma : implications for adjuvant therapeutic strategies. Cancer 98 (8) : 1689-1700, 2003.
PubMed
2) Hyder O, et al : Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma : a propensity score-matched Surveillance, Epidemiology, and End Results analysis. Surgery 155 (1) : 85-93, 2014.
PubMed
3) Wang SJ, et al : Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 29 : 4627-4632, 2011.
PubMed
4) Gold DG, et al : Adjuvant therapy for gallbladder carcinoma : the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys 75 (1) : 150-155, 2009.
 
5) Horgan AM, et al : Adjuvant therapy in the treatment of biliary tract cancer : a systematic review and meta-analysis. J Clin Oncol 30 (16) : 1934-1940, 2012.
PubMed
6) Lim H, et al : Prognostic factors in patients with gallbladder cancer after surgical resection : analysis of 279 operated patients. J Clin Gastroenterol 47 (5) : 443-448, 2013.
PubMed
7) Takada T, et al : Is postoperative adjuvant chemotherapy usefU1 for gallbladder carcinoma ? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 (8) : 1685-1695, 2002.
PubMed
8) de Aretxabala X, et al : Preoperative chemoradiotherapy in the treatment of gallbladder cancer. Am Surg 65 (3) : 241-246, 1999.
PubMed
9) de Areixabala X, et al : Neoadjuvant chemoradiotherapy in gallbladder cancer. Rev Med Chil 132 (1) : 51-57, 2004.
PubMed
10) Glazer ES, et al : Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins, J Gastrointest Surg 16 (9) : 1666-1671, 2012.
PubMed
11) Engineer R, et al : Chemoradiation for unresectable gall bladder cancer : time to review historic nihilism? J Gastrointest Cancer 42 (4) : 222-227, 2011.
PubMed
12) Alden ME, Mohiuddin M : The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 28 (4) : 945-951, 1994.
PubMed
13) Yoshioka Y, et al : Impact of intraluminal brachytherapy on survival outcome for radiation therapy for unresectable biliary tract cancer : a propensity-score matched-pair analysis. Int J Radiat Oncol Biol Phys 89 (4) : 822-829, 2014.
PubMed
14) Emami B, et al : Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 : 109-122, 1991.
PubMed
15) 幕内雅敏ほか : 肝硬変合併肝癌治療のstrategy. 外科診療 29 : 1530-1536, 1987.
 
16) Katayose Y, et al : Phase I trial of neoadjuvant chemoradiation with gemcitabine and surgical resection for cholangiocarcinoma patients (NACRAC study). Hepatogastroenterology 58 (112) : 1866-1872, 2011.
PubMed
17) Sun XN, et al : Adjuvant radiotherapy for gallbladder cancer : a dosimetric comparison of conformal radiotherapy and intensity-modulated radiotherapy. World J Gastroenterol 17 (3) : 397-402, 2011.
PubMed
18) Foo ML, et al : External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 39 : 929-935, 1997.
PubMed
19) Bi AH, et al : Impact factors for microinvasion in intrahepatic cholangiocarcinoma : a possible system for defining clinical target volume. Int J Radiat Oncol Biol Phys 78 (5) : 1427-1436, 2010.
PubMed
20) Shimada H, et al : The role of lymph node dissection in the treatment of gallbladder carcinoma. Cancer 79 (5) : 892-899, 1997.
PubMed
21) 樋口亮太ほか : ss胆嚢癌に対するリンパ節郭清および術式に関する検討. 胆道 22 : 650-657, 2008.
Medical*Online
P.599 掲載の参考文献
1) 胆道癌診療ガイドライン出版委員会 (編) : 第V章 術前胆道ドレナージ. エビデンスに基づいた胆道癌診療ガイドライン, 第1版, 医学図書出版, 2007.
 
2) 近藤哲ほか : 胆嚢癌の進展様式と術式の選択. 外科治療 75 : 483-488, 1996.
Medical*Online
3) Speer AG, et al : Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 2 : 57-62, 1987.
PubMed
4) Wagner HJ, et al : Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. Endoscopy 25 : 213-218, 1993.
PubMed
5) Mukai T, et al : Metallic stents are more efficacious than plastic stents in unresectable malignant hilar biliary strictures : a randomized controlled trial. J Hepatobiliary Pancreat Sci 20 : 214-222, 2013.
PubMed
6) Perdue DG, et al : Plastic versus self-expanding metallic stents for malignant hilar biliary obstruction : a prospective multicenter observational cohort study. J Clin Gastroenterol 42 : 1040-1046, 2008.
PubMed
7) Moss AC, et al : Malignant distal biliary obstruction : a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev 33 : 213-221, 2007.
PubMed
8) Moss AC, et al : Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol 19 : 1119-1124, 2007.
 
9) Isayama H, et al : A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 53 : 729-734, 2004.
PubMed
10) Saleem A, et al : Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc 74 : 321-327, 2011.
PubMed
11) Ung KA, et al : Covered and uncovered self-expandable metallic Hanarostents are equally efficacious in the drainage of extrahepatic malignant strictures. Results of a double-blind randomized study. Scand J Gastroenterol 48 : 459-465, 2013.
PubMed
12) Kitano M, et al : Covered self-expandable meta1 stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma : a randomized multicenter trial. Am J Gastroenterol 108 : 1713-1722, 2013.
 
13) Lee SJ, et al : Comparison of the Efficacy of Covered versus Uncovered Metallic Stents in Treating Inoperable Malignant Common Bile Duct Obstruction : A Randomized Trial. J Vasc Interv Radiol 25 : 1912-1920, 2014.
 
14) Kawakami H, et al : Technical tips and troubleshooting of endoscopic biliary drainage for unresectable malignant hilar biliary obstruction. J Hepatobiliary Pancreat Sci, 2014. [Epub ahead of print]
 
15) Naitoh I, et al : Side-by-side versus stent-in-stent deployment in bilateral endoscopic metal stenting for malignant hilar biliary obstruction. Dig Dis Sci 57 : 3279-3285, 2012.
PubMed
16) 河上洋ほか : 切除不能膵癌に対する内視鏡的intervention-現状と本邦よりのevidence-. 肝胆膵 68 : 935-947, 2014.
Medical*Online
17) Jeurnink SM, et al : Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction : a systematic review. BMC Gastroenterol 7 : 18, 2007.
PubMed
18) Jeurnink SM, et al : Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study) : a multicenter randomized trial. Gastrointest Endosc 71 : 490-499, 2010.
 
19) Jeurnink SM, et al : Predictors of survival in patients with malignant gastric outlet obstruction : a patient-oriented decision approach for palliative treatment. Dig Liver Dis 43 : 548-552, 2011.
PubMed
20) Maetani I, et al : Placement of a triple-layered covered versus uncovered metallic stent for palliation of malignant gastric outlet obstruction : a multicenter randomized trial. Dig Endosc 26 : 192-199, 2014.
PubMed
21) Lim SG, et al : Conformable covered versus uncovered self-expandable metallic stents for palliation of malignant gastroduodenal obstruction : a randomized prospective study. Dig Liver Dis 46 : 603-608, 2014.
PubMed
P.604 掲載の参考文献
1) Miyakawa S, et al : Biliary tract cancer treatment : 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16 : 1-7, 2009.
PubMed
2) Yamao K et al : EUS-guided choledochoduodenostomy for palliative biliary drainage in patients with malignant biliary obstruction : results of long-term follow-up. Endoscopy 40 : 340-342, 2008.
PubMed
3) Watson M, et al : Cahexia anorexia and fatigue. In : Oxford Handbook of Palliative Care, 2nd ed, p349-357, Oxford University Press, Oxford, 2009.
 
4) Saunders C : The Management of Terminal Malignant Disease (ed by Saunders C, Sykes N), p1-14, Edward Arnold, London, 1993.
 
P.608 掲載の参考文献
1) Miyakawa S, et al : Biliary tract cancer treatment : 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16 (1) : 1-7, 2009.
PubMed
2) 石原慎ほか : 胆道癌全国登録データよりみた胆嚢癌の動向. 肝胆膵 64 (4) : 461-466, 2012.
Medical*Online
3) Suzuki K, et al : Long-term prognosis of gallbladder cancer diagnosed after laparoscopic cholecystectomy. Surg Endosc 14 (8) : 712-716, 2000.
PubMed
4) Wakai T, et al : Early gallbladder carcinoma does not warrant radical resection. Br J Surg 88 (5) : 675-678, 2001.
 
5) Goetze TO, Paolucci V : Prognosis of incidental gallbladder carcinoma is not influenced by the primary access technique : analysis of 837 incidental gallbladder carcinomas in the German Registry. Surg Endosc 27 (8) : 2821-2828, 2013.
 
6) Hari DM, et al : A 21-year analysis of stage I gallbladder carcinoma : is cholecystectomy alone adequate? HPB (Oxford) 15 (1) : 40-48, 2013.
 
7) Dixon E, et al : An aggressive surgical approach leads to improved survival in patients with gallbladder cancer : a 12-year study at a North American Center. Ann Surg 241 (3) : 385-394, 2005.
 
8) Shindoh J, et al : Tumor Location Is a Strong Predictor of Tumor Progression and Survival in T2 Gallbladder Cancer : An International Multicenter Study. Ann Surg, 2014. [Epub ahead of print]
 
9) 遠藤格ほか : 胆嚢癌に対する外科治療の現況と今後の展望. 日消誌 110 (8) : 1408-1414, 2013.
Medical*Online
10) Foster JM, et al : Gallbladder cancer : Defining the indications for primary radical resection and radical re-resection. Ann Surg Oncol 14 (2) : 833-840, 2007.
PubMed
11) Fong Y, et al : Gallbladder cancer : comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention, Ann Surg 232 (4) : 557-569, 2000.
PubMed
12) Horiguchi A, et al : Gallbladder bed resection or hepatectomy of segments 4a and 5 for pT2 gallbladder carcinoma : analysis of Japanese registration cases by the study groupfor biliary surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20 (5) : 518-524, 2013.
PubMed
13) Reddy SK et al : Extended hepatic resection for gallbladder cancer. Am J Surg 194 (3) : 355-361, 2007.
PubMed
14) Sakamoto Y, et al : Is extended hemihepatectomy plus pancreaticoduodenectomy justified for advanced bile duct cancer and gallbladder cancer? Surgery 153 (6) : 794-800, 2013.
PubMed
15) Horgan AM, et al : Adjuvant therapy in the treatment of biliary tract cancer : a systematic review and meta-analysis. J Clin Oncol 30 (16) : 1934-1940, 2012.
PubMed
P.613 掲載の参考文献
1) エビデンスに基づいた胆道癌診療ガイドライン (胆道癌診療ガイドライン作成出版委員会編), 医学図書出版, 2007.
 
2) Higuchi R, et al : Surgical Approaches to Advanced Gallbladder Cancer : A 40-Year Single-Institution Study of Prognostic Factors and Resectability. Ann Surg Oncol 21 (13) : 4308-4316, 2014.
PubMed
3) Murakami Y, et al : Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection. J Gastrointest Surg 15 (6) : 1007-1016, 2011.
PubMed
4) Kim WS, et al : Risk factors influencing recurrence, pattems of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma. J Gastrointest Surg 14 (4) : 679-687, 2010.
 
5) Miura F, et al : New prognostic factor influencing long-term survival of patients with advanced gallbladder carcinoma. Surgery 148 (2) : 271-277, 2010.
PubMed
6) Choi SB, et al : Surgical outcomes and prognostic factors for T2 gallbladder cancer following surgical resection. J Gastrointest Surg 14 (4) : 668-678, 2010.
PubMed
7) Wakai T, et al : Mode of hepatic spread from gallbladder carcinoma : an immunohistochemical analysis of 42 hepatectomized specimens. Am J Surg Pathol 34 (1) : 65-74, 2010.
PubMed
8) Shibata K, et al : Lymphatic invasion : an important prognostic factor for stages T1b-T3 gallbladder cancer and an indication for additional radical resection of incidental gallbladder cancer. World J Surg 33 (5) : 1035-1041, 2009.
 
9) Kayahara M, et al : Prognostic factors for gallbladder cancer in Japan. Ann Surg 248 (5) : 807-814, 2008.
PubMed
10) Kai M, et al : A curative resection improves the postoperative survival rate even in patients with advanced gallbladder carcinoma. J Gastrointest Surg 11 (8) : 1025-1032, 2007.
PubMed
11) Yokomizo H, et al : Surgical treatment of pT2 gallbladder carcinoma : a reevaluation of the therapeutic effect of hepatectomy and extrahepatic bile duct resection based on the long-term outcome. Ann Surg Oncol 14 (4) : 1366-1373, 2007.
 
12) Yagi H, et al : Retrospective analysis of outcome in 63 gallbladder carcinoma patients after radical resection. J Hepatobiliary Pancreat Surg 13 (6) : 530-536, 2006.
PubMed
13) Endo I, et al : Prognostic significance of the number of positive lymph nodes in gallbladder cancer. J Gastrointest Surg 10 (7) : 999-1007, 2006.
PubMed
14) Kokudo N, et al : Strategies for surgical treatment of gallbladder carcinoma based on information available before resection. Arch Surg 138 (7) : 741-750 ; discussion 750, 2003.
PubMed
15) Yamaguchi R, et al : Perineural invasion has a negative impact on survival of patients with gallbladder carcinoma. Br J Surg 89 (9) : 1130-1136, 2002.
 
P.617 掲載の参考文献
1) 永川宅和, 萱原正都 : 胆道癌治療成績からみた胆道癌治療の実態. 胆道 14 (1) : 23-28, 2000.
Medical*Online
2) 「がんの統計」編集委員会 : がんの統計 '13. 公益財団法人がん研究振興財団, 2013.
 
3) 独立行政法人国立がん研究センターがん対策情報センター : 人口動態統計によるがん死亡データ (1958年-2012年). [http://ganjoho.jp/professional/index.html]
 
4) 独立行政法人国立がん研究センターがん対策情報センター : 地域がん登録全国推計によるがん罹患データ (1975年-2010年). [http://ganjoho.jp/professional/index.html]
 
5) Waterhouse J, et al : Cancer Incidence in Five Continents Vol IV. IARC Scientific Publications No.42, IARC, Lyon, 1982.
 
6) Randi G, et al : Epidemiology of biliary tract cancers : an update. Ann Oncol 20 : 146-159, 2009.
PubMed
7) Ishiguro S, et al : Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (JPHC study) ; with special focus on cholelithiasis, body mass index, and their effect modification. Cancer Causes Control 19 (1) : 33-41, 2008.
 
8) Tominaga S, et al : Epidemiologic aspects of biliary tract cancer in Japan. Natl Cancer Inst Monogr (53) : 25-34, 1979.
PubMed
9) 松葉剛ほか : 胆管・胆のうがんと食生活との関連. 癌の臨床 49 : 665-670, 2003.
Medical*Online
10) 森根裕二ほか : 全国集計からみた先天性胆道拡張症, 膵・胆管合流異常の胆道癌発生率とその特徴. 胆と膵 31 (11) : 1293-1299, 2010.
Medical*Online
P.620 掲載の参考文献
1) 胆道癌診療ガイドライン作成出版委員会 (編) : エビデンスに基づいた胆道癌診療ガイドライン, 第1版, 医学図書出版, 2007.
 
2) Funabiki T, et al : Pancreaticobiliary maljunction and carcinogenesis to biliary and pancreatic malignancy. Langenbecks Arch Surg 394 : 159-169, 2009.
PubMed
3) Morine Y, et al : Clinical features of pancreaticobiliary maljunction : update analysis of 2nd Japan-nationwide survey. J Hepatobiliary Pancreat Sci 20 : 472-480, 2013.
PubMed
4) 松原俊樹ほか : 胆道形成異常の臨床 発生から発癌まで, 第1版 (松本由朗編), p195-198, 金原出版, 2003.
 
5) Peng NF, et al : Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China : a possible role of hepatitis B virus. Ann Surg Oncol 18 : 1258-1266, 2011.
 
6) Tanaka M, et al : Risk factors for intrahepatic cholangiocarcinoma : a possible role of hepatitis B virus. J Viral Hepat 17 : 742-748, 2010.
PubMed
7) Shaib YH, et al : Risk factors for intrahepatic and extrahepatic cholangiocarcinoma : a hospitalbased case-control study. Am J Gastroenterol 102 : 1016-1021, 2007.
PubMed
8) Perumal V, et al : Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol 37 : 1211-1216, 2006.
PubMed
9) Li T, et al : Epithelial-mesenchymal transition induced by hepatitis C virus core protein in cholangiocarcinoma. Ann Surg Oncol 17 : 1937-1944, 2010.
PubMed
10) 森俊幸 : 疫学予後ワーキング・グループ報告. 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 肝内結石分科会, 平成20年度分担研究報告書, p139-141, 2009.
 
11) 佐田尚宏ほか : 肝内胆管癌合併肝内結石症のProfile調査. 胆道 26 : 367, 2012.
Medical*Online
12) 田中篤, 滝川一: 全国調査からみた原発性硬化性胆管炎の病態. 胆と膵 31 : 727-731, 2010.
Medical*Online
13) 平野賢二ほか : 原発性硬化性胆管炎における胆道癌のリスク. 胆と膵 34 : 491-495, 2013.
Medical*Online
14) Al Mamari S, et al : Improvement of serum alkaline phosphatase to<1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 58 : 329-334, 2013.
PubMed
15) Ehlken H, Schramm C : Primary sclerosing cholangitis and cholangiocarcinoma : pathogenesis and modes of diagnostics. Dig Dis 31 : 118-125, 2013.
PubMed
P.626 掲載の参考文献
1) 日本肝胆膵外科学会 (編) : 胆道癌取扱い規約 (第6版補訂版), 金原出版, 2013.
 
2) Hoang MP, et al : Invasive papillary carcinomas of the extrahepatic bile ducts : a clinicopathologic and immunohistochemical study of 13 cases. Mod Pathol 15 : 1251-1258, 2002.
PubMed
3) Jarnagin WR, et al : Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 241 : 703-712, 2005.
PubMed
4) Nakanishi Y, et al : Extrahepatic bile duct carcinoma with extensive intraepithelial spread : a clinicopathological study of 21 cases. Mod Pathol 21 : 807-816, 2008.
PubMed
5) Igami T, et al : Clinicopathologic study of cholangiocarcinoma with superficial spread. Ann Surg 249 : 296-302, 2009.
PubMed
6) Nakanishi Y, et al : Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. J Hepatobiliary Pancreat Sci 17 : 166-173, 2010.
PubMed
7) Aishima S, et al : Proposal of progression model for intrahepatic cholangiocarcinoma : clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol 31 : 1059-1067, 2007.
PubMed
8) Liau JY, et al : Morphological subclassification of intrahepatic cholangiocarcinoma : etiological, clinicopathological, and molecular features. Mod Pathol 27 : 1163-1173, 2014.
PubMed
9) Zen Y, et al : Tubulin β-III : a novel immunohistochemical marker for intrahepatic peripheral cholangiocarcinoma. Histopathology 65 : 784-792, 2014.
 
10) Guedj N, et al : Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinoma, J Hepatol 51 : 93-101, 2009.
PubMed
P.629 掲載の参考文献
1) 胆道癌取扱い規約 (日本肝胆膵外科学会編), 金原出版, 2013.
 
2) 久保正二ほか : 新たな職業癌 : 印刷労働者にみられた胆管癌. Jpn J Cancer Chemother 40 : 1451-1454, 2013,
 
3) 胆道癌診療ガイドライン (日本肝胆膵外科学会, 日本癌治療学会編), 医学図書出版, 2007.
 
4) Konstantinos N, et al : Cholangiocarcinoma. Gastroenterology 128 : 1655-1667, 2005.
 
5) Sugiyama M, et al : Bile duct carcinoma without jaundice : clues to early diagnosis. Hepatogastroenterology 44 : 1477-1483, 1997.
PubMed
P.633 掲載の参考文献
1) Rizvi S, Gores GJ : Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145 : 1215-1229, 2013.
PubMed
2) Miyakawa S, et al : Flowcharts for the management of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 15 : 7-14, 2008.
PubMed
3) Kawakami H, et al : Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol 46 : 242-248, 2011.
PubMed
4) Tillich M, et al : Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am J Roentgenol 171 : 651-658, 1998.
PubMed
5) Akamatsu N, et al : Diagnostic accuracy of multidetector-row computed tomography for hilar cholangiocarcinoma. J Gastroenterol Hepatol 25 : 731-737, 2010.
PubMed
6) Choi BI, et al : Imaging of intrahepatic and hilar cholangiocarcinoma. Abdom Imaging 29 : 548-557, 2004.
PubMed
7) Razumilava N, Gores GJ : Cholangiocarcinoma. Lancet 383 : 2168-2179, 2014.
PubMed
8) Mohamadnejad M, et al : Role of EUS for preoperative evaluation of cholangiocarcinoma : a large single-center experience. Gastrointest Endosc 73 : 71-78, 2011.
PubMed
9) DeWitt J, et al : EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. Gastrointest Endosc 64 : 325-333, 2006.
PubMed
10) Osanai M, et al : Peroral video cholangioscopy to evaluate indeterminate bile duct lesions and preoperative mucosal cancerous extension : a prospective multicenter study. Endoscopy 45 : 635-642, 2013.
PubMed
11) Hijioka S, et al : A novel technique for endoscopic transpapillary "mapping biopsy specimens" of superficial intraductal spread of bile duct carcinoma (with videos). Gastrointest Endosc 79 : 1020-1025, 2014.
PubMed
12) Choi ER, et al : Preoperative evaluation of the longitudinal extent of borderline resectable hilar cholangiocarcinoma by intraductal ultrasonography. J Gastroenterol Hepatol 26 : 1804-1810, 2011.
PubMed
13) Itoi T, et al : Clinical evaluation of a prototype multi-bending peroral direct cholangioscope. Dig Endosc 26 : 100-107, 2014.
PubMed
14) Meining A, et al : Classification of probe-based confocal laser endomicroscopy findings in pancreaticobiliary strictures. Endoscopy 44 : 251-257, 2012.
PubMed
15) Razumilava N, Gores GJ : Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 11 : 13-21. e1 ; quiz e3-4, 2013.
 
P.638 掲載の参考文献
1) Nimura Y, et al : Aggressive surgical treatment of hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 5 : 52-61, 1998.
PubMed
2) Joo I, Lee JM : Imaging bile duct tumors : pathologic concepts, classification, and early tumor detection. Abdom Imaging 38 : 1334-1350, 2013.
PubMed
3) Igami T, et al : Clinicopathologic study of cholangiocarcinoma with superficial spread. Ann Surg 249 : 296-302, 2009.
PubMed
4) Sasaki R et al : Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma. World J Surg 31 : 1788-1796, 2007.
PubMed
5) Ojima H, et al : Intraductal carcinoma component as a favorable prognostic factor in biliary tract carcinoma. Cancer Sci 100 : 62-70, 2009.
PubMed
6) Kondo S, et al : Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins. Ann Surg 240 : 95-101, 2004.
PubMed
7) Choi BI, et al : Imaging of intrahepatic and hilar cholangiocarcinoma. Abdom Imaging 29 : 548-557, 2004.
PubMed
8) Nakanuma Y, et al : Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2 : 419-427, 2010.
PubMed
P.643 掲載の参考文献
1) 中沼安二ほか : 良性胆管狭窄の病理. 肝胆膵画像 12 : 287-295, 2010.
 
2) Nakazawa T, et al : Diagnosis of IgG4-related sclerosing cholangitis. World J Gastroenterol 19 : 7661-7670, 2013.
 
3) Nakayama A, et al : Proximal bile duct stricture disguised as malignant neoplasm. Surgery 125 : 514-521, 1999.
PubMed
4) Kloek JJ, et al : Differentiation of malignant and benign proximal bile duct strictures : the diagnostic dilemma. World J Gastroenterol 14 : 5032-5038, 2008.
PubMed
5) 菅原元ほか : 癌との鑑別が問題となった良性胆管狭窄切除例の検討. 肝門部胆管癌疑診例. 肝胆膵画像 12 : 349-359, 2010.
 
6) Wakai T, et al : Clinicopathological features of benign biliary strictures masquerading as biliary malignancy. Am Surg 78 : 1388-1391, 2012.
PubMed
7) Takikawa H, et al : Analysis of 388 cases of primary sclerosing cholangitis in Japan ; Presence of a subgroupwithout pancreatic involvement in older patients. Hepatol Res 29 : 153-159, 2004.
PubMed
8) Nakazawa T, et al : Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc 60 : 937-944, 2004.
PubMed
9) Nakazawa T, et al : Inflammatory bowel disease of primary sclerosing cholangitis : Adistinct entity? World J Gastroenterol 20 : 3245-3254, 2014.
 
10) Nakazawa T, et al : Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis. Pancreas 30 : 20-25, 2005.
PubMed
11) Nakazawa T, et al : A case of advanced-stage sclerosing cholangitis with autoimmune pancreatitis not responsive to steroid therapy. JOP 11 : 58-60, 2010.
 
12) Ohara H, et al : Clinical diagnostic criteria of lgG4-related sclerosing cholangitis, 2012. J Hepatobiliary Pancreat Sci 19 : 536-542, 2012.
 
13) Naitoh I, et al : Endoscopic transpapillary intraductal ultrasonography and biopsy in the diagnosis of IgG4-related sclerosing cholangitis. J Gastroenterol 44 : 1147-1155, 2009.
PubMed
14) Kawakami H, et al : IgG4-related sclerosing cholangitis and autoimmune pancreatitis : histological assessment of biopsies from Vater's ampulla and the bile duct. J Gastroenterol Hepatol 25 : 1648-1655, 2010.
PubMed
15) Nakazawa T, et al : Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification. J Gastroenterol 47 : 79-87, 2012.
PubMed
P.648 掲載の参考文献
1) Pisters PW, et al : Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 234 (1) : 47-55, 2001.
PubMed
2) Takahashi Y, et al : Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg 97 (12) : 1860-1866, 2010.
PubMed
3) Kamiya S, et al : The value of bile replacement during external biliary drainage : an analysis of intestinal permeability, integrity, and microflora. Ann Surg 239 (4) : 510-517, 2004.
PubMed
4) Sugawara G, et al : The effect of preoperative biliary drainage on infectious complications after hepatobiliary resection with cholangiojejunostomy. Surgery 153 (2) : 200-210, 2013.
PubMed
5) Nagino M, et al : Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer : surgical outcome and long-term follow-up. Ann Surg 243 (3) : 364-372, 2006.
PubMed
6) Nagino M, et al : Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization. Hepatology 21 (2) : 434-439, 1995.
PubMed
7) Igami T, et al : Clinicopathologic stUdy of cholangiocarcinoma with superficial spread. Ann Surg 249 (2) : 296-302, 2009.
PubMed
8) Nagino M, et al : Evolution of surgical treatment for perihilar cholangiocarcinom : a single-center 34-year review of 574 consecutive resections. Ann Surg 258 (1) : 129-140, 2013.
 
9) Ikeyama T, et al : Surgical approach to bismuth Type I and II hilar cholangiocarcinomas : audit of 54 consecutive cases. Ann Surg 246 (6) : 1052-1057, 2007,
PubMed
10) Natsume S, et al : Clinical significance of left trisectionectomy for perihilar cholangiocarcinoma : an appraisal and comparison with left hepatectomy. Ann Surg 255 (4) : 754-762, 2012.
PubMed
11) Nagino M, et al : "Anatomic" right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma. Ann Surg 243 (1) : 28-32, 2006.
PubMed
12) Nagino M, et al : Hepaticojejunostomy using a Roux-en-Y jejunal limb via the retrocolic-retrogastric route. Langenbecks Arch Surg 387 (3-4) : 188-189, 2002.
 
13) Ebata T, et al : Hepatopancreatoduodenectomy for cholangiocarcinoma : asingle-center review of 85 consecutive patients. Ann Surg 256 (2) : 297-305, 2012.
 
14) Nagino M, et al : Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma : an audit of 50 consecutive cases. Ann Surg 252 (1) : 115-123, 2010.
PubMed
15) Ishii H, et al : Chemotherapy in the treatment of advanced gallbladder cancer. Oncology 66 (2) : 138-142, 2004.
PubMed
P.653 掲載の参考文献
1) Takahashi Y, et al : Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg 97 (12) : 1860-1866, 2010.
PubMed
2) Kawashima H, et al : Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma : a retrospective study of efficacy and risk factors related to complications. Ann Surg 257 (1) : 121-127, 2013.
PubMed
3) Yokoyama Y, et al : Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg 97 (8) : 1260-1268, 2010.
PubMed
4) Yokoyama Y, et al : Predictive power of prothrombin time and serum total bilirubin for postoperative mortality after major hepatectomy with extrahepatic bile duct resection. Surgery 155 (3) : 504-511, 2014.
PubMed
5) Yokoyama Y, et al : The adverse effects of preoperative cholangitis on the outcome of porta1 vein embolization and subsequent major hepatectomies. Surgery, 2014. [Epub ahead of print]
 
6) Cherqui D, et al : Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. Arch Surg 135 (3) : 302-308, 2000.
PubMed
7) Oya S, et al : Inhibition of Toll-like receptor 4 suppresses liver injury induced by biliary obstruction and subsequent intraportal lipopolysaccharide injection. Am J Physiol Gastrointest Liver Physiol 306 (3) : G244-252, 2014.
PubMed
8) Mizuno T, et al : Intraoperative bacterial translocation detected by bacterium-specific ribosomal rna-targeted reverse-transcriptase polymerase chain reaction for the mesenteric lymph node strongly predicts postoperative infectious complications after major hepatectomy for biliary malignancies. Ann Surg 252 (6) : 1013-1019, 2010.
PubMed
9) Neuhaus P, et al : Extended resections for hilar cholangiocarcinoma. Ann Surg 230 (6) : 808-818, 1999.
PubMed
10) Miyazaki M, et al : Combined vascular resection in operative resection for hilar cholangiocarcinoma : does it work or not? Surgery 141 (5) : 581-588, 2007.
 
11) Nagino M, et al : Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma : an audit of 50 consecutive cases. Ann Surg 252 (1) : 115-123, 2010.
PubMed
12) Ebata T, et al : Hepatopancreatoduodenectomy for cholangiocarcinoma : a single-center review of 85 consecutive patients. Ann Surg 256 (2) : 297-305, 2012.
PubMed
13) Kamiya S, et al : The value of bile replacement during external biliary drainage : an analysis of intestinal permeabiHty, integrity, and microflora. Ann Surg 239 (4) : 510-517, 2004.
PubMed
14) Sugawara G, et al : Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery : a randomized controlled trial. Ann Surg 244 (5) : 706-714, 2006.
PubMed
15) Nagino M, et al : One hundred consecutive hepatobiliary resections for biliary hilar malignancy : preoperative blood donation, blood loss, transfusion, and outcome. Surgery 137 (2) : 148-155, 2005.
PubMed
P.658 掲載の参考文献
1) 日本胆道外科研究会 (編) : 胆道癌取扱い規約, 第5版, 金原出版, 2003.
 
2) 日本肝胆膵外科学会 (編) : 胆道癌取扱い規約, 第6版, 金原出版, 2013.
 
3) Edge SB, et a1 (ed) : AJCC Cancer Staging Manual, 7th ed, Springer, New York, 2010.
 
4) Miyakawa S, et al : Biliary tract cancer treatment : 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16 (1) : 1-7, 2009.
PubMed
5) Kimura W, et al : A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system : the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg 259 (4) : 773-780, 2014.
PubMed
6) Kayahara M, et al : Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg 229 (1) : 76-83, 1999.
PubMed
7) Koops A, et al : Anatomic variations of the hepatic arteries in 604 selective celiac and superior mesenteric angiographies. Surg Radiol Anat 26 (3) : 239-244, 2004.
PubMed
8) Miyazaki M, et al : Unilatera1 hepatic artery reconstruction is unnecessary in biliary tract carcinomas involving lobar hepatic artery : implications of interlobar hepatic artery and its preservation. Hepatogastroenterology 47 (36) : 1526-1530, 2000.
 
9) Tohma T, et al : Communicating arcade between the right and left hepatic arteries : evaluation with CT and angiography during temporary balloon occlusion of the right or left hepatic artery. Radiology 237 (1) : 361-365, 2005.
PubMed
10) Ebata T, et al : Pathological appraisal of lmes of resection for bile duct carcinoma Br J Surg 89 (10) : 1260-1267, 2002,
 
11) Igami T, et al : Clinicopathologic stUdy of cholangiocarcinoma with superficial spread. Ann Surg 249 (2) : 296-302, 2009.
PubMed
12) Ebata T, et al : Hepatopancreatoduodenectomy for cholangiocarcinoma : a single-center review of 85 consecutive patients. Ann Surg 256 (2) : 297-305, 2012.
PubMed
13) Wakai T, et al : Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer 103 (6) : 1210-1216, 2005.
PubMed
14) Natsume S, et al : Hepatopancreatoduodenectomy for anastomotic recurrence from residual cholangiocarcinoma : report of a case. Surg Today 44 (5) : 952-956, 2014.
PubMed
15) Nakase A, et al : Surgical treatment of cancer of the pancreas and the periampullary region : cumulative results in 57 institutions in Japan. Ann Surg 185 (1) : 52-57, 1977.
PubMed
16) Horgan AM, et al : Adjuvant therapy in the treatment of biliary tract cancer : a systematic review and meta-analysis. J Clin Oncol 30 (16) : 1934-1940, 2012.
PubMed
P.662 掲載の参考文献
1) 日本肝癌研究会 (編) : 原発性肝癌取扱い規約, 第5版, 金原出版, 2009.
 
2) Greene FL, et al (ed) : AJCC Cancer Staging Manual, 6th ed, Springer, New York, 2002.
 
3) Sobin LH, Wittekind Ch (ed) ; International Union Against Cancer (UICC) : TNM Classification of Malignant Tumours, 6th ed, Wiley-Blackwell, Oxford, 2002.
 
4) Edge SB, et al (ed) : AJCC Cancer Staging Manual, 7th ed, Springer, New York, 2009.
 
5) Sobin LH, et al (ed) ; International Union Against Cancer (UICC) : TNM Classification of Malignant Tumours, 7th ed, Wiley-Blackwell, Oxford, 2009.
 
6) Senda Y, et al : Value of multidetector row CT in the assessment of longitudinal extension of cholangiocarcinoma : Correlation between MDCT and microscopic findings. World J Surg 33 : 1459-1467, 2009.
PubMed
7) Sugiura T, et al : Value of multidetector-row computed tomography in diagnosis of portal vein invasion by perihilar cholangiocarcinoma. World J Surg 32 : 1478-1484, 2008.
PubMed
8) Fukami Y, et al : Diagnostic ability of MDCT to assess right hepatic artery invasion by perihilar cholangiocarcinoma with left-sided predominance. J Hepatobiliary Pancreat Sci 19 : 179-186, 2009.
 
9) Nagino M, et al : Selective percutaneous transhepatic embolization of the portal vein in preparation for extensive liver resection : the ipsilateral approach. Radiology 200 : 559-563, 1996.
PubMed
10) Nagino M, et al : Right or left trisegment portal vein embolization before hepatic trisegmentectomy for hilar bile duct carcinoma. Surgery 117 : 677-681, 1995.
 
11) Nagino M, et al : Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer : surgical outcome and long-term follow-up. Ann Surg 243 : 364-372, 2006.
PubMed
12) Yokoyama Y, et al : Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg 97 : 1260-1268, 2010.
PubMed
13) Ebata T, et al : The concept of perihilar cholangiocarcinoma is valid. Br J Surg 96 : 926-934, 2009.
PubMed
14) Ebata T, et al : Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas. Br J Surg 101 : 79-88, 2014.
PubMed
15) Kawashima H, et al : Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma : a retrospective study of efficacy and risk factors related to complications. Ann Surg 257 : 121-127, 2013.
PubMed
16) Takahashi Y, et al : Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg 97 : 1860-1866, 2010.
PubMed
17) Kanai M, et al : Preoperative intrahepatic segmental cholangitis in patients with advanced carcinoma involving the hepatic hilus. Surgery 119 : 498-504, 1996.
PubMed
18) Igami T, et al : Staging of peripheral-type intrahepatic cholangiocarcinoma : appraisal of the new TNM classification and its modifications. World J Surg 35 : 2501-2509, 2011.
PubMed
19) Igami T, et al : Surgical treatment of hilar cholangiocarcinoma in the "new era" : the Nagoya University experience. J Hepatobiliary Pancreat Sci 17 : 449-454, 2010.
PubMed
20) Nagino M, et al : Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma : an audit of 50 consecutive cases, Ann Surg 353 : 115-123, 2010.
 
21) Nakagawa A, et al : Hepatobiliary resection with concomitant resection of the inferior vena cava for advanced intrahepatic cholangiocarcinoma : report of a case. Surg Today 43 : 1321-1325, 2013.
PubMed
22) Kobayashi SI, et al : Long-term survival following extended hepatectomy with concomitant resection of all major hepatic veins for intrahepatic cholangiocarcinoma : report of a case. Surg Today, 2014. [Epub ahead of print]
 
23) Harimoto N, et al : Laparoscopic hepatectomy and dissection of lymph nodes for intrahepatic cholangiocarcinoma-Case report-. Surg Endosc 16 : 419-425, 2002.
 
24) Abu Hilal M, et al : Pure laparoscopic en bloc left hemihepatectomy and caudate lobe resection in patients with intrahepatic cholangiocarcinoma. J Laparoendosc Adv Surg Tech A 21 : 845-849, 2011.
PubMed
25) Rotellar F, et al : Laparoscopic right hepatectomy extended to middle hepatic vein after right portal vein embolization. Ann Surg Oncol 21 : 165-166, 2014.
PubMed
26) Takahashi M, et al : Pure laparoscopic right hepatectomy by anterior approach With hanging maneuver for large intrahepatic cholangiocarcinoma. Surg Endosc 27 : 4732-4733, 2013.
PubMed
27) Casavilla FA, et al : Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 185 : 429-436, 1997,
PubMed
28) Becker NS, et al : Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over 18-year period. J Gastrointest Surg 12 : 117-122, 2008.
PubMed
29) Goss JA, et al : Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-yeat single center experience. Ann Surg 225 : 472-481, 1997.
 
30) Sapisochin G, et al : "Very early" intrahepatic cholagiocarcinoma in cirrhotic patients : should liver transplantation be reconsidered in these patients? Am J Transplant 14 : 660-667, 2014.
 
P.667 掲載の参考文献
1) Takada T, et al : Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 : 1685-1695, 2002.
PubMed
2) Valle J, et al : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Eng J Med 362 : 1273-1281, 2010.
 
3) Okusaka T, et al : Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer 103 : 469-474, 2010.
 
4) Furuse J, et al : S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer : a multicenter phase II study. Cancer Chemother Pharmacol 62 (5) : 849-855, 2008.
PubMed
5) Sasaki T, et al : Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65 : 1101-1107, 2010.
PubMed
6) Gu TL, et al : Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6 : e15640, 2011.
PubMed
7) Wu YM, et al : Identification of targetable FGFR gene fusions in diverse cancers, Cancer Discov 3 : 636-647, 2013.
PubMed
8) Arai Y, et al : Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59 : 1427-1434, 2014.
PubMed
9) Borad MJ, et al : Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 10 : e1004135, 2014.
PubMed
10) Borger DR, et al : Frequent mutation of isocitrate dehydrogenase (IDH) 1 and IDH2 in cholangiocarcinoma identh6ed through broad-based tumor genotyping. Oncologist 17 : 72-79, 2012.
PubMed
11) Kipp BR, et al : Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol 43 : 1552-1558, 2012.
PubMed
12) Wang P, et al : Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32 : 3091-3100, 2013.
PubMed
P.673 掲載の参考文献
1) 新地洋之, 高尾尊身 : 切除不能胆管癌に対する放射線化学療法. 肝胆膵 59 : 973-979, 2009.
Medical*Online
2) 朝倉浩文, 西村哲夫 : 胆道癌診療における放射線治療の役割. 胆道 27 : 247-256, 2013.
Medical*Online
3) 古瀬純司 : 胆道癌に対する化学療法の現状と今後の展望. 胆道 28 : 43-48, 2014.
Medical*Online
4) 胆道癌診療ガイドライン作成出版委員会 (編) : エビデンスに基づいた胆道癌診療ガイドライン, 2007年版. p98-103, 医学図書出版, 2007.
 
5) Pitt HA, et al : Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 221 : 788-797, 1995.
 
6) Todoroki T, et al : Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 46 : 581-587, 2000.
PubMed
7) Gerhards MF, et al : Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 27 : 173-179, 2003.
PubMed
8) Cheng Q, et al : Predictive factors for complications after pancreaticoduodenectomy. J Surg Res 139 : 22-29, 2007.
PubMed
9) 田端正己ほか : 進行胆道癌に対する術前加療の意義とその問題点. 消化器内科 58 : 792-797, 2014.
 
10) Liang SX, et al : Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma : the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 65 : 426-434, 2006.
PubMed
11) Isayama H, et al : Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma. World J Gastroenterol 18 : 2364-2370, 2012.
PubMed
12) Valek V, et al : Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma : a prospective randomised study. Eur J Radiol 62 : 175-179, 2007.
PubMed
13) Brunner TB, et al : Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis. Strahlenther Onkol 180 : 751-757, 2004.
PubMed
14) Gonzalez Gonzalez D, et al : Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma. Ann Oncol 10 (Suppl 4) : 215-220, 1999.
 
15) Morizane C, et al : Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer : a Japan Clinical Oncology Grouptrial (JCOG O805). Cancer Sci 104 : 1211-1216, 2013.
 
P.680 掲載の参考文献
1) Isayama H, et al : A prospective randomized study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 53 : 729-734, 2004.
PubMed
2) Katsinelos P, et al : Tannenbaum and metal stents in the palliative treatment of malignant distal bile duct obstruction : A comparative study of patency and cost effectiveness. Surg Endosc 20 : 1587-1593, 2006.
PubMed
3) Wagner HJ : Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction : A prospective and randomized trial. Endoscopy 25 : 213-216, 1993.
PubMed
4) Hamada T, et al : Novel antireflux covered metal stent for recurrent occlusion of biliary metal stents : a pilot study. Dig Endosc 26 : 264-269, 2014.
PubMed
5) 林香月ほか : 悪性十二指腸狭窄に対するステンティング. Gastroenterol Endosc 47 : 1444-1454, 2005.
 
6) Espinel J, et al : Malignant gastrointestinal obstruction : endoscopic stenting versus surgical palliation. Surg Endosc 20 : 1083-1087, 2006.
PubMed
7) Jeurnink SM, et al : Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction : a systematic review. BMC Gastroenterol 7 : 18, 2007.
PubMed
P.687 掲載の参考文献
1) 日本肝胆膵外科学会 (編) : 臨床・病理 胆道癌取扱い規約, 第6版, 金原出版, 2013.
 
2) 特定非営利活動法人 日本緩和医療学会緩和医療ガイドライン委員会 (編) : 癌疾痛の薬物療法に関するガイドライン, 金原出版, 2014.
 
3) Hanna M : The effects of liver impairment on opioids used to relieve pain in cancer patients. Palliat Med 25 : 604-605, 2011.
PubMed
4) 胆道癌診療ガイドライン作成出版委員会 (編) : 胆道癌診療ガイドライン, 医学図書出版, 2014.
 
5) Shariff MI, et al : The palliation of cholangiocarcinoma. Curr Opin Support Palliat Care 7 (2) : 168-174, 2013.
PubMed
6) Pan H, et al : Hepato-biliary-enteric stent drainage as palliative treatment for proximal malignant obstructive jaundice. Med Oncol 31 (3) : 853, 2014.
PubMed
7) Sangchan A, et al : Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma : a randomized controlled trial. Gastrointest Endosc 76 (1) : 93-99, 2012.
PubMed
8) 急性胆管炎・胆嚢炎診療ガイドライン改訂出版委員会 (編) : 急性胆管炎・胆嚢炎診療ガイドライン 2013, 医学図書出版, 2013.
 
9) 木村陽, 大坂巌 : 胆道癌に対する緩和医療の現状. 胆道27 (5) : 868-875, 2013.
 
10) 前谷容ほか : 悪性胆管・十二指腸狭窄に対するダブル・メタリックステンティング. 胆と膵 30 (Suppl) : 1161-1167, 2009.
 
11) Jeurnink SM, et al : Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study) : a multicenter randomized trial. Gastrointest Endosc 71 : 490-499, 2010.
 
12) 東口高志 : 障害肝外科治療における代謝栄養管理. Frontiers in Gastroenterology 14 : 276-281, 2009.
Medical*Online
13) 中川雅夫 : 厚生省特定疾患血液凝固異常症調査研究班, 平成10年度業績報告書, p57-64, 1999.
 
14) Welsh FK, et al : Increased intestinal permeability and altered mucosal immunity in cholestatic jaundice. Ann Surg 227 : 205-212, 1998.
PubMed
15) Harrington DJ, et al : A study of the prevalence of vitamin K deficiency in patients with cancer referred to a hospital palliative care team and its association with abnormal haemostasis. J Clin Pathol 61 : 537-540, 2008.
PubMed
16) 内田清久 : 抗生物質とビタミンK. ビタミンの事典 (日本ビタミン学会編), p123-149, 朝倉書店, 1996.
 
P.691 掲載の参考文献
1) Miyakawa S, et al : Biliary tract cancer treatment : 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16 (1) : 1-7, 2009.
PubMed
2) Nagakawa T, et al : Biliary tract cancer treatment : results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 9 (5) : 569-575, 2002.
PubMed
3) Nathan H, et al : Trends in survival after surgery for cholangiocarcinoma : a30-year populationbased SEER database analysis. J Gastrointest Surg 11 (11) : 1488-1496 ; discussion 1496-1497, 2007.
 
4) Launois B, et al : Surgery for hilar cholangiocarcinoma : French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg 7 (2) : 128-134, 2000.
 
5) Nagino M, at al : Evolution of surgical treatment for perihilar cholangiocarcinoma : a single-center 34-year review of 574 consecutive resections. Ann Surg 258 (1) : 129-140, 2013.
 
6) Sano T, et al : One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg 244 (2) : 240-247, 2006.
PubMed
7) DeOliveira ML, et al : Cholangiocarcinoma : thirty-one-year experience with 564 patients at a single institution. Ann Surg 245 (5) : 755-762, 2007.
 
8) Young AL, et al : Evolution of the surgical management of perihilar cholangiocarcinoma in a Western centre demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion. HPB (Oxford) 13 (7) : 483-493, 2011.
 
9) van Gulik TM, et al : Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor) : extended resection is associated with improved survival. Eur J Surg Oncol 37 (1) : 65-71, 2011.
PubMed
10) Rosen CB, et al : Liver transplantation for cholangiocarcinoma. Transpl Int 23 (7) : 692-697, 2010.
PubMed
11) Darwish Murad S, et al : Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143 (1) : 88-98, 2012.
PubMed
12) Sakamoto Y, et al : Prognostic factors of surgical resection in middle and distal bile duct cancer : an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 137 (4) : 396-402, 2005.
PubMed
13) Ebata T, et al : Pancreatic and duodenal invasion in distal bile duct cancer : paradox in the tumor classification of the American Joint Committee on Cancer. World J Surg 31 (10) : 2008-2015, 2007.
PubMed
14) Bahra M, et al : Carcinoma of the distal and middle bile duct : surgical results, prognostic factors, and long-term follow-up. J Hepatobiliary Pancreat Surg 15 (5) : 501-507, 2008.
PubMed
P.695 掲載の参考文献
1) Burke EC, et al : Hilar Cholangiocarcinoma : patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 228 : 385-394, 1998.
 
2) 胆道癌診療ガイドライン作成出版委員会 (編) : エビデンスに基づいた胆道癌診療ガイドライン, 第1版 (高田忠敬編), 医学図書出版, 2007.
 
3) Kondo S, et al : Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins : results of a prospective study. Ann Surg 240 : 95-101, 2004.
PubMed
4) Sobin LH, et al (ed) : TNM Classification of Malignant Tumors, 7ed. (UICC) IUAC, Wiley-Blackwell, New York, 2009.
 
5) 日本肝胆膵外科学会 (編) : 臨床・病理 胆道癌取扱い規約, 第6版, 金原出版, 2013,
 
6) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約, 第5版補訂版, 金原出版, 2009.
 
7) Aoba T, et al : Assessment of nodal status for perihilar cholangiocarcinoma : location, number, or ratio of involved nodes. Ann Surg 257 : 718-725, 2013.
PubMed
8) Igami T, et al : Staging of peripheral-type intrahepatic cholangiocarcinoma : appraisal of the new TNM classification and its modifications. World J Surg 35 : 2501-2509, 2011.
PubMed
9) Uenishi T, et al : Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma : a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 21 : 499-508, 2014.
 
10) Nagino M, et al : Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma : an audit of 50 consecutive cases. Ann Surg 252 : 115-123, 2010.
PubMed
11) Ebata T, et al : Hepatopancreatoduodenectomy for cholangiocarcinoma : a single-center review of 85 consecutive patients. Ann Surg 256 : 297-305, 2012.
PubMed
12) Uenishi T, et al : The long-term outcomes after curative resection for mass-forming intrahepatic cholangiocarcinoma associated with hepatitis C viral infection : amulticenter analysis by Osaka Hepatic Surgery Study Group. J Surg Oncol 110 : 176-181, 2014.
 
13) Takahashi Y, et al : Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg 97 : 1860-1866, 2010.
PubMed
14) Hirano S, et al : Oncological benefit of preoperative endoscopic biliary drainage in patients with hilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 21 : 533-540, 2014.
PubMed
15) Ruys AT, et al : Prognostic biomarkers in patients with resected cholangiocarcinoma : a systematic review and meta-analysis. Ann Surg Oncol 21 : 487-500, 2014.
PubMed
16) Kobayashi H, et al : Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann Surg 256 : 288-296, 2012.
PubMed
17) Horgan AM, et al : Adjuvant therapy in the treatment of biliary tract cancer : a systematic review and meta-analysis. J Clin Oncol 30 : 1934-1940, 2012.
PubMed
18) Forrest LM, et al : Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89 : 1028-1030, 2003.
PubMed
19) Oshiro Y, et al : Inflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 20 : 389-395, 2013.
PubMed
P.700 掲載の参考文献
1) がんの統計編集委員会 (編) : がんの統計'13 CANCER STATISTICS IN JAPAN-2013, 公益財団法人がん研究振興財団, 2013.
 
2) 厚生労働省 : 平成25年人口動態統計月報年計 (概数) の概況, 統計表 死亡数・死亡率 (人口10万対), 死因簡単分類別. [http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai13/dl/h6.pdf]
 
3) 永川宅和, 萱原正都 : 胆道癌登録成績が教える胆道癌の診断と治療のありかた. 金原出版, 2005.
 
4) 石原慎ほか : 本邦における十二指腸乳頭部癌の現状-1998～2004年登録症例の集計から-. 肝胆膵 54 : 737-746, 2007.
 
5) 独立行政法人国立がん研究センターがん対策情報センター : がん情報サービス. 部位別罹患率, 年次推移. [http://gdb.ganjoho.jp/graph_db/gdb4?dataType=30]
 
6) 2012年-統計表一覧 政府統計の総合窓口GL0802103. 悪性新生物の主な部位別にみた性・年次別死亡数及び率 (人口10万対). [http://www.e-stat.go.jp/sg1/estat/glO8020103.do?_tog108020103_&listid=000001108739&requestsender=estat]
 
7) 向谷充宏ほか : 胆道癌の疫学に関する最新のデータ. 臨床外科 62 : 251-256, 2007.
 
P.702 掲載の参考文献
1) 胆道癌診療ガイドライン作成出版委員会 (編) : 胆道癌診療ガイドライン第1版, 医学図書出版, 2007.
 
2) 山本正治ほか : 胆道癌の疫学. 肝胆膵 23 : 463-473, 1991.
 
3) 松葉剛ほか, JACC Study Group : 胆管・胆のうがんと食生活との関連. 癌の臨床 49 : 665-669, 2003.
 
4) Fischer HP, Zhou H : Pathogenesis of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg 11 : 301-309, 2004.
PubMed
5) Chung CH, et al : Clinical significance of K-ras oncogene activation in ampullary neoplasms. J Clin Pathol 49 : 460-464, 1996.
PubMed
6) Howe JR, et al : K-ras mutation in adenomas and carcinomas of ampulla of vater. Clin Cancer Res 3 : 129-133, 1997.
PubMed
7) Zhao B, et al : p-53 and p21/Wafl protein expression and K-ras codon 12 mutation in carcinoma of the papilla of Vater. Am J Gastroenterol 94 : 2128-2134, 1999.
 
8) Sugiyama M, et al : Endoscopic ultrasonography for differential diagnosis of polypoid gall bladder lesions : analysis in surgical and follow upseries. Gut 46 : 250-254, 2000.
PubMed
9) 牧野勲ほか : 十二指腸乳頭部腫瘍をめぐる最近の話題-内視鏡治療を中心として-. 肝胆膵 54 (6) : 841-856, 2007.
 
10) Kimura W, et al : Neoplastic diseases of the papilla of Vater. J Hepatobiliary Pancreat Surg 11 : 223-231, 2004.
PubMed
11) Park SH, et al : Clinicopathologic correlation of p53 protein overexpression in adenoma and carcinoma of ampulla of Vater. World J Surg 24 : 54-59, 2000.
PubMed
12) Jagelman DG, et al : Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet 1 (8595) : 1149-1151, 1988.
PubMed
13) Offerhaus GJ, et al : The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 102 : 1980-1982, 1992.
PubMed
14) Spigelman AD, et al : Evidence for adenoma-carcinoma sequence in the duodenum of patients with familial adenomatous polyposis. The Leeds Castle Polyposis Group (Upper Gastrointestinal Committee). J Clin Pathol 47 : 709-710, 1994.
 
15) Groves CJ, et al : Duodenal cancer in patients with familial adenomatous polyposis (FAP) : results of a 10 year prospective study. Gut 50 : 636-641, 2002.
PubMed
P.706 掲載の参考文献
1) 日本肝胆膵外科学会 (編) : 胆道癌取扱い規約 (第6版補訂版), 金原出版, 2013.
 
2) Albores-Saavedra J, et al : Invasive adenocarcinoma of the ampullary region. In : World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System (ed by Bosman FT, et al). p87-91, IARC Press, Lyon, 2010.
 
3) Morini S, et al : Carcinoma of the ampulla of Vater : morphological and immunophenotypical classification predicts overall survival. Pancreas 42 : 60-66, 2013.
PubMed
4) Ang DC, et al : The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of Vater. Am J Surg Pathol 38 : 1371-1379, 2014.
PubMed
5) Adsay V, et al : Ampullary region carcinomas : definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. Am J Surg Pathol 36 : 1592-1608, 2012.
 
6) Mikhitarian K, et al : Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. Mod Pathol 27 : 665-674, 2014.
PubMed
7) Sessa F, et al : Prognostic factors for ampullary adenocarcinomas : tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability. Virchows Arch 451 : 649-657, 2007.
PubMed
8) Adsay NV, et al : Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers : pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. Semin Diagn Pathol 29 : 127-141, 2012.
PubMed
P.710 掲載の参考文献
1) Jeppson B, Bengmark S : Tumor of the papilla and ampulla. In : Bockus Gastroenterology, 5th ed, p2788-2791, WB Saunders, Philadelphia, 1995.
 
2) 吉田正, 中山和道 : 十二指腸乳頭部疾患. ベッドサイド消化器病学 (丹羽寛文ほか編), p828-835, 南江堂, 1996.
 
3) 岩本淳一ほか : 腫瘍発見の契機ならびに臨床所見. 肝胆膵 54 : 747-752, 2007.
Medical*Online
4) 嶋田紘 : 乳頭部癌. 臨床消化器病学 (石井裕正ほか編), p552-556, 朝倉書店, 2005.
 
5) 田尻久雄 : 十二指腸乳頭部癌. 臨床消化器内科 4 : 469-477, 1997.
 
6) 山雄健次, 清水泰博 : 専門医のための消化器病学, p518-525, 医学書院 2005.
 
7) Kamisawa T, et al : Clinicopathological features of ampullary carcinoma without jaundice. J Clin Gastroenterol 40 : 162-166, 2006.
PubMed
8) 小泉理美ほか : 総胆管十二指腸瘻を形成した無黄疸性乳頭部癌の1例. Progress of Digestive Endoscopy 83 : 124-125, 2013.
Medical*Online
9) Hayes DH, et el : Carcinoma of the ampulla of Vater. Ann Surg 206 : 572-577, 1987.
 
10) Batsis JA, et el : Acute pancreatitis secondary to adenomatous transformation of the ampulla of Vater in a patient with familial adenomatous polyposis, Surg Laparosc Endosc Percutan Tech 17 : 45-48, 2007.
 
11) Shiota K, et al : Carcinoid tumor of the Vater's papilla presenting with chronic pancreatitis-a case report-. Kurume Med J 52 : 105-109, 2005.
 
P.714 掲載の参考文献
1) 胆道癌取扱い規約 (第6版) (日本肝胆膵外科学会編), 金原出版, 2013.
 
2) CQ-9乳頭部癌診断のセカンドステップは? エビデンスに基づいた胆道癌診療ガイドライン (第1版) (胆道癌診療ガイドライン作成出版委員会編), p47-50, 医学図書出版, 2007.
 
3) Yamaguchi K, et al : Endoscopic biopsy has limited accuracy in diagnosis of ampullary tumors. Gastrointest Endosc 36 : 588-592, 1990.
PubMed
4) 伊藤彰浩ほか : 十二指腸乳頭部腫瘍. 消化器病学 (浅香正博ほか編), p1437-1443, 西村書店, 2013.
 
5) Ito K, et al : Diagnosis of ampullary cancer. Dig Surg 27 : 115-118, 2010.
PubMed
P.718 掲載の参考文献
1) Ito K, et al : Diagnosis of ampullary cancer. Dig Surg 27 : 115-118, 2010.
PubMed
2) 胆道癌診療ガイドライン作成出版委員会 (編) : CQ-9乳頭部癌診断のセカンドステップは? エビデンスに基づいた胆道癌診療ガイドライン, 第1版, p47-50, 医学図書出版, 2007.
 
3) 伊藤彰浩ほか : 十二指腸乳頭部腫瘍. 消化器病学 (浅香正博ほか編), p1437-1443, 西村書店, 2013.
 
4) Ogura T, et al : Can endoscopic ultrasound-guided fine needle aspiration offer clinical benefit for tumors of the ampulla of Vater? -an initial study. Endosc Ultrasound 1 (2) : 84-89, 2012.
PubMed
5) Yamaguchi K. et al : Endoscopic biopsy has limited accuracy in diagnosis of ampullary tumors. Gastrointest Endosc 36 : 588-592, 1990.
PubMed
6) Skordilis P, et al : Is endosonography an effective method for detection and local staging of the ampullary carcinoma? A prospective study. BMC Surg 2 : 1-8, 2002.
PubMed
7) Artifon ELA, et al : Prospective evaluation of EUS versus CT scan for staging of ampullary cancer. Gastrointest Endosc 70 : 290-296, 2009.
PubMed
8) Cannon ME, et al : EUS compared with CT, magnetic resonance imaging, and angiography and the influence of biliary stenting on staging accuracy of ampullary neoplasms. Gastrointest Endosc 50 : 27-33, 1999.
PubMed
P.723 掲載の参考文献
1) Scarpa A, et al : Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations. Am J Pathol 142 : 1163-1172, 1993.
PubMed
2) Ellert J. van Soest, Fockens P : Ampullary neoplasm. In : ERCP, p273-285, Saunders, Philadelphia, 2008.
 
3) 山野三紀ほか : 十二指腸乳頭部腫瘍の病理. 消化器画像 3 : 159-171, 2001.
 
4) 内山勇二郎ほか : 乳頭部腫瘍に対するnarrow banding imaging (NBI) 併用拡大内視鏡による診断. 外科 68 : 1122-1128, 2006.
 
5) Yamaguchi K, et al : Endoscopic biopsy has limited accuracy in diagnosis of ampullary tumor. Gastrointest Endosc 36 : 588-592, 1990.
PubMed
6) Baczako K, et al : Morphogenesis and possible precursor lesion of invasive carcinoma of the papilla of Vater : epithelial dysplasia and adenoma. Hum Pathol 16 : 305-310, 1985.
PubMed
7) 国村利明ほか : 乳頭部の前癌状態とは-病理学的立場から-. 胆と膵 16 : 1001-1005, 1995.
Medical*Online
8) Igarashi Y, et al : Endoscopic snare excision of a major duodenal papillary tumor. Digestive Surgery 27 : 119-122, 2010.
 
9) 伊藤啓ほか : 十二指腸乳頭部腫瘍の画像診断 超音波内視鏡検査および腔内超音波検査による進展度診断. 肝胆膵 54 : 753-761, 2007.
Medical*Online
10) 大藤正雄 : 良性十二指腸乳頭部病変の概念. 胆と膵 4 : 1457-1458, 1983.
 
11) 五十嵐良典ほか : 乳頭部腫瘍-乳頭部癌との鑑別. 胆道 26 : 756-760, 2012.
Medical*Online
12) Scherubl H, et al : Neuroendocrine tumors of the small bowels are on the rise : Early aspects and management. World J Gastrointest Endosc 2 : 325-334, 2010.
PubMed
13) Wong A, et al : Locally advanced duodenal gangliocytic paraganglioma treated with adjuvant radiation therapy : case report and review of the literature. World J Surg Oncol 3 : 15, 2005.
PubMed
14) Jerraya H, et al : Stromal tumor of the ampulla of vater : report of a case and systematic review of reported cases. Tunis Med 87 : 556-559, 2009.
PubMed
15) Yoshino T, et al : Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 24 : 688-693, 2000.
PubMed
P.726 掲載の参考文献
1) 胆道癌診療ガイドライン作成出版委員会 (編) : エビデンスに基づいた胆道癌診療ガイドライン, 第2版, 医学図書出版, 2014.
 
2) Jarnagin WR, et al : Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234 : 507-517, 2001.
PubMed
3) Duffy A, et al : Gallbladder cancer (GBC) : 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol 98 : 485-489, 2008.
PubMed
4) Klein F, et al : Prognostic factors for long-term survival in patients with ampullary carcinoma : The results of a 15-year observation period after pancreaticoduodenectomy. HPB Surg 2014 : 970234, 2014.
PubMed
5) Beenen E, et al : Staging laparoscopy in patients scheduled for pancreaticoduodenectomy minimizes hospitalization in the remaining life time when metastatic carcinoma is found. Eur J Surg Oncol 40 : 989-994, 2014.
PubMed
5) 木村陽, 大阪巌 : 胆道癌に対する緩和医療の現状. 胆道 27 : 868-875, 2013.
 
6) Fang Y, et al : Meta-analysis of randomized clinical trials on safety and efficacy of biliary drainage before surgery for obstructive jaundice. Br J Surg 100 : 1589-1596, 2013.
PubMed
7) Sugawara G, et al : The effect of preoperative biliary drainage on infectious complications after hepatobiliary resection with cholangiojejunostomy. Surgery 153 : 200-210, 2013.
PubMed
8) Hirano S, et al : Oncological benefit of preoperative endoscopic biliary drainage in patients with hilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 21 : 533-540, 2014.
PubMed
9) Kawabata Y, et al : What is an adequate surgical management for pTis and pTI early ampullary carcinoma? Hepatogastroenterology 61 : 12-17, 2014.
 
10) Napoleon B, et al : Endoscopic papillectomy for early ampullary tumors : long-term results from a large multicenter prospective study. Endoscopy 46 : 127-134, 2014.
PubMed
11) John PK, et al : Updates in management of ampullary carcinomas. JOP 15 : 140-143, 2014.
PubMed
12) Palta M, et al : Carcinoma of the ampulla of Vater : patterns of failure following resection and benefit of chemoradiotherapy. Ann Surg Oncol 19 : 1535-1540, 2012.
 
13) Saleem A, et al : Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc 74 : 321-327, 2011.
PubMed
14) Shoji H, et al : Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy. Jpn J Clin Oncol 44 : 324-330, 2014.
PubMed
P.731 掲載の参考文献
1) 中尾昭公, 原田明生ほか : 十二指腸乳頭部癌の外科治療成績と問題点. 日外会誌 93 : 805-810, 1992.
 
2) Halsted WS : Contribution to the surgery of the bilepassages, especially the common bile duct. Boston Med Surg J 141 : 645-654, 1899.
 
3) Maithel SK Fong Y : Technical aspects of performing transduodenal ampullectomy. J Gastrointest Surg 12 : 1582-1585, 2008.
PubMed
4) Knox RA, Kingston RD : Carcinoma of the ampulla of Vater. Br J Surg 73 : 72-73, 1986.
PubMed
5) Branum GD, et al : The management of tumors of the ampulla of Vater by local resection. Ann Surg 224 : 621-627, 1996.
PubMed
6) 永川宅和, 菅原正都 : 胆道癌登録成績が教える胆道癌の診断と治療のあり方, 金原出版, 2005.
 
7) Klein P, et al : Is local excision of pT1-ampullary carcinomas justified? Eur J Surg Oncol 22 : 366-371, 1996.
PubMed
8) Beger HG, et al : Tumor of the ampulla of Vater : experience with local or radical resection in 171 consecutively treated patients. Arch Surg 134 : 526-532, 1999.
 
9) 鈴木大亮ほか : 胆道癌における内視鏡による深達度進展度評価と外科治療への応用. 臨床外科 66 : 1620-1627, 2011.
 
10) 胆道癌診療ガイドライン作成出版委員会 (編) : エビデンスに基づいた胆道癌診療ガイドライン, 第1版, 医学図書出版, 2007.
 
11) 高崎健ほか : 膵, 乳頭温存十二指腸切除および膵温存十二指腸切除の各1例の経験. 日臨外会誌 48 : 2041-2045, 1987.
 
P.735 掲載の参考文献
1) Heinzow HS, et al : Feasibility of snare papillectomy in ampulla of Vater tumors : meta-analysis and study results from a tertiary referral center. Hepatogastroenterology 59 : 332-335, 2012.
PubMed
2) Ito K, et al : Preoperative evaluation of ampullary neoplasm with EUS and transpapillary intraducta US : a prospectivc and histopathologically controlled stUdy. Gastrointest Endosc 66 : 740-747, 2007.
 
3) Okano N, et al : Endosonographic preoperative evaluation for tumors of the ampulla of Vater using endoscopic ultrasonography and intraductal ultrasonography. Clin Endosc 47 : 174-177, 2014.
PubMed
4) Yamao T, et al : Endoscopic snare papillectomy with biliary and pancreatic stent placement for tumors of the major duodenal papilla. Surg Endosc 24 : 119-124, 2010.
PubMed
5) Will U, et al : Endoscopic papillectomy : Data of a prospective observational study. World J Gastroenterol 19 : 4316-4324, 2013.
 
6) Kim JH, et al : Management after endoscopic snare papillectomy for ampullary adenomas. Hepatogastroenterology 60 : 1268-1273, 2013.
PubMed
7) Napoleon B, et al : Endoscopic papillectomy for early ampullary tumors : long-term results from a large multicenter prospective study. Endoscopy 46 : 127-134, 2014.
PubMed
8) Mutignani M, et al : Endoscopic hemostasis with fibrin glue for refractory postsphincterotomy and postpapillectomy bleeding. Gastrointest Endosc 71 : 856-860, 2010.
PubMed
P.740 掲載の参考文献
1) 日本胆道外科研究会 (編) : 胆道癌取扱い規約, 第6版, 金原出版, 2003.
 
2) Miyakawa S, et al : Biliary truct cancer treatment : 5,584 result from the Biliary Tract Cancer Statistic Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16 : 1-7, 2009.
 
3) Terasawa H, et al : Impact of lymph node metastasis on survival in patients with pathological T1 carcinoma of the ampulla of Vater. J Gastrointest Surg 10 : 823-828, 2006.
PubMed
4) Klinkenbijl JH, et al : Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region : phase III trial of the EORTC gastrointestinal tract cancer cooperative group, Ann Surg 230 : 776-782, 1999.
PubMed
5) Takada T, et al : Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 : 1685-1695, 2002.
PubMed
6) Neoptolemos JP, et al : Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma : the ESPAC-3 periampullary cancer randomized trial. JAMA 308 : 147-156, 2012.
 
7) Noda T, et al : Liver perfUsion chemotherapy for selected patients at a high-risk of liver metastasis after resection of duodenal and ampullary cancers. Ann Surg 246 : 799-805, 2007.
 
8) Narang AK, et al : Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma : the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol 6 : 126, 2011.
 
9) Valle J, et al : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 : 1273-1281, 2010.
PubMed
10) Okusaka T, et al : Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer lO3 : 469-474, 2010.
 
11) Shoji H, et al : Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy. Jpn J Clin Oncol 44 : 324-330, 2014.
PubMed
12) Takahashi A, et al : Randomized phase II stUdy of gemcitabine plus S-1 combination therapy vs, S-1 in advanced biliary tract cancer : Japan Clinical Oncology Group Study (JCOG0805). Cancer Sci 104 : 1211-1216, 2013.
 
13) PhillippA et al : Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24 : 3069-3074, 2006.
 
14) Arai Y, et al : Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59 : 1427-1434, 2014.
PubMed
15) Overman MJ, et al : Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLos One 11 : e65144, 2013.
 
P.743 掲載の参考文献
1) 山野三紀ほか : 十二指腸乳頭部の病理. 消化器画像 3 : 159-171, 2001.
 
2) Matsubayashi H, et al : Differences in mucus and K-ras mutation in relation to phenotypes of tumors of the papillar of Vater. Cancer 86 : 596-607, 1999.
 
3) 山下泰伸ほか : 閉塞性黄疸の病態-胆道ドレナージの必要性. 胆と膵 34 : 773-777, 2013.
Medical*Online
4) 櫻井洋至ほか : 閉塞性黄疸の予後. 肝胆膵 37 : 1005-1014, 1998.
 
5) 本庄一夫 : 膵臓外科の草昧期. 膵臓 1 : 8-13, 1986.
 
6) 吉田雅博ほか : 膵癌手術法の歴史的推移. 外科治療 90 : 272-281, 2004.
Medical*Online
7) 高田忠敬 : PTCD-そのはじめから発展-. 胆道 7 : 555-559, 1993.
Medical*Online
8) Iacono C, et al : Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection : highlights and drawbacks. Ann Surg 257 : 191-204, 2013.
PubMed
9) Lai EC, et al : The current status of preoperative biliary drainage for patients who receive pancreaticoduodenectomy for periampullary carcinoma : Acomprehensive review. Surgeon 12 : 290-296, 2014.
 
10) Singhirunnusorn J, et al : Value of preoperative biliary drainage in a consecutive series of resectable periampullary lesions. From randomized studies to real medical practice. Langenbecks Arch Surg 398 : 295-302, 2013.
 
11) van der Gaag NA, et al : Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 362 : 129-137, 2010.
PubMed
12) Dawwas MF, et al : Preoperative drainage in pancreatic cancer. N Engl J Med 362 (14) : 1342-1343, 2010.
PubMed
13) Abdullah SA, et al : Ampullary carcinoma : effect of preoperative biliary drainage on surgical outcome. World J Gastroenterol 15 : 2908-2912, 2009.
PubMed
14) 川久保和道ほか : 原疾患の腫瘍進展様式を考慮したStenting Strategy. 胆と膵 31 : 1121-1129, 2010.
Medical*Online
15) Tringali A, et al : Endoscopic treatment of malignant gastric and duodenal strictures : a prospective, multicenter study. Gastrointest Endosc 79 : 66-75, 2014.
PubMed
P.748 掲載の参考文献
1) 石原慎ほか : 本邦における十二指腸乳頭部癌の現状-1998～2004年登録症例の集計から-. 肝胆膵 54 : 737-746, 2007.
 
2) O'Connell JB, et al : Survival after resection of ampullary carcinoma : a nation population-based study. Ann Surg Oncol 15 : 1820-1827, 2008.
PubMed
3) 石川博人ほか : 十二指腸乳頭部癌に対する膵頭十二指腸切除の長期成績と予後因子. 胆と膵 33 : 267-270, 2012.
Medical*Online
4) Okano K, et al : Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma. J Surg Oncol 110 : 156-162, 2014.
PubMed
5) Sakata J, et al : Assessment of the nodal status in ampullary carcinoma : the number of positive lymph nodes versus lymph node ratio. World J Surg 35 : 2118-2124, 2011.
PubMed
6) Winter JM, et al : Clinicopathologic analysis of ampullary neoplasms in 450 patients : implications for surgical strategy and long-term prognosis. J Gastrointest Surg 14 : 379-387, 2010.
PubMed
7) Hornick JR, et al : A single-institution review of 157 patients presenting with benign and malignant tumors of the ampulla of Vater : management and outcomes. Surgery 150 : 169-176, 2011.
PubMed
8) de Castro SMM, et al : Surgical management of neoplasms of the ampulla of Vater : local resection or pancreatoduodenectomy and prognostic factors for survival. Surgery 136 : 994-1002, 2004.
PubMed
9) Zhong J, et al : The role of local excision in invasive adenocarcinoma of the ampulla of Vater. J Gastrointest Oncol 4 : 8-13, 2013.
PubMed
10) Demetriades H, et al : Local excision as a treatment for tumors of ampulla of Vater. World J Surg Oncol 4 : 14, 2006.
PubMed
11) 木村理ほか : 乳頭部癌に対する縮小手術-その術式と適応. 医学のあゆみ 170 : 253-256, 1994.
Medical*Online
12) 木下壽文ほか : 経十二指腸的乳頭部切除. 胆と膵 24 : 27-32, 2003.
Medical*Online
13) Laleman W, et al : Endoscopic resection of ampullary Iesions : a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. Surg Endosc 27 : 3865-3876, 2013.
 
14) Petrone G, et al : Endoscopic snare papillectomy : a possible radical treatment for a subgroup of T1 ampullary adenocarcinoma. Endoscopy 45 : 401-404, 2013.
PubMed
15) Napoleon B, et al : Endoscopic papillectomy for early ampullary tumors : 10ng-term results from a large multicenter prospective study. Endoscopy 46 : 127-134, 2014.
 
16) 伊藤彰浩ほか : 内視鏡切除術の治療成績と予後. 肝胆膵 54 : 835-839, 2007.
 
17) Kim ST, et al : The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater. Med Oncol 27 : 1149-1154, 2010.
PubMed
18) Shoji H, et al : Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy. Jpn J Clin Oncol 44 : 324-330, 2014.
PubMed
19) Valle J, et al : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 : 1273-1281, 2010.
PubMed
P.752 掲載の参考文献
1) 日本胆道外科研究会 : 全国胆道癌登録調査報告, 2004年度症例, 山菊印刷, 2005.
 
2) Nagakawa T, et al : Biliary tract cancer treatment : results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 9 : 569-575, 2002.
PubMed
3) Yonemoto N, et al : A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 37 : 843-851, 2007.
PubMed
4) Cattell RB, Pyrtek LJ : Premalignant lesions of the ampulla of Vater. Surg Gynecol Obstet 90 : 21-30, 1950.
PubMed
5) Pauli RM, et al : Gardner syndrome and periampullary malignancy. Am J Med Genet 6 : 205-219, 1980.
PubMed
6) Chan C, et al : Clinical behavior and prognostic factors of periampullary adenocarcinoma. Ann Surg 222 : 632-637, 1995.
PubMed
7) 石原慎ほか : 胆道癌登録からみた乳頭部癌の動向-進行度とリンパ節転移を中心に-. 胆と膵 33 : 221-224, 2012.
Medical*Online
8) 新井田達雄 : 十二指腸乳頭部癌の臨床病理学的研究 ; 予後規定因子と再発形式について. 日消外会誌 22 : 2009-2017, 1989.
 
9) 中村光司ほか : 十二指腸乳頭部癌の臨床病理学的検討. 日消外会誌 11 : 941-946, 1978.
 
10) 羽生富士夫ほか : 十二指腸乳頭部癌の外科治療と問題点. 胆と膵 11 : 1041-1045, 1995.
Medical*Online
11) 緒方賢司ほか : 十二指腸乳頭部癌に対する外科治療成績-進展様式と予後を中心に-. 肝胆膵 54 : 817-824, 2007.
Medical*Online
12) 菅原元ほか : 十二指腸乳頭部癌の臨床病理学的検討. 日臨外会誌 61 : 2269-2275, 2000.
 
13) 永池幸雄ほか : 十二指腸乳頭部癌切除例の臨床病理学的検討. 胆道 23 : 74-79, 2009.
 
14) 石川博人ほか : 乳頭部癌外科切除術後のAdjuvant Chemotherapy. 胆と膵 30 : 1439-1443, 2009.
 
15) Shirai Y, et al : Patterns of lymphatic spread of carcinoma of the ampulla of Vater. Br J Surg 84 : 1012-1016, 1997.
PubMed
16) Kayahara M, et al : Surgical strategy for carcinoma of the papilla of Vater based on the lymphatic spread and mode of recurrence. Surgery 121 : 611-617, 1997.
 
17) Mizuno T, et al : Clinical significance of immunohistochemically detectable lymph node metastasis in adenocarcinoma of the ampulla of Vater. Br J Surg 93 : 221-225, 2006.
PubMed
18) Sakata J, et al : Assessment of the nodal status in ampullary carcinoma : the number of positive lymph nodes versus the lymph node ratio. World J Surg 35 : 118-124, 2011.
 
19) Ohike N, et al : Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am J Surg Pathol 34 (10) : 1417-1424, 2010.
 
20) 石川博人ほか : 十二指腸乳頭部癌に対する膵頭十二指腸切除の長期成績と予後因子. 胆と膵 33 : 267-270, 2012.
Medical*Online
21) Hatzaras I, et al : Predictors of survival in periampullary cancers following pancreaticoduode nectomy. Ann Surg Oncol 17 : 991-997, 2010.
 
22) Haddad LB, et al : Lymph node involvement and not the histopathologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of Vater. J Gastrointestinal Surg 14 : 719-728, 2010.
 
23) Zhao XQ, et al : Prognosis of amupllary cancer based on immunochemical type and expression of osteopontin. Diagn Pathol 6 : 98, 2011.
 
24) 三浦靖彦ほか : Vater乳頭部に対する縮小・拡大根治手術. 消化器外科 25 : 1831-1837, 2002.
 
25) Goldberg M, et al : Wide local excision as an alternative treatment for periampullary carcinoma. Am J Gastroenterol 82 : 1168-1171, 1987.
 
26) Sharp KW, Barandes JL : Local resection of tumor of the ampulla of Vater. Am Surg 56 : 214-217, 1990.
 
27) Tarazi RY, et al : Results of surgical treatment of periampullary tumors : a thirty-five year experience. Surgery 100 : 716-723, 1986.
PubMed
28) Knox RA, Kingston RD : Carcinoma of the ampulla of Vater. Br J Surg 72 : 72-73, 1986.
PubMed
29) Yoon YS, et al : Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy. Ann Surg 242 : 92-100, 2005.
PubMed
30) Roggin KK, et al : Limitations of ampullectomy in the treatment of nonfamilial ampulllary neoplasms. Ann Surg Oncol 12 : 971-980, 2005.
PubMed
31) De Castro SM, et al : Surgical management of neoplasms of the ampulla of Vater : local resection or pancreatoduodenectomy and prognostic factors for survival. Surgery 136 : 994-1002, 2004.
PubMed
32) Beger HG, et al : Tumor of the ampulla of Vater. Arch Surg 134 : 526-532, 1999.
PubMed
33) Branum GD, et al : The management of tumors of the ampulla of Vater by local resection. Ann Surg 224 : 621-627, 1996.
PubMed
34) 永川宏和 : 膵頭部領域癌に対する拡大手術. 外科治療52 : 189-196, 1985.
 
P.757 掲載の参考文献
1) 日本肝胆膵外科学会 (編) : 胆道癌取扱い規約, 第6版, 金原出版, 2013.
 
2) 梛野正人ほか : 粘液産生胆管癌の臨床病理学的研究. 日外会誌 91 : 695-704, 1990.
 
3) 高良大介ほか : 著明な胆管拡張を呈した下部胆管原発粘液癌の1例. 胆道 22 : 99-104, 2008.
Medical*Online
4) 岡崎太郎ほか : 肝外胆管原発印環細胞癌に対して胆管切除術を施行した1例. 日消外会誌 46 : 840-846, 2013.
 
5) 松本知訓ほか : 胆管印環細胞癌の1例. 日消誌 108 : 2042-2049, 2011.
Medical*Online
6) 真木健裕ほか : 胆嚢印環細胞癌の1例. 日消外会誌 40 : 1811-1815, 2007.
 
7) 中沼安二ほか : 肝胆膵の粘液癌. 肝胆膵 52 : 251-258, 2006.
Medical*Online
8) Adsay NV, et al : Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol 25 : 26-42, 2001.
PubMed
9) 中沼安二ほか : 胆管内乳頭状腫瘍intraductal papillary neoplasm of bile duct (IPNB) 新しい疾患概念の提唱とその病理学的スペクトラム. 胆道 21 : 45-54, 2007.
Medical*Online
10) Kubo S, et al : Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. J Hepatobiliary Pancreat Sci 21 : 479-488, 2014.
PubMed
11) 金子麗奈ほか : 若年性胆管癌の疫学的特徴について-職業性胆管癌調査の予備的解析-. 日消誌 111 : 510-511, 2014.
Medical*Online
12) Hayashi M, et al : Imaging findings of mucinous type of cholangiocellular carcinoma. J Comput Assist Tomogr 20 : 386-389, 1996.
PubMed
13) 山本淳史ほか : 胆嚢高分化型粘液癌の1例. 日消誌 107 : 1821-1827, 2010.
Medical*Online
14) Nozoe T, et al : Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J Surg Oncol 75 : 103-107, 2000.
PubMed
15) Adsay NV, et al : Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs : Coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. Am J Surg Pathol 27 : 571-578, 2003
PubMed
P.762 掲載の参考文献
1) 日本膵臓学会 (編) : 膵癌取扱い規約, 第6版, 金原出版, 2013.
 
2) Baylor SM, Berg JW : Cross-classification and survival characteristics of 5,000 cases of cancer of the pancreas. J Surg Oncol 5 : 335-358, 1973.
PubMed
3) Chen J, Baithun S : Morphologic study of 391 cases of exocrine pancreatic tumors with special reference to the classification of exocrine pancreatic carcinoma. J Pathol 146 : 17-29, 1985.
 
4) Egawa S, et al : Clinicopathological aspects of small pancreatic cancer. Pancreas 28 : 235-240, 2004.
PubMed
5) Wood DA : Adenoacanthoma of the pyloric end of the stomach : a consideration of the its histogenesis and a report of two cases. Arch Pathol 36 : 177-189, 1943.
 
6) Bowel JT, Helwig EB : Squamous cell carcinoma and adenocarcinoma of the stomach. Cancer 18 : 181-192, 1965.
 
7) Cook CB, Klickstein GD : Adenoacanthoma of the colon. Arch Pathol 65 : 681-687, 1958.
PubMed
8) Barr RJ, Hancock DE : Adenosquamous carcinoma of the liver. Gastroenterology 69 : 1326-1330, 1975.
PubMed
9) Straus R, et al : Primary adenosquamous carcinoma of the stomach. A cases report and review. Cancer 24 : 985-995, 1969.
 
10) 世古口務 : 膵腺扁平上皮癌. 肝胆膵の外科-疾患編- (川原田嘉文編, 水本龍二監), p208-209, 医学図書出版, 2000.
 
11) 山野三紀ほか : 膵の腺房細胞癌と退形成膵管癌の病理形態的特徴. 消化器画像 2 (3) : 315-323, 2000.
 
12) 伊藤康博ほか : 膵扁平上皮癌の4切除例. 膵臓 28 : 651-660, 2013.
 
13) Charbit A, et al : Relation between the pathological and the growth rate of human tumors. Eur J Cancer 7 : 307-317, 1971.
 
14) 石渡裕俊ほか : 膵腺扁平上皮癌の画像診断の特徴. 膵臓 21 : 62-69, 2006.
 
15) 鈴木慶一ほか : 膵腺扁平上皮癌の5例. 日消外会誌33 (4) : 497-501, 2000.
 
16) 吉田隆典ほか : 膵全摘後長期生存中の膵腺扁平上皮癌の1例. 日臨外会誌 58 : 1640-1644, 1997.
 
17) 山永成美ほか : 術前化学放射線療法が著効し, R0切除可能となった膵腺扁平上皮癌の1例. 手術 68 (2) : 221-224, 2014.
 
P.767 掲載の参考文献
1) 胆道癌取扱い規約, 第6版 (日本肝胆膵外科学会編), 金原出版, 2013.
 
2) 膵癌取扱い規約, 第6版補訂版 (日本膵臓学会編), 金原出版, 2013.
 
3) 田中雅夫 : 膵癌登録報告2007. 膵臓 22 : e1-427, 2007.
 
4) 永川宅和, 萱原正都 : 胆道癌登録成績が教える胆道癌の診断と治療のあり方, 金原出版, 2005.
 
5) 二川康郎, 岡本友好 : 肝外胆管の扁平上皮癌. 別冊日本臨牀 肝・胆道系症候群 (第2版) III 肝外胆道編, p75-79, 日本臨牀社, 2011.
 
6) 鈴村和大ほか : 胆嚢扁平上皮癌の1切除例. 日外科系連会誌 38 : 1265-1269, 2013.
 
7) 堀口実ほか : 術前に胆管癌と診断された胆嚢扁平上皮癌の1切除例と本邦切除例28例の検討. 胆道 13 : 21-31, 1999.
Medical*Online
8) 二川康郎ほか : 原発性胆嚢管扁平上皮癌の1例. 胆道 27 : 232-239, 2013.
Medical*Online
9) 武藤良弘ほか : 胆道の腺扁平上皮癌症例の臨床病理学的検討. 癌の臨床 28 : 440-444, 1982.
 
10) Iemura A, et al : A cholangiocellular carcinoma nude mouse strain showing histologic alteration from adenocarcinoma to squamous cell carcinoma. Cancer 70 : 415-422, 1992.
PubMed
11) 湯浅典博ほか : 扁平上皮化生をともなった下部胆管腺扁平上皮癌の1例. 日消外会誌 20 : 2782-2785, 1987.
 
12) Gatof D, et al : Primary squamous cell carcinoma of the bile duct diagnosed by transpapillary cholangioscopy : case report and review. Gastrointest Endosc 60 : 300-304, 2004.
PubMed
13) 小林裕幸ほか : 胆嚢十二指腸瘻を伴った胆嚢扁平上皮癌の1例. 日臨外会誌 61 : 2747-2751, 2000.
 
14) 水島睦枝ほか : 胆嚢の扁平上皮癌-4症例報告と本邦13剖検例の臨床病理学的研究. 胆と膵 5 : 1311-1318, 1984.
 
15) Valle J, et al : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 (14) : 1273-1281, 2010.
PubMed
P.772 掲載の参考文献
1) 日本肝胆膵外科学会 : 胆道癌取扱い規約, 第6版, p42, 金原出版, 2013.
 
2) Guo KJ, et al : Undifferentiated carcinoma of the gallbladder. A clinicopathologic, histochemical, and immunohistochemical study of 21 patients with a poor prognosis. Cancer 61 : 1872-1879, 1988.
PubMed
3) Albores-Saavedra J, et al : Carcinoma of the gallbladder and extrahepatic bile ducts. In : WHO Classification of Tumours. Pathology & Genetics of Tumours of the Digestive System, IARC Press, Lyon, 2000.
 
4) Strauch GO : Primary carcinoma of the gallbladder, presentation of seventy cases from the Rhode Island Hospital and a cumulative review of the last ten years of the American literature. Surgery 47 : 368-383, 1960.
 
5) Piehler JM, Crichlow RW : Primary carcinoma of the gallbladder. Surg Gynecol Obstet 147 : 929-942, 1978.
PubMed
6) Ogura Y, et al : Radical operations for carcinoma of the gallbladder : present status in Japan. World J Surg 15 : 337-343, 1991.
PubMed
7) Nishihara K, Tsuneyoshi M : Undifferatiated spindle cell carcinoma of the gallbladder : a clinicopathologic, immunohistochemical, and flow cytometric study of 11 cases. Hum Pathol 24 : 1298-1305, 1993.
PubMed
8) 日本胆道外科研究会 : 全国胆道癌登録調査報告, 1997年度症例, p6-17, 1998.
 
9) 水崎馨ほか : 術後急激な転機をとった胆嚢未分化癌の1例. 胆道 21 (4) : 567-573, 2007.
 
10) 田中彰一ほか : 剖検にて確定診断しえた胆嚢未分化癌の1例. 日消誌 99 : 1366-1371, 2002.
Medical*Online
11) 大西久司ほか : 胆嚢紡錘細胞型未分化癌の1例. 日臨外会誌 62 (2) : 501-507, 2001.
 
12) 萩原資久ほか : 胆嚢未分化癌の1例. 日臨外会誌 64 (12) : 3135-3139, 2003.
 
13) 槙かおりほか : 巨大発育を来した胆嚢未分化癌の1例. 画像診断 23 : 1198-1202, 2003.
 
14) Appleman HD, Coopersmith N : Pleomorphic spindle-cell carcinoma of the gallbladder. Cancer 25 : 535-541, 1970.
 
15) Suster S, et al : Adenosquamous carcinoma of the gallbladder with spindle cell features. A light microscopic and immunohistochemical study of a case. Histopathology 11 : 209-214, 1987.
 
16) Kubota K, et al : Undifferentiated spindle-cell carcinoma of the gallbladder : an immunohistochemical study. J Hepatobiliary Pancreat Surg 13 : 468-471, 2006.
PubMed
17) Ota T, et al : Successful radical surgery for an undifferentiated gallbladder carcinoma with lymph node metastases to the mesocolon. Jpn J Clin Oncol 26 : 484-487, 1996.
 
P.777 掲載の参考文献
1) 日本肝胆膵外科学会 (編) : 胆道癌取扱い規約, 第6版, p42, 金原出版, 2013.
 
2) Albores-Saavedra J, et al : Carcinoma of the gallbladder and extrahepatic bile ducts. In : WHO Classification of Tumours of the Digestive System, IARC Press, Lyon, 2010.
 
3) Siriaunkgul S, Tavassoli FA : Invasive micropapillary carcinoma of the breast. Mod Pathol 6 : 660-662, 1993.
PubMed
4) Nassar H, et al : Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma. Mod Pathol 14 : 836-841, 2001.
PubMed
5) Reis-Fiho JS, Ellis IO : Invasive micropapillary carcinoma. In : WHO Classification of Tumours of the Breast, IARC Press, Lyon, 2012.
 
6) Hara S, et al : Invasive micropapillary variant of the gallbladder adenocarcinoma and its aggressive potential for lymph node metastasis. Biomed Res 31 : 89-95, 2010.
PubMed
7) Yoshizawa T, et al : Invasive micropapillary carcinoma of the extrahepatic bile duct and its malignant potential. Oncol Rep32 : 1355-1361, 2014.
PubMed
P.783 掲載の参考文献
1) Meyer R : Mischgeschwulste des Uterus : die Komplizierten Tumoren. In : HandBuch der Speziellen Pathologischen Anatomie und Histologie (ed by Henke E Lubarsch O), p412-415, Julius Springer, Berlin, 1930.
 
2) 松本俊治, 藤井博昭 : 卵巣癌肉腫の病理・予後および女性生殖器における癌肉腫の組織発生. 病理と臨床 18 : 431-434, 2000.
Medical*Online
3) Willis RA : Pathology of Tumours, 4th ed, p128, Butterworth, London, 1967.
 
4) 廣田誠一, 梶本仙子 : 消化管非上皮性腫瘍の病理診断. 病理と臨床 29 : 978-984, 2011.
Medical*Online
5) Inoshita S, et al : Carcinosarcoma of the gallbladder. Acta Pathol Jpn 36 : 913-920, 1986.
PubMed
6) 荒木政人ほか : 希な真の胆嚢癌肉腫の1切除例. 胆道 25 : 214-219, 2011.
 
7) Okabayashi T, et al : Surgical outcome for 131 cases of carcinosarcoma of the hepatobiliary tract. J Gastroenterol 49 : 982-991, 2014.
PubMed
8) 星野崇ほか : 術前診断が可能であった中部胆管原発のいわゆる癌肉腫の1例. 日消誌110 : 263-270, 2013.
 
P.787 掲載の参考文献
1) Tatarinov IuS : Detection of embryo-specific alpha-globulin in the blood serum of a patient with primary liver cancer. Vopr Med Khim 10 : 90-91, 1964.
PubMed
2) 玉置大器 : 腫瘍マーカーとしてのα-フェトプロテイン-その発現調節の分子機構を考える. 化学と生物 29 : 631-639, 1991.
 
3) Morinaga T, et al : A human alpha-fetoprotein enhancer-binding protein, ATBF1, contains four homeodomains and seventeen zinc fingers. Mol Cell Biol 11 : 6041-6049, 1991.
PubMed
4) 玉置大器, 橋本知子 : ヒトα-フェトプロテイン遺伝子の発現を制御する塩基配列と転写因子. 生物物理化学39 : 149-154, 1995.
 
5) Zhou YM, et al : Clinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoprotein. World J Gastroenterol 14 : 2251-2254, 2008.
PubMed
6) 宍戸忠幸ほか : 動注化学療法が有効であったAFP産生胆嚢癌の1例. 内科 85 : 175-178, 2000.
 
7) 安部智之ほか : AFP産生胆嚢癌の1例. 日臨外会誌 69 : 1197-1201, 2008.
 
8) Miyazawa M, et al : Alpha-fetoprotein-producing clear cell carcinoma of the extrahepatic bile ducts. J Clin Gastroenterol 40 : 555-557, 2006.
PubMed
9) Abdullah A, et al : Primary hepatoid carcinoma of the biliary tree : a radiologic mimicker of Klatskin-type tumor. Cancer Imaging 10 : 198-201, 2010.
PubMed
10) Salman B, et al : The diagnosis and surgical treatment of pancreatoblastoma in adults : a case series and review of the literature. J Gastrointest Surg 17 : 2153-2161, 2013.
PubMed
11) 森早耶香ほか : EUS FNAで診断し, 動注化学療法が有効であったAFP産生膵腺房細胞癌の1例. 日消誌 101 : 177-182, 2004.
 
12) Sasaki N, et al : Alpha-fetoprotein-producing pancreatic cancer cells possess cancer stem cell characteristics. Cancer Lett 308 : 152-161, 2011.
PubMed
13) Yamauchi N, et al : The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 18 : 1591-1598, 2005.
PubMed
14) Ushiku T, et al : Glypican 3-expressing gastric carcinoma : distinct subgroupunifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas. Cancer Sci 100 : 626-632, 2009.
PubMed
15) Ikeda M, et al : Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci 105 : 455-462, 2014.
PubMed
P.791 掲載の参考文献
1) Ito T, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 (2) : 234-243, 2010.
PubMed
2) Hamilton NA, et al : Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery 152 (1) : 107-113, 2012.
PubMed
3) Larghi A, et al : Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition : a prospective study. Gastrointest Endosc 76 (3) : 570-577, 2012.
PubMed
4) Hasegawa T, et al : Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. Endoscopy 46 (1) : 32-38, 2014.
PubMed
5) Sorbye H, et al : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : the NORDIC NEC study. Ann Oncol 24 (1) : 152-160, 2013.
 
6) Rinke A, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 27 (28) : 4656-4663, 2009.
 
7) Caplin ME, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371 (3) : 224-233, 2014.
PubMed
8) Okuwaki K, et al : Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Cancer 119 (23) : 4094-4102, 2013.
PubMed
9) Yao JC, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 (6) 514-523, 2011.
PubMed
10) Raymond E, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364 (6) : 501-513, 2011.
PubMed
11) Bosman FT, et al : WHO Classification of Tumours of the Digestive System (World Health Organization Classification of Tumours), IARC Press, Lyon, 2010.
 
P.796 掲載の参考文献
1) Fred T, et al : WHO Classification of Tumours of the Digestive System, IARC Press, Lyon, 2010.
 
2) 日本肝癌研究会 (編) : 原発性肝癌取扱い規約, 第5版補訂版, 金原出版, 2009.
 
3) 中沼安二 : WHO新分類による胆道癌の前癌病変および早期癌病変. 胆道 28 : 154-162, 2014.
Medical*Online
4) Kubota K, et al : Clinicopathological features and prognosis of mucin-producing bile duct tumor and mucinous cystic tumor of the liver : amulti-institutional study by the Japan Biliary Association. J Hepatobiliary Pancreat Sci 21 : 176-185, 2014.
 
5) Ishibashi Y, et al : Invasive biliary cystic tumor without ovarian-like stroma. Pathol Int 57 : 794-798, 2007.
PubMed
6) Mano Y, et al : Cystic tumors of the liver : on the problems of diagnostic criteria. Pathol Res Pract 207 : 659-663, 2011.
PubMed
P.803 掲載の参考文献
1) 胆道癌診療ガイドライン作成委員会 (編) : エビデンスに基づいた胆道癌診療ガイドライン, 医学図書出版, 2007.
 
2) Takada T : Purpose, use, and preparation of clinical practice guidelines for the management of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg l 5 (1) : 2-6, 2008.
 
3) 胆道癌診療ガイドライン作成委員会 (編) : エビデンスに基づいた胆道癌診療ガイドライン改訂第2版, 医学図書出版, 2014.
 
4) 吉富秀幸ほか : 胆道癌診療ガイドラインの現状と改訂へ向けての課題 ガイドライン利用アンケート調査結果を中心に. 胆と膵 32 : 263-269, 2011.
Medical*Online
5) Atkins D, et al : Grading quality of evidence and strength of recommendations. BMJ 328 : 1490, 2004.
PubMed
P.808 掲載の参考文献
1) Kanai M, et al : A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 67 (6) : 1429-1434, 2011.
PubMed
2) Sasaki T, et al : Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65 (6) : 1101-1107, 2010.
PubMed
3) Valle J, et al : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 : 1273-1281, 2010.
PubMed
4) Okusaka T, et al : Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer 103 (4) : 469-474, 2010.
 
5) Vaccaro V, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 365 (8) : 768-769, 2011.
PubMed
6) Gruenberger B, et al : Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer : a phase 2 study. Lancet Oncol 11 (12) : 1142-1148, 2010.
PubMed
7) Kanai M, et al : Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). Cancer Chemother Pharmacol 69 (5) : 1181-1188, 2012.
 
8) Yamashita Y, et al : Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers. Jpn J Clin Oncol 40 (1) : 24-28, 2010.
PubMed
9) Andre T, et al : Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma : a GERCOR study. Ann Oncol 15 (9) : 1339-1343, 2004.
PubMed
P.812 掲載の参考文献
1) Zen Y, et al : Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct-an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol 44 : 350-358, 2006.
PubMed
2) Zen Y, et al : Biliary papillary tumors share pathological features With intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44 : 1333-1343, 2006.
PubMed
3) Zen Y, et al : Intraductal tubulopapillary neoplasm of the bile duct : potential origin from peribiliary cysts. Hum Pathol 43 : 440-445, 2012.
PubMed
4) Zen Y, et al : Mucinous cystic neoplasms of the liver : a clinicopathological study and comparison with intraductal papillary neoplasms of the bile duct. Mod Pathol 24 : 1079-1089, 2011.
PubMed
5) Zen Y, et al : Biliary intraepithelial neoplasia : an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 20 : 701-709, 2007.
PubMed
6) Nakanishi Y, et al : Expression of cell cycle-related molecules in biliary premalignant lesions : biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. Hum Pathol 39 : 1153-1161, 2008.
PubMed
7) Schlitter AM, et al : Intraductal papillary neoplasms of the bile duct : stepwise progression to carcinoma involves common molecular pathways. Mod Pathol 27 : 73-86, 2014.
PubMed
P.818 掲載の参考文献
1) Ferlay J, et al : GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide, IARC Cancer Base No.5, version 2.0, IARC oress, Lyon, 2004.
 
2) 厚生労働省大臣官房統計情報部 : 人口動態統計, 厚生労働省ホームページ [http://www.mhlw.go.jp/toukei/saikin/index.html]
 
3) Khan SA, et al : Cholangiocarcinoma. Lancet 366 : 1303-1314, 2005.
PubMed
4) Ishiguro S, et al : Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (JPHC study) : with special focus on cholelithiasis, body mass index, and their effect modification. Cancer Causes Control 19 : 33-41, 2008.
 
5) Randi G, et al : Gallbladder cancer world wide : geographical distribution and risk factors. Int J Cancer 118 : 1591-1602, 2006.
 
6) Palmer WC, et al : Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 57 : 69-76, 2012.
PubMed
7) Jing W, et al : Diabetes mellitus and increased risk of cholangiocarcinoma : a meta-analysis. Eur J Cancer Prev 21 : 24-31, 2012.
PubMed
8) Calle EE, et al : Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 348 : 1625-1638, 2003.
 
9) Kuriyama S, et al : Obesity and risk of cancer in Japan. Int J Cancer 113 : 148-157, 2005.
PubMed
10) Larsson SC, WOIk A : Obesity and the risk of gallbladder cancer : a meta-analysis. Br J Cancer 96 : 457-461, 2007.
 
11) Dandona P, et al : Oxidative damage to DNA in diabetes mellitus. Lancet 347 : 444-445, 1996.
PubMed
12) Alvaro D, et al : Estrogens and insulin-like growth factor I modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 169 : 877-888, 2006.
PubMed
13) Gallagher EJ, et al : IGF, insulin, and cancer. Endocrinology 152 : 2546-2551, 2011.
PubMed
14) Suzuki H, et al : Expression of insulin-like growth factor receptor (IGFR) as a useful biomarker for predicting prognosis in biliary tract cancer patients. Mol Clin Oncol, 2014. (in press)
 
P.822 掲載の参考文献
1) Remolar J, et al : Percutaneous transhepatic cholangiography. Gastroenterology 31 : 39-46, 1956.
PubMed
2) Nagai N, et al : Continuous endoscopic pancreatocholedochal catheterization. Gastrointest Endosc 23 : 78-81, 1976.
PubMed
3) Soehendra N, Reynders-Frederix V : Palliative bile duct drainage-a new endoscopic method of introducing a transpapillary drain. Endoscopy 12 : 8-11, 1980.
PubMed
4) Giovannini M, et al : Endoscopic ultrasound-guided bilioduodenal anastomosis : a new technique for biliary drainage. Endoscopy 33 : 898-900, 2001.
PubMed
5) Davids PH, et al : Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 340 : 1488-1492, 1992.
PubMed
6) Moss AC, et al : Do the benefits of metal stents justify the costs? Asystematic review and metaanalysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol 19 : 1119-1124, 2007.
 
7) Isayama H, et al : A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 53 : 729-734, 2004.
PubMed
8) Kitano M, et al : Covered self-expandable meta1 stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma : a randomized multicenter trial. Am J Gastroenterol 108 : 1713-1722, 2013.
 
9) Mukai T, et al : Metallic stents are more efficacious than plastic stents in unresectable malignant hilar biliary strictures : a randomized controlled trial. J Hepatobiliary Pancreat Sci 20 : 214-222, 2013.
PubMed
10) Yasuda I, et al : Unilateral versus bilateral endoscopic biliary stenting for malignant hilar biliary strictures. Dig Endosc 25 (Suppl 2) : 81-85, 2013.
 
11) van der Gaag NA, et al : Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 362 : 129-137, 2010.
PubMed
12) Cavell LK, et al : Biliary self-expandable metal stents do not adversely affect pancreaticoduodenectomy. Am J Gastroenterol 108 : 1168-1173, 2013.
 
13) Nimura Y : Preoperative biliary drainage before resection for cholangiocarcinoma (Pro). HPB (Oxford) 10 : 130-133, 2008.
PubMed
14) Takahashi Y, et al : Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg 97 : 1860-1866, 2010.
PubMed
15) Kawakami H, et al : Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol 46 : 242-248, 2011.
PubMed
16) Itoi T, et al : Stent selection and tips on placement technique of EUS-guided biliary drainage : transduodenal and transgastric stenting. J Hepatobiliary Pancreat Sci 18 : 664-672, 2011.
PubMed
17) Park do H, et al : EUS-guided biliary drainage with transluminal stenting after failed ERCP : predictors of adverse events and long-term results. Gastrointest Endosc 74 : 1276-1284, 2011.
PubMed
18) Dhir V, et al : Comparison of EUS-guided rendezvous and precut papillotomy techniques for biliary access (with videos). Gastrointest Endosc 75 : 354-359, 2012.
PubMed
19) Iwashita T, et al : Endoscopic ultrasound-guided antegrade treatments for biliary disorders in patients with surgically altered anatomy. Dig Dis Sci 58 : 2417-2422, 2013.
PubMed
P.826 掲載の参考文献
1) Takahashi R, et al : Current status of immunotherapy for the treatment of biliary tract cancer. Hum Vaccin Immunother 9 (5) : 1069-1072, 2013.
PubMed
2) Cheever MA, et al : The prioritization of cancer antigens : A National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 15 (17) : 5323-5337, 2009.
PubMed
3) Kaida M, et al : Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother 34 (1) : 92-99, 2011.
PubMed
4) Okusaka T, et al : Possibility of immunotherapy for biliary tract cancer : how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor l peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial). J Hepatobiliary Pancreat Sci 19 (4) : 314-318, 2012.
 
5) Matsumura N, et al : Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer 94 (6) : 1770-1776, 2002.
PubMed
6) Yamamoto K, et al : MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 25 : 3575-3580, 2005.
PubMed
7) Aruga A, et al : Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer. Clin Cancer Res 19 (8) : 2224-2231, 2013.
 
8) Aruga A, et al : Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. J Transl Med 12 : 61, 2014.
PubMed
9) Yoshitomi M, et al : Personalized peptide vaccination for advanced biliary tract cancer : IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 3 (3) : 463-469, 2012.
PubMed
10) Furuse J, et al : Phase II open-label single-arm trial of combining the epitope peptide derived from Vascular Endothelial Growth Factor Receptor-2 with gemcitabine for patients with unresectable biliary tract cancer OTS102 Study 202. Eur J Cancer 49 (Suppl 2) : 2608, 2013.
 
11) Ohno S, et al : Phase I trial of Wilm's Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anticancer Res 32 (6) : 2263-2269, 2012.
PubMed
12) Morse MA, et al : Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112 : 610-618, 2008.
PubMed
13) Duraiswamy J, et al : Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively response T-cell rejection function in tumors. Cancer Res 73 (12) : 3591-3603, 2013.
 
14) Wolchok JD, et al : Guidelines for the evaluation of immune therapy activity in solid tumors : immunerelated response criteria. Clin Cancer Res 15 (23) : 7412-7420, 2009.
PubMed
15) Chen TT : Statistical issues and challenges in immuno-oncology. J Immunother Cancer 1 : 18, 2013.
PubMed
P.831 掲載の参考文献
1) Kumagai S, et al : Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane. Occup Environ Med 70 : 508-510, 2013.
 
2) Utada M, et al : Long-term trends in incidence and mortality of intrahepatic and extrahepatic bileduct cancer in Japan. J Epidemiol 24 : 193-199, 2014.
 
3) Kubo S, et al : Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. J Hepatobiliary Pancreat Sci 21 : 479-488, 2014.
PubMed
4) Khan SA, et al : Cholangiocarcinoma, Lancet 366 : 1303-1314, 2005.
PubMed
5) 独立行政法人労働安全衛生総合研究所 : 災害調査報告書A-2012-02大阪府の印刷工場における疾病災害, 2012. [http://www.mhlw.go.jp/stf/houdou/2r9852000002ioeh-att/2r9852000002ioik.pdf]
 
6) Kumagai S, et al : Time course of blood parameters in printing workers with cholangiocarcinoma. J Occup Health 56 : 280-285, 2014.
 
7) Yamada K, et al : Chemical exposure levels in printing workers with cholangiocarcinoma. J Occup Health, 2014. [Epub ahead of print]
 
8) Kumagai S : Two offset printing workers with cholangiocarcinoma. J Occup Health 56 : 164-168, 2014.
PubMed
9) NTP (National Toxicology Program) : Toxicology and carcinogenesis studies of dichloromethane in F344/N rats and B6C3Fi mice (inhalation studies). NTP Technical Report 306, U. S Dept. Health and Human Services, Washington, DC, 1986.
 
10) NTP (National Toxicology Program) : Toxicology and carcinogenesis studies of 1,2-dichloropropane in F344/N rats and B6C3Fi mice (gavage studies). NTP Technical Report 263, U. S Dept. Health and Human Services, Washington, DC, 1986.
 
11) Sherratt PJ, et al : Direct comparison of the nature of mouse and human GST T1-1 and the implications on dichloromethane carcinogenicity. Toxicol Appl Pharmacol 179 : 89-97, 2002.
PubMed
12) Lanes SF, et al : Mortality of cellulose fiber production workers. Scand J Work Environ Health 16 : 247-251, 1990.
PubMed
13) Okamoto E, et al : Prevalence of bile duct cancer among printing industry workers in comparison with other industries. J OccupHealth 55 : 511-515, 2014.
 
14) Vlaanderen J, et al : Cholangiocarcinoma among workers in the printing industry : using the NOCCA database to elucidate the generalisability of a cluster report from Japan. Occup Environ Med 70 : 828-830, 2013.
PubMed
15) Ahrens W, et al : Biliary tract cancer in male printers and typesetters in the European rare cancer case-control study. Occup Environ Med 71 : 591-592, 2014.
PubMed

書評

最近チェックした商品履歴

Loading...